WO2002022650A2 - Haplotypes of the per1 gene - Google Patents

Abstract

Novel genetic variants of the Period (Drosophila) Homolog 1 (PER1) gene are described. Various genotypes, haplotypes, and haplotype pairs that exist in the general United States population are disclosed for the PER1 gene. Compositions and methods for haplotyping and/or genotyping the PER1 gene in an individual are also disclosed. Polynucleotides defined by the haplotypes disclosed herein are also described.

Description

HAPLOTYPES OF THE PERI GENE

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application Serial No. 60/232,468 filed September 13, 2000.

FIELD OF THE INVENTION

This invention relates to variation in genes that encode pharmaceuticalϊy-important proteins. In particular, this invention provides genetic variants of the human period (Drosophila) homolog 1 (PERI) gene and methods for identifying which variant(s) of this gene is/are possessed by an individual.

BACKGROUND OF THE INVENTION

Current methods for identifying pharmaceuticals to treat disease often start by identifying, cloning, and expressing an important target protein related to the disease. A determination of whether an agonist or antagonist is needed to produce an effect that may benefit a patient with the disease is . then made. Then, vast numbers of compounds are screened against the target protein to find new potential drugs. The desired outcome of this process is a lead compound that is specific for the target, thereby reducing the incidence of the undesired side effects usually caused by activity at non-intended targets. The lead compound identified in this screening process then undergoes further in vitro and in vivo testing to determine its absorption, disposition, metabolism and toxicological profiles. Typically, this testing involves use of cell lines and animal models with limited, if any, genetic diversity.

What this approach fails to consider, however, is that natural genetic variability exists between individuals in any and every population with respect to pharmaceutically-important proteins, including the protein targets of candidate drugs, the enzymes that metabolize these drugs and the proteins whose activity is modulated by such drug targets. Subtle alterations) in the primary nucleotide sequence of a gene encoding a pharmaceutically-important protein may be manifested as significant variation in expression, structure and/or function of the protein. Such alterations may explain the relatively high degree of uncertainty inherent in the treatment of individuals with a drug whose design is based upon a single representative example of the target or enzyme(s) involved in metabolizing the drug. For example, it is well-established that some drugs frequently have lower efficacy in some individuals than others, which means such individuals and their physicians must weigh the possible benefit of a larger dosage against a greater risk of side effects. Also, there is significant variation in how well people metabolize drugs and other exogenous chemicals, resulting in substantial interindividual variation in the toxicity and/or efficacy of such exogenous substances (Evans et al, 1999, Science 286:487-491). This variability in efficacy or toxicity of a drug in genetically-diverse patients makes many drugs ineffective or even dangerous in certain groups of the population, leading to the failure of such drugs in clinical trials or their early withdrawal from the market even though they could be highly beneficial for other groups in the population. This problem significantly increases the time and cost of drug discovery and development, which is a matter of great public concern.

It is well-recognized by pharmaceutical scientists that considering the impact of the genetic variability of pharmaceutically-important proteins in the early phases of drug discovery and development is likely to reduce the failure rate of candidate and approved drugs (Marshall A 1997 Nature Biotech 15:1249-52; Kleyn PW et al. 1998 Science 281: 1820-21; Kola 1 1999 Curr Opin Biotech 10:589-92; Hill AVS et al. 1999 mEvolution in Health and Disease Stearns SS (Ed.) Oxford University Press, New York, pp 62-76; Meyer U. A. 1999 in Evolution in Health and Disease Stearns SS (Ed.) Oxford University Press, New York, pp 41-49; Kalow. W et al. 1999 Clin. Pharm. Therap.

66:445-7; Marshall, E 1999 Science 284:406-7; Judson R et al. 2000 Pharmacogenomics 1:1-12; Roses AD 2000 Nature 405:857-65). However, in practice this has been difficult to do, in large part because of the time and cost required for discovering the amount of genetic variation that exists in the population (Chakravarti A 1998 Nature Genet 19:216-7; Wang DG et al 1998 Science 280:1077-82;. Chakravarti A 1999 Nat Genet 21:56-60 (suppl); Stephens JC 1999 Mol. Diagnosis 4:309-317; Kwok PY and Gu S 1999 Mol. Med. Today 5:538-43; Davidson S 2000 Nature Biotech 18: 1134-5).

The standard for measuring genetic variation among individuals is the haplotype, which is the ordered combination of polymorphisms in the sequence of each form of a gene that exists in the population. Because haplotypes represent the variation across each form of a gene, they provide a more accurate and reliable measurement of genetic variation than individual polymoφhisms. For example, while specific variations in gene sequences have been associated with a particular phenotype such as disease susceptibility (Roses AD supra; Ulbrecht M et al. 2000 Am JRespir Crit Care Med 161: 469-74) and drag response (Wolfe CR et al. 2000 BMJ 320:987-90; Dahl BS 1997 Acta Psychiatr Scand 96 (Suppl 391): 14-21), in many other cases an individual polymoφhism may be found in a variety of genomic backgrounds, i.e, different haplotypes, and therefore shows no definitive coupling between the polymoφhism and the causative site for the phenotype (Clark AG et al. 1998 Am JHum Genet 63:595-612; Ulbrecht M et al. 2000 supra; Drysdale et al. 2000 PNAS 97:10483-10488). Thus, there is an unmet need in the pharmaceutical industry for information on what haplotypes exist in the population for pharmaceutically-important genes. Such haplotype information would be useful in improving the efficiency and output of several steps in the drag discovery and development process, including target validation, identifying lead compounds, and early phase clinical trials (Marshall et al, supra).

One pharmaceutically-important gene for the treatment of disorders associated with circadian rhythm regulation is the period (Drosophila) homolog 1 (PERI) gene or its encoded product. PERI is a regulator of the complex series of rhythyms in humans known as circadian rhythms. An intrinsic body clock residing in the suprachiasmatic nucleus (SCΝ) within the brain regulates circadian* rhythms in humans, including sleep/wakefulness. Defects in pathways that control circadian rhythms have been associated with sleep disorders such as chronic insomnia (Zisapel CNS Drugs 2001; 15(4):311-328).

Expression of mammalian circadian regulators within the SCN oscillate within a 24-hour cycle. In mouse retina, Sun et al, (1997, Cell 90: 1003-1011) showed that the expression of PERI oscillated over a 24-hour period, with highest expression at onset of dark in a 12-hour light/dark cycle. The authors also detected oscillation of PERI expression in the SCN, pars tuberalis, afrd Purkinje neurons of the cerebellum. The pars tuberalis releases luteinizing hormone, which is negatively regulated by circulating melatonin. Differences in PERI expression in the pars tuberalis may reflect the difference in melatonin production, implicating melatonin as a regulator of PERI expression in this area of the brain (Sun et al, supra). Yokota et al. (Br J Pharmacol 2000 Dec; 131(8): 1739-1747) studied the expression of PERI and PER2 in hamsters that were administered brotizolam. Brotizolam induced large phase advances in hamster rhythm when injected during mid-subjective daytime. The authors found that phase advance and expression of PERI and PER2 were diminished following injection of this drag. These results suggest that brotizolam may be useful in the treatment of insomnia, and since expression of PERI accompanies phase advance in animal models, this gene may be a potential target for treatment of insomnia.

The period (Drosophila) homolog 1 gene is located on chromosome 17pl3.1-17pl2 and contains 23 exons that encode a 1290 amino acid protein. A reference sequence for the PERI gene is shown in the contiguous lines of Figure 1 (Genaissance Reference No. 2856063; SEQ ID NO: 1). Reference sequences for the coding sequence (GenBank Accession No. NM_002616.1) and protein are shown in Figures 2 (SEQ ID NO: 2) and 3 (SEQ ID NO: 3), respectively.

Single nucleotide polymoφhisms in the PERI gene have been previously reported in the literature. A SNP of cytosine or guanine at a position corresponding to nucleotide 7310 in Figure 1 has been reported (NCBI SNP ID:rs885747). Because of the potential for variation in the PERI gene to affect the expression and function of the encoded protein, it would be useful to know whether additional polymoφhisms exist in the PERI gene, as well as how such polymoφhisms are combined in different copies of the gene. Such information could be applied for studying the biological function of PERI as well as in identifying drugs targeting this protein for the treatment of disorders related to its abnormal expression or function.

SUMMARY OF THE INVENTION

Accordingly, the inventors herein have discovered 27 novel polymoφhic sites in the PERI gene. These polymoφhic sites (PS) correspond to the following nucleotide positions in Figure 1 : 1967 (PSl), 1979 (PS2), 2048 (PS3), 2218 (PS4), 2324 (PS5), 3830 (PS6), 3833 (PS7), 3973 (PS8), 4131 (PS9), 4157 (PS10), 4314 (PS11), 4365 (PS12), 4433 (PS13), 4962 (PS14), 6408 (PS15), 7068 (PS16), 7116 (PS17), 7371 (PS19), 7392 (PS20), 7991 (PS21), 8608 (PS22), 9656 (PS23), 9764 (PS24), 9878 (PS25), 9976 (PS26), 12132 (PS27) and 13622 (PS28). The polymoφhisms at these sites are cytosine or guanine at PSl, thymine or guanine at PS2, guanine or thymine at PS3, guanine or adenine at PS4, thymine or cytosine at PS5, cytosine or thymine at PS6, thymine or cytosine at PS7, cytosine or thymine at PS8, cytosine or thymine at PS9, cytosine or thymine at PS10, adenine or guanine at PSl 1, thymine or cytosine at PS12, cytosine or guanine at PS13, adenine or cytosine at

PS14, thymine or cytosine at PS15, thymine or cytosine at PS16, cytosine or thymine at PS17, guanine or adenine at PS 19, cytosine or thymine at PS20, thymine or cytosine at PS21, guanine or adenine at PS22, adenine or guanine at PS23, cytosine or thymine at PS24, adenine or guanine at PS25, guanine or adenine at PS26, cytosine or thymine at PS27 and cytosine or thymine at PS28. In addition, the inventors have determined the identity of the alleles at these sites, as well as at the previously identified site at nucleotide position 7310 (PS 18), in a human reference population of 79 unrelated individuals self-identified as belonging to one of four major population groups: African descent, Asian, Caucasian and Hispanic/Latino. From this information, the inventors deduced a set of haplotypes and haplotype pairs for PS1-PS28 in the PERI gene, which are shown below in Tables 5 and 4, respectively. Each of these PERI haplotypes constitutes a code that defines the variant nucleotides that exist in the human population at this set of polymoφhic sites in the PERI gene. Thus each PERI haplotype also represents a nararally-occurring isoform (also referred to herein as an "isogene") of the PERI gene. The frequency of each haplotype and haplotype pair within the totaL reference population and within each of the four major population groups included in the reference population was also determined.

Thus, in one embodiment, the invention provides a method, composition and kit for genotyping the PERI gene in an individual. The genotyping method comprises identifying the nucleotide pair that is present at one or more polymoφhic sites selected from the group consisting of PSl, PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS11, PS12, PS13, PS14, PS15, PS16, PS17, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS26, PS27 and PS28 in both copies of the PERI gene from the individual. A genotyping composition of the invention comprises an oligonucleotide probe or primer which is designed to specifically hybridize to a target region containing, or adjacent to, one of these novel PERI polymoφhic sites. A genotyping kit of the invention comprises a set of oligonucleotides designed to genotype each of these novel PERI polymoφhic sites. In a preferred embodiment, the genotyping kit comprises a set of oligonucleotides designed to genotype each of PS1-PS28^'. The genotyping method, composition, and kit are useful in determining whether an individual has one of the haplotypes in Table 5 below or has one of the haplotype pairs in Table 4 below.

The invention also provides a method for haplotyping the PERI gene in an individual. In one embodiment, the haplotyping method comprises determining, for one copy of the PERI gene, the identity of the nucleotide at one or more polymoφhic sites selected from the group consisting of PSl, PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS11, PS12, PS13, PS14, PS15, PS16, PS17, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS26, PS27 and PS28. In another embodiment, the haplotyping method comprises determining whether one copy of the individual's PERI gene is defined by one of the PERI haplotypes shown in Table 5, below, or a sub-haplotype thereof. In a preferred embodiment, the haplotyping method comprises determining whether both copies of the individual's PERI gene are defined by one of the PERI haplotype pairs shown in Table 4 below, or a sub-haplotype pair thereof. Establishing the PERI haplotype or haplotype pair of an individual is useful for improving the efficiency and reliability of several steps in the discovery and development of drags for treating diseases associated with PERI activity, e.g., disorders associated with circadian rhythm regulation. For example, the haplotyping method can be used by the pharmaceutical research scientist to validate PERI as a candidate target for treating a specific condition or disease predicted to be associated with PERI activity. Determining for a particular population the frequency of one or more of the individual PERI haplotypes or haplotype pairs described herein will facilitate a decision on whether to pursue PERI as a target for treating the specific disease of interest. In particular, if variable PERI activity is associated with the disease, then one or more PERI haplotypes or haplotype pairs will be found at a higher frequency in disease cohorts than in appropriately genetically matched controls. Conversely, if each of the observed PERI haplotypes are of similar frequencies in the disease and control groups, then it may be inferred that variable PERI activity has little, if any, involvement with that disease. In either case, the pharmaceutical research scientist can, without a priori knowledge as to the phenotypic effect of any PERI haplotype or haplotype pair, apply the information derived from detecting PERI haplotypes in an individual to decide whether modulating PERI activity would be useful in treating the disease.

The claimed invention is also useful in screening for compounds targeting PERI to treat a specific condition or disease predicted to be associated with PERI activity. For example, detecting which of the PERI haplotypes or haplotype pairs disclosed herein are present in individual members of a population with the specific disease of interest enables the pharmaceutical scientist to screen for a compound(s) that displays the highest desired agonist or antagonist activity for each of the PERI isoforms present in the disease population, or for only the most frequent PERI isoforms present in the disease population. Thus, without requiring any a priori knowledge of the phenotypic effect of any particular PERI haplotype or haplotype pair, the claimed haplotyping method provides the scientist with a tool to identify lead compounds that are more likely to show efficacy in clinical trials.

Haplotyping the PERI gene in an individual is also useful in the design of clinical trials of candidate drags for treating a specific condition or disease predicted to be associated with PERI activity. For example, instead of randomly assigning patients with the disease of interest to the treatment or control group as is typically done now, determining which of the PERI haplotype(s) disclosed herein are present in individual patients enables the pharmaceutical scientist to distribute PERI haplotypes and or haplotype pairs evenly to treatment and control groups, thereby reducing the potential for bias in the results that could be introduced by a larger frequency of a PERI haplotype or haplotype pair that is associated with response to the drag being studied in the trial, even if this association was previously unknown. Thus, by practicing the claimed invention, the scientist can more confidently rely on the information learned from the trial, without first determining the phenotypic effect of any PERI haplotype or haplotype pair. In another embodiment, the invention provides a method for identifying an association between a trait and a PERI genotype, haplotype, or haplotype pair for one or more of the novel polymoφhic sites described herein. The method comprises comparing the frequency of the PERI genotype, haplotype, or haplotype pair in a population exhibiting the trait with the frequency of the PERI genotype or haplotype in a reference population. A higher frequency of the PERI genotype, haplotype, or haplotype pair in the trait population than in the reference population indicates the trait is associated with the PERI genotype, haplotype, or haplotype pair. In preferred embodiments, the trait is susceptibility to a disease, severity of a disease, the staging of a disease or response to a drag. In a particularly preferred embodiment, the PERI haplotype is selected from the haplotypes shown in Table 5, or a sub-haplotype thereof. Such methods have applicability in developing diagnostic tests and therapeutic treatments for disorders associated with circadian rhythm regulation.

In yet another embodiment, the invention provides an isolated polynucleotide comprising a nucleotide sequence which is a polymoφhic variant of a reference sequence for the PERI gene or a fragment thereof. The reference sequence comprises the contiguous sequences shown in Figure 1 and the polymoφhic variant comprises at least one polymoφhism selected from the group consisting of guanine at PSl, guanine at PS2, thymine at PS3, adenine at PS4, cytosine at PS5, thymine at PS6, cytosine at PS7, thymine at PS8, thymine at PS9, thymine at PS10, guanine at PSl 1, cytosine at PS12, guanine at PS13, cytosine at PS14, cytosine at PS15, cytosine at PS16, thymine at PS17, adenine at PS19, thymine at PS20, cytosine at PS21, adenine at PS22, guanine at PS23, thymine at PS24, guanine at PS25, adenine at PS26, thymine at PS27 and thymine at PS28. In a preferred embodiment, the polymoφhic variant comprises an additional polymoφhism of guanine at PS 18.

A particularly preferred polymoφhic variant is an isogene of the PERI gene. A PERI isogene of the invention comprises cytosine or guanine at PSl, thymine or guanine at PS2, guanine or thymine at PS3, guanine or adenine at PS4, thymine or cytosine at PS5, cytosine or thymine at PS6, thymine or cytosine at PS7, cytosine or thymine at PS8, cytosine or thymine at PS9, cytosine or thymine at PS 10, adenine or guanine at PSl 1, thymine or cytosine at PS12, cytosine or guanine at PS13, adenine or cytosine at PS14, thymine or cytosine at PS15, thymine or cytosine at PS16, cytosine or thymine at PS 17, cytosine or guanine at PS 18, guanine or adenine at PS 19, cytosine or thymine at PS20, thymine or cytosine at PS21, guanine or adenine at PS22, adenine or guanine at PS23, cytosine or thymine at PS24, adenine or guanine at PS25, guanine or adenine at PS26, cytosine or thymine at PS27 and cytosine or thymine at PS28. The invention also provides a collection of PERI isogenes, referred to herein as a PERI genome anthology.

In another embodiment, the invention provides a polynucleotide comprising a polymoφhic variant of a reference sequence for a PERI cDNA or a fragment thereof. The reference sequence comprises SEQ ID NO:2 (Fig.2) and the polymoφhic cDNA comprises at least one polymoφhism selected from the group consisting of thymine at a position corresponding to nucleotide 109, thymine at a position corresponding to nucleotide 135, guanine at a position corresponding to nucleotide 297, cytosine at a position corresponding to nucleotide 639, adenine at a position corresponding to nucleotide 1521, thymine at a position corresponding to nucleotide 1542, cytosine at a position corresponding to nucleotide 1763, adenine at a position corresponding to nucleotide 2055, thymine at a position corresponding to nucleotide 2247, guanine at a position corresponding to nucleotide 2361, adenine at a position corresponding to nucleotide 2459 and thymine at a position corresponding to nucleotide 3834. A particularly preferred polymoφhic cDNA variant comprises the coding sequence of a PERl isogene defined by haplotypes 1-11, 13, 14, 17, 19-21, and 23-32.

Polynucleotides complementary to these PERI genomic and cDNA variants are also provided by the invention. It is believed that polymoφhic variants of the PERI gene will be useful in studying the expression and function of PERI, and in expressing PERI protein for use in screening for candidate drags to treat diseases related to PERI activity.

In other embodiments, the invention provides a recombinant expression vector comprising one of the polymorphic genomic and cDNA variants operably linked to expression regulatory elements as well as a recombinant host cell transformed or transfected with the expression vector. The recombinant vector and host cell may be used to express PERI for protein structure analysis and drag binding studies.

In yet another embodiment, the invention provides a polypeptide comprising a polymoφhic variant of a reference amino acid sequence for the PERI protein. The reference amino acid sequence comprises SEQ JD NO:3 (Fig.3) and the polymoφhic variant comprises at least one variant amino acid selected from the group consisting of serine at a position corresponding to amino acid position 37, proline at a position corresponding to amino acid position 588 and glutamine at a position corresponding to amino acid position 820. A polymoφhic variant of PERI is useful in studying the effect of the variation on the biological activity of PERI as well as on the binding affinity of candidate drags targeting PERI for the treatment of disorders associated with circadian rhythm regulation. The present invention also provides antibodies that recognize and bind to the above polymoφhic PERI protein variant. Such antibodies can be utilized in a variety of diagnostic and prognostic formats and therapeutic methods.

The present invention also provides nonhuman transgenic animals comprising one or more of the PERI polymoφhic genomic variants described herein and methods for producing such animals. The transgenic animals are useful for studying expression of the PERI isogenes in vivo, for in vivo screening and testing of drugs targeted against PERI protein, and for testing the efficacy of therapeutic agents and compounds for disorders associated with circadian rhythm regulation in a biological system. The present invention also provides a computer system for storing and displaying polymoφhism data determined for the PERI gene. The computer system comprises a computer processing unit; a display; and a database containing the polymoφhism data. The polymoφhism data includes one or more of the following: the polymoφhisms, the genotypes, the haplotypes, and the haplotype pairs identified for the PERI gene in a reference population. In a preferred embodiment, the computer system is capable of producing a display showing PERI haplotypes organized according to their evolutionary relationships.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 illustrates a reference sequence for the PERI gene (Genaissance Reference No.

2856063; contiguous lines), with the start and stop positions of each region of coding sequence indicated with a bracket ([ or ]) and the numerical position below the sequence and the polymoφhic site(s) and polymoφhism(s) identified by Applicants in a reference population indicated by the variant nucleotide positioned below the polymoφhic site in the sequence. SEQ ID NO:l is equivalent to Figure 1 , with the two alternative allelic variants of each polymoφhic site indicated by the appropriate nucleotide symbol (R= G or A, Y= T or C, M= A or C, K= G or T, S= G or C, and W= A or T; WTPO standard ST.25). SEQ JD NO: 139 is a modified version of SEQ JD NO: 1 that shows the context sequence of each polymoφhic site, PS1-PS28, in a uniform format to facilitate electronic searching. For each polymoφhic site, SEQ ID NO: 139 contains a block of 60 bases of the nucleotide sequence encompassing the centrally-located polymoφhic site at the 30^th position, followed by 60 bases of unspecified sequence to represent that each PS is separated by genomic sequence whose composition is defined elsewhere herein.

Figure 2 illustrates a reference sequence for the PERI coding sequence (contiguous lines; SEQ ID NO:2), with the polymoφhic site(s) and polymoφhism(s) identified by Applicants in a reference population indicated by the variant nucleotide positioned below the polymoφhic site in the sequence. Figure 3 illustrates a reference sequence for the PERI protein (contiguous lines; SEQ ID NO:3), with the variant amino acid(s) caused by the polymoφhism(s) of Figure 2 positioned below the polymoφhic site in the sequence.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is based on the discovery of novel variants of the PERI gene. As described in more detail below, the inventors herein discovered 32 isogenes of the PERI gene by characterizing the PERI gene found in genomic DNAs isolated from an Index Repository that contains immortalized cell lines from one chimpanzee and 93 human individuals. The human individuals included a reference population of 79 unrelated individuals self-identified as belonging to one of four major population groups: Caucasian (21 individuals), African descent (20 individuals), Asian (20 individuals), or Hispanic/Latino (18 individuals). To the extent possible, the members of this reference population were organized into population subgroups by their self-identified ethnogeographic origin as shown in Table 1 below.

In addition, the Index Repository contains three unrelated indigenous American Indians (one from each of North, Central and South America), one three-generation Caucasian family (from the CEPH Utah cohort) and one two-generation African- American family.

The PERI isogenes present in the human reference population are defined by haplotypes for 28 polymoφhic sites in the PERI gene, 27 of which are believed to be novel. The PERI polymoφhic sites identified by the inventors are referred to as PS1-PS28 to designate the order in which they are located in the gene (see Table 3 below), with the novel polymoφhic sites referred to as PSl, PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PSl 1, PS12, PS13, PS14, PS15, PS16, PS17, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS26, PS27 and PS28. Using the genotypes identified in the Index Repository for PS1-PS28 and the methodology described in the Examples below, the inventors herein also determined the pair of haplotypes for the PERI gene present in individual human members of this repository. The human genotypes and haplotypes found in the repository for the PERI gene include those shown in Tables 4 and 5, respectively. The polymoφhism and haplotype data disclosed herein are useful for validating whether PERI is a suitable target for drags to treat disorders associated with circadian rhythm regulation, screening for such drags and reducing bias in clinical trials of such drags. In the context of this disclosure, the following terms shall be defined as follows unless otherwise indicated:

Allele - A particular form of a genetic locus, distinguished from other forms by its particular nucleotide sequence. Candidate Gene - A gene which is hypothesized to be responsible for a disease, condition, or the response to a treatment, or to be correlated with one of these.

Gene - A segment of DNA that contains all the information for the regulated biosynthesis of an RNA product, including promoters, exons, introns, and other untranslated regions that control expression. Genotype — An unphased 5 ' to 3 ' sequence of nucleotide pair(s) found at one or more polymoφhic sites in a locus on a pair of homologous chromosomes in an individual. As used herein, genotype includes a full-genotype and/or a sub-genotype as described below.

Full-genotype - The unphased 5' to 3' sequence of nucleotide pairs found at all polymoφhic sites examined herein in a locus on a pair of homologous chromosomes in a single individual. Sub-genotype - The unphased 5 ' to 3 ' sequence of nucleotides seen at a subset of the polymoφhic sites examined herein in a locus on a pair of homologous chromosomes in a single individual.

Genotyping - A process for determining a genotype of an individual. . Haplotype - A 5' to 3' sequence of nucleotides found at one or more polymoφhic sites in a locus on a single chromosome from a single individual. As used herein, haplotype includes a fb.ll- haplotype and/or a sub-haplotype as described below.

Full-haplotype - The 5' to 3' sequence of nucleotides found at all polymoφhic sites examined herein in a locus on a single chromosome from a single individual.

Sub-haplotype - The 5' to 3' sequence of nucleotides seen at a subset of the polymoφhic sites examined herein in a locus on a single chromosome from a single individual.

Haplotype pair - The two haplotypes found for a locus in a single individual. Haplotyping - A process for determining one or more haplotypes in an individual and includes use of family pedigrees, molecular techniques and/or statistical inference.

Haplotype data - Information concerning one or more of the following for a specific gene: a listing of the haplotype pairs in each individual in a population; a listing of the different haplotypes in a population; frequency of each haplotype in that or other populations, and any known associations between one or more haplotypes and a trait.

Isoform - A particular form of a gene, mRNA, cDNA or the protein encoded thereby, distinguished from other forms by its particular sequence and/or structure. Isogene - One of the isoforms (e.g., alleles) of a gene found in a population. An isogene (or allele) contains all of the polymoφhisms present in the particular isoform of the gene.

Isolated - As applied to a biological molecule such as RNA, DNA, oligonucleotide, or protein, isolated means the molecule is substantially free of other biological molecules such as nucleic acids, proteins, lipids, carbohydrates, or other material such as cellular debris and growth media. Generally, the term "isolated" is not intended to refer to a complete absence of such material or to absence of water, buffers, or salts, unless they are present in amounts that substantially interfere with the methods of the present invention.

Locus - A location on a chromosome or DNA molecule corresponding to a gene or a physical or phenotypic feature, where physical features include polymoφhic sites.

Naturally-occurring - A term used to designate that the object it is applied to, e.g., naturally- occurring polynucleotide or polypeptide, can be isolated from a source in nature and which has not been intentionally modified by man.

Nucleotide pair - The nucleotides found at a polymoφhic site on the two copies of a chromosome from an individual.

Phased - As applied to a sequence of nucleotide pairs for two or more polymoφhic sites in a locus, phased means the combination of nucleotides present at those polymoφhic sites on a single copy of the locus is known.

Polymorphic site (PS) - A position on a chromosome or DNA molecule at which at least two alternative sequences are found in a population.

Polymorphic variant - A gene, mRNA, cDNA, polypeptide or peptide whose nucleotide or amino acid sequence varies from a reference sequence due to the presence of a polymoφhism in the gene.

Polymorphism - The sequence variation observed in an individual at a polymoφhic site. Polymoφhisms include nucleotide substitutions, insertions, deletions and microsatellites and may, but need not, result in detectable differences in gene expression or protein function.

Polymorphism data - Information concerning one or more of the following for a specific gene: location of polymoφhic sites; sequence variation at those sites; frequency of polymoφhisms in one or more populations; the different genotypes and/or haplotypes determined for the gene; frequency of one or more of these genotypes and/or haplotypes in one or more populations; any known association^) between a trait and a genotype or a haplotype for the gene.

Polymorphism Database - A collection of polymoφhism data arranged in a systematic or methodical way and capable of being individually accessed by electronic or other means.

Polynucleotide - A nucleic acid molecule comprised of single-stranded RNA or DNA or comprised of complementary, double-stranded DNA.

Population Group - A group of individuals sharing a common ethnogeographic origin. Reference Population - A group of subjects or individuals who are predicted to be representative of the genetic variation found in the general population. Typically, the reference population represents the genetic variation in the population at a certainty level of at least 85%, preferably at least 90%, more preferably at least 95% and even more preferably at least 99%. Single Nucleotide Polymorphism (SNP) - Typically, the specific pair of nucleotides observed at a single polymoφhic site. In rare cases, three or four nucleotides may be found.

Subject - A human individual whose genotypes or haplotypes or response to treatment or disease state are to be determined. Treatment - A stimulus administered internally or externally to a subject.

Unphased - As applied to a sequence of nucleotide pairs for two or more polymoφhic sites in a locus, unphased means the combination of nucleotides present at those polymoφhic sites on a single copy of the locus is not known.

As discussed above, information on the identity of genotypes and haplotypes for the PERI gene of any particular individual as well as the frequency of such genotypes and haplotypes in any particular population of individuals is useful for a variety of drug discovery and development applications. Thus, the invention also provides compositions and methods for detecting the novel PERI polymoφhisms, haplotypes and haplotype pairs identified herein.

The compositions comprise at least one oligonucleotide for detecting the variant nucleotide or nucleotide pair located at a novel PERI polymoφhic site in one copy or two copies of the PERI gene. Such oligonucleotides are referred to herein as PERI haplotyping oligonucleotides or genotyping oligonucleotides, respectively, and collectively as PERI oligonucleotides. In one embodiment, a PERI haplotyping or genotyping oligonucleotide is a probe or primer capable of hybridizing to a target region that contains, or that is located close to, one of the novel polymoφhic sites described herein. As used herein, the term "oligonucleotide" refers to a polynucleotide molecule having less than about 100 nucleotides. A preferred oligonucleotide of the invention is 10 to 35 nucleotides long. More preferably, the oligonucleotide is between 15 and 30, and most preferably, between 20 and 25 nucleotides in length. The exact length of the oligonucleotide will depend on many factors that are routinely considered and practiced by the skilled artisan. The oligonucleotide may be comprised of any phosphorylation state of ribonucleotides, deoxyribonucleotides, and acyclic nucleotide derivatives, and other functionally equivalent derivatives. Alternatively, oligonucleotides may have a phosphate- free backbone, which may be comprised of linkages such as carboxymethyl, acetamidate, carbamate, polyamide (peptide nucleic acid (PNA)) and the like (Varma, R. in Molecular Biology and Biotechnology, A Comprehensive Desk Reference, Ed. R. Meyers, VCH Publishers, Inc. (1995), pages 617-620) . Oligonucleotides of the invention may be prepared by chemical synthesis using any suitable methodology known in the art, or may be derived from a biological sample, for example, by restriction digestion. The oligonucleotides may be labeled, according to any technique known in the art, including use of radiolabels, fluorescent labels, enzymatic labels, proteins, haptens, antibodies, sequence tags and the like. Haplotyping or genotyping oligonucleotides of the invention must be capable of specifically hybridizing to a target region of a PERI polynucleotide. Preferably, the target region is located in a PERI isogene. As used herein, specific hybridization means the oligonucleotide forms an anti-parallel double-stranded structure with the target region under certain hybridizing conditions, while failing to form such a structure when incubated with another region in the PERI polynucleotide or with a non- PER1 polynucleotide under the same hybridizing conditions. Preferably, the oligonucleotide specifically hybridizes to the target region under conventional high stringency conditions. The skilled artisan can readily design and test oligonucleotide probes and primers suitable for detecting polymoφhisms in the PERI gene using the polymoφhism information provided herein in conjunction with the known sequence information for the PERI gene and routine techniques.

A nucleic acid molecule such as an oligonucleotide or polynucleotide is said to be a "perfect" or "complete" complement of another nucleic acid molecule if every nucleotide of one of the molecules is complementary to the nucleotide at the corresponding position of the other molecule. A nucleic acid molecule is "substantially complementary" to another molecule if it hybridizes to that molecule with sufficient stability to remain in a duplex form under conventional low-stringency conditions. Conventional hybridization conditions are. described, for example, by Sambrook J. et al, in Molecular Cloning, A Laboratory Manual, 2^nd Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989) and by Haymes, B.D. et al. in Nucleic Acid Hybridization, A Practical Approach, IRL Press, Washington, D.C. (1985). While perfectly complementary oligonucleotides are preferred for detecting polymoφhisms, departures from complete complementarity are contemplated where such departures do not prevent the molecule from specifically hybridizing to the target region. For example, an oligonucleotide primer may have a non-complementary fragment at its 5' end, with the remainder of the primer being complementary to the target region. Alternatively, non-complementary nucleotides may be interspersed into the probe or primer as long as the resulting probe or primer is still capable of specifically hybridizing to the target region.

Preferred haplotyping or genotyping oligonucleotides of the invention are allele-specific oligonucleotides. As used herein, the term allele-specific oligonucleotide (ASO) means an oligonucleotide that is able, under sufficiently stringent conditions, to hybridize specifically to one allele of a gene, or other locus, at a target region containing a polymoφhic site while not hybridizing to the corresponding region in another allele(s). As understood by the skilled artisan, allele-specificity will depend upon a variety of readily optimized stringency conditions, including salt and formamide concentrations, as well as temperatures for both the hybridization and washing steps. Examples of hybridization and washing conditions typically used for ASO probes are found in Kogan et al, "Genetic Prediction of Hemophilia A" in PCR Protocols, A Guide to Methods and Applications, Academic Press, .1990 and Ruano et al, 87 Proc. Natl Acad. Sci. USA 6296-6300, 1990. Typically, an ASO will be perfectly complementary to one allele while containing a single mismatch for another allele. Allele-specific oligonucleotides of the invention include ASO probes and ASO primers. ASO probes which usually provide good discrimination between different alleles are those in which a central position of the oligonucleotide probe aligns with the polymoφhic site in the target region (e.g., approximately the 7^th or 8^th position in a 15mer, the 8^th or 9^th position in a 16mer, and the 10^th or 11^th position in a 20mer). An ASO primer of the invention has a 3 ' terminal nucleotide, or preferably a 3 ' penultimate nucleotide, that is complementary to only one nucleotide of a particular SNP, thereby acting as a primer for polymerase-mediated extension only if the allele containing that nucleotide is present. ASO probes and primers hybridizing to either the coding or noncoding strand are contemplated by the invention. ASO probes and primers Usted below use the appropriate nucleotide symbol (R= G or A, Y= T or C, M= A or C, K= G or T, S= G or C, and W= A or T; WTPO standard ST.25) at the position of the polymoφhic site to represent that the ASO contains either of the two alternative allelic variants observed at that polymoφhic site.

A preferred ASO probe for detecting PERI gene polymoφhisms comprises a nucleotide sequence, listed 5 ' to 3 ', selected from the group consisting of:

TTGTGTTSTGCAAGG (SEQ ID NO 4) and its complement,

AGGCTAGKGCGTTCA (SEQ ID NO 5) and its complement,

GCGCAGCKTATCTCC (SEQ ID NO 6) and its complement,

GCGCCGGRAAGAGAT (SEQ ID NO 7) and its complement,

CGCCCGGYGGAGCTT (SEQ ID NO 8) and its complement,

GCAGGTGYTCTGGAG (SEQ ID NO 9) and its complement,

GGTGCTCYGGAGTTA (SEQ ID NO 10 and its complement,

CGTGCATYCGTGGTG (SEQ ID NO 11 and its complement,

GCCTTGCYCAGGCCC (SEQ ID NO 12 and its complement,

ATGACACYGATGCCA (SEQ ID NO 13 and its complement,

GATGTGTRTGTTGGG (SEQ ID NO 14 and its complement,

ACAGGCCYCGCACTG (SEQ ID NO 15 and its complement,

GCCCATCSCCACCCA (SEQ ID NO 16 and its complement,

AGTACAC CTTCAGA (SEQ ID NO 17 and its complement,

GGCAGAGYGGAGGGC (SEQ ID NO 18 and its complement,

TGGGCCAYGCCCCCG (SEQ ID NO 19 and its complement,

GACAGGAYCGGGCCA (SEQ ID NO 20 and its complement,

GCCCCACRGGACTCT (SEQ ID NO 21 and its complement,

TCGGCGCYGTGACAT (SEQ ID NO 22 and its complement,

AAGGCCCYTCCCTGC (SEQ ID NO 23 and its complement,

CAGCAGCRCTGTCTG (SEQ ID NO 24 and its complement,

CTAGGCTRTCAGACA (SEQ ID NO 25 and its complement,

TGCCTGGYCTAGCCC (SEQ ID NO 26 . and its complement,

TGCACACRCAGAAGG (SEQ ID NO 27 and its complement,

GGCGAGCRAGGTAGC (SEQ ID NO 28 and its complement,

GGGGAGCYGGGAGCC (SEQ ID NO 29 ^' and its complement, and

GCTCATCYAGTCCAG (SEQ ID NO 30 and its complement. A preferred ASO primer for detecting PERI gene polymoφhisms comprises a nucleotide sequence, listed 5' to 3', selected from the group consisting of:

AAGATGTTGTGTTST (SEQ ID NO 31); CACTAGCCTTGCASA (SEQ ID NO 32) TCTGCAAGGCTAGKG (SEQ ID NO 33); ACTTCCTGAACGCMC (SEQ ID NO 34) AAAGAGGCGCAGCKT (SEQ ID NO 35); AGAGAGGGAGATAMG (SEQ ID NO 36) AATCAGGCGCCGGRA (SEQ ID NO 37); CTGGGGATCTCTTYC (SEQ ID NO 38) CCCGCCCGCCCGGYG (SEQ ID NO 39); GAGTGGAAGCTCCRC (SEQ ID NO 40) AAGCCAGCAGGTGYT (SEQ ID NO 41); GTTTAACTCCAGARC (SEQ ID NO 42) CCAGCAGGTGCTCYG (SEQ ID NO 43); CTGGTTTAACTCCRG (SEQ ID NO 44) CCCCCTCGTGCATYC SEQ ID NO 45) AGAGGCCACCACGRA (SEQ ID NO:46) ;

GCACCGGCCTTGCYC SEQ ID NO 47) AGGCTGGGGCCTGRG (SEQ ID NO:48)

TGGCCGATGACACYG SEQ ID NO 49) TGCTGTTGGCATCRG (SEQ ID NO:50)

TGTATGGATGTGTRT SEQ ID NO 51) CCTAGACCCAACAYA (SEQ ID NO:52)

TGGGTGACAGGCCYC SEQ ID NO 53) GGCCAGCAGTGCGRG (SEQ ID NO:54)

CTCAGAGCCCATCSC SEQ ID NO 55) AACTGCTGGGTGGSG (SEQ ID NO:56)

CGTCTGAGTACACMC SEQ ID NO^' 57) CCTGGTTCTGAAGKG (SEQ ID NO:58)

GGCCCAGGCAGAGYG SEQ ID NO 59) TCCTCAGCCCTCCRC (SEQ ID NO: 60)

CGTAAGTGGGCCAYG SEQ ID NO 61) CCAGCTCGGGGGCRT (SEQ ID NO: 62)

GTGGGGGACAGGAYC SEQ ID NO 63) CAGCCCTGGCCCGRT (SEQ ID NO: 64)

GCCCCAGCCCCACRG SEQ ID NO 65) CTCCACAGAGTCCYG (SEQ ID NO: 66)

GTGGAGTCGGCGCYG SEQ ID NO 67) CTGGGGATGTCACRG (SEQ ID NO: 68)

AAGGCCAAGGCCCYT SEQ ID NO 69) GGATTGGCAGGGARG (SEQ ID NO:70)

CGCCGTCAGCAGCRC SEQ ID NO 71) CCTCCCCAGACAGYG (SEQ ID NO:72)

GGTTGGCTAGGCTRT SEQ ID NO 73) CCTCCCTGTCTGAYA (SEQ ID NO:74)

AGGACCTGCCTGGYC SEQ ID NO 75) GGCCTGGGGCTAGRC (SEQ ID NO:76)

TGTCCCTGCACACRC SEQ ID NO 77) GCTCTTCCTTCTGYG (SEQ ID NO:78)

GCCCTTGGCGAGCRA SEQ ID NO 79) CAGGTGGCTACCTYG (SEQ ID NO:80)

GTGATTGGGGAGCYG SEQ ID NO 81) GGCCTGGGCTCCCRG (SEQ ID NO,: 82)

GCAGGAGCTCATCYA SEQ ID NO 83) and GTAAGGCTGGACTRG (SEQ ID NO:84)

Other oligonucleotides of the invention hybridize to a target region located one to several nucleotides downstream of one of the novel polymoφhic sites identified herein. Such oligonucleotides are useful in polymerase-mediated primer extension methods for detecting one of the novel polymoφhisms described herein and therefore such oligonucleotides are referred to herein as "primer- extension oligonucleotides". In a preferred embodiment, the 3 '-terminus of a primer-extension oligonucleotide is a deoxynucleotide complementary to the nucleotide located immediately adjacent to the polymoφhic site.

A particularly preferred oligonucleotide primer for detecting PERI gene polymoφhisms by primer extension terminates in a nucleotide sequence, listed 5' to 3', selected from the group consisting of:

ATGTTGTGTT (SEQ ID NO 85), TAGCCTTGCA (SEQ ID NO 86) ;

GCAAGGCTAG (SEQ ID NO 87), TCCTGAACGC (SEQ ID NO 88) ;

GAGGCGCAGC (SEQ ID NO 89), GAGGGAGATA (SEQ ID NO 90) ;

CAGGCGCCGG (SEQ ID NO 91), GGGATCTCTT (SEQ ID NO 92) ;

GCCCGCCCGG (SEQ ID NO 93), TGGAAGCTCC (SEQ ID NO 94);

CCAGCAGGTG (SEQ ID NO 95), TAACTCCAGA (SEQ ID NO 96);

GCAGGTGCTC (SEQ ID NO 97), GTTTAACTCC (SEQ ID NO 98);

CCTCGTGCAT (SEQ ID NO 99), GGCCACCACG (SEQ ID NO 100)

CCGGCCTTGC (SEQ ID NO 101) CTGGGGCCTG (SEQ ID NO 102)

CCGATGACAC (SEQ ID NO 103) ; . TGTTGGCATC (SEQ ID NO 104)

ATGGATGTGT (SEQ ID NO 105) AGACCCAACA (SEQ ID NO 106)

GTGACAGGCC (SEQ ID NO 107) CAGCAGTGCG (SEQ ID NO 108)

AGAGCCCATC (SEQ ID NO 109) TGCTGGGTGG (SEQ ID NO 110)

CTGAGTACAC (SEQ ID NO 111) GGTTCTGAAG (SEQ ID NO 112)

CCAGGCAGAG (SEQ ID NO 113) TCAGCCCTCC (SEQ ID NO 114)

AAGTGGGCCA (SEQ ID NO 115) GCTCGGGGGC (SEQ ID NO 116)

GGGGACAGGA (SEQ ID NO 117) CCCTGGCCCG (SEQ ID NO 118)

CCAGCCCCAC (SEQ ID NO 119) CACAGAGTCC (SEQ ID NO 120)

GAGTCGGCGC (SEQ ID NO 121) * GGGATGTCAC (SEQ ID NO 122) GCCAAGGCCC (SEQ ID NO:123) TTGGCAGGGA (SEQ ID NO : 124 ) ; CGTCAGCAGC (SEQ ID NO:125) CCCCAGACAG (SEQ ID NO : 126) ; TGGCTAGGCT (SEQ ID NO:127) CCCTGTCTGA (SEQ ID NO : 128 ) ; ACCTGCCTGG (SEQ ID NO:129) CTGGGGCTAG ( SEQ ID NO : 130 ) ; CCCTGCACAC (SEQ ID NO: 131) CTTCCTTCTG (SEQ ID NO : 132 ) ; CTTGGCGAGC (SEQ ID NO:133) GTGGCTACCT ( SEQ ID NO : 134 ) ; ATTGGGGAGC (SEQ ID NO:135) CTGGGCTCCC (SEQ ID NO : 136) ; GGAGCTCATC (SEQ ID NO:137) and AGGCTGGACT (SEQ ID NO : 138 ) .

In some embodiments, a composition contains two or more differently labeled PERI oligonucleotides for simultaneously probing the identity of nucleotides or nucleotide pairs at two or more polymoφhic sites. It is also contemplated that primer compositions may contain two or more sets of allele-specific primer pairs to allow simultaneous targeting and amplification of two or more regions containing a polymoφhic site.

PERI oligonucleotides of the invention may also be immobilized on or synthesized on a solid surface such as a microchip, bead, or glass slide (see, e.g., WO 98/20020 and WO 98/20019). Such immobilized oligonucleotides may be used in a variety of polymoφhism detection assays, including but not limited to probe hybridization and polymerase extension assays. Immobilized PERI oligonucleotides of the invention may comprise an ordered array of oligonucleotides designed to rapidly screen a DNA sample for polymoφhisms in multiple genes at the same time.

In another embodiment, the invention provides a kit comprising at least two PERI oligonucleotides packaged in separate containers. The kit may also contain other components such as hybridization buffer (where the oligonucleotides are to be used as a probe) packaged in a separate container. Alternatively, where the oligonucleotides are to be used to amplify a target region, the kit may contain, packaged in separate containers, a polymerase and a reaction buffer optimized for primer extension mediated by the polymerase, such as PCR.

The above described oligonucleotide compositions and kits are useful in methods for genotyping and/or haplotyping the PERI gene in an individual. As used herein, the terms "PERI genotype" and "PERI haplotype" mean the genotype or haplotype contains the nucleotide pair or nucleotide, respectively, that is present at one or more of the novel polymoφhic sites described herein and may optionally also include the nucleotide pair or nucleotide present at one or more additional polymoφhic sites in the PERI gene. The additional polymoφhic sites may be currently known polymoφhic sites or sites that are subsequently discovered. One embodiment of a genotyping method of the invention involves isolating from the individual a nucleic acid sample comprising the two copies of the PERI gene, mRNA transcripts thereof or cDNA copies thereof, or a fragment of any of the foregoing, that are present in the individual, and determining the identity of the nucleotide pair at one or more polymoφhic sites selected from the group consisting of PSl, PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS11, PS12, PS13, PS14, PS15, PS16, PS17, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS26, PS27 and PS28 in the two copies to assign a PERI genotype to the individual. As will be readily understood by the skilled artisan, the two "copies" of a gene, mRNA or cDNA (or fragment of such PERI* molecules) in an individual may be the same allele or may be different alleles. In a preferred embodiment of the method for assigning a PERI genotype, the identity of the nucleotide pair at PS 18 is also determined. In another embodiment, a genotyping method of the invention comprises deteπnining the identity of the nucleotide pair at each of PS1-PS28.

Typically, the nucleic acid sample is isolated from a biological sample taken from the individual, such as a blood sample or tissue sample. Suitable tissue samples include whole blood, semen, saliva, tears, urine, fecal material, sweat, buccal, skin and hair. The nucleic acid sample may be comprised of genomic DNA, mRNA, or cDNA and, in the latter two cases, the biological sample must be obtained from a tissue in which the PERI gene is expressed. Furthermore it will be understood by the skilled artisan that mRNA or cDNA preparations would not be used to detect polymoφhisms located in introns or in 5 ' and 3 ' untranslated regions if not present in the mRNA or cDNA. If a PERI gene fragment is isolated, it must contain the polymoφhic site(s) to be genotyped. One embodiment of a haplotyping method of the invention comprises isolating from the individual a nucleic acid sample containing only one of the two copies of the PERI gene, mRNA or cDNA, or a fragment of such PERI molecules, that is present in the individual and determining in that copy the identity of the nucleotide at one or more polymoφhic sites selected from the group consisting of PSl, PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PSl 1, PS12, PS13, PS14, PS15, PS16, PS17, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS26, PS27 and PS28 in that copy to assign a PERI haplotype to the individual.

The nucleic acid used in the above haplotyping methods of the invention may be isolated using any method capable of separating the two copies of the PERI gene or fragment such as one of the methods described above for preparing PERI isogenes, with targeted in vivo cloning being the preferred approach. As will be readily appreciated by those skilled in the art, any individual clone will typically only provide haplotype information on one of the two PERI gene copies present in an individual. If haplotype information is desired for the individual's other copy, additional PERI clones will usually need to be examined. Typically, at least five clones should be examined to have more than a 90% probability of haplotyping both copies of the PERI gene in an individual. In some cases, however, once the haplotype for one PERI allele is directly determined, the haplotype for the other allele may be inferred if the individual has a known genotype for the polymoφhic sites of interest or if the haplotype frequency or haplotype pair frequency for the individual's population group is known. In some embodiments, the PERI haplotype is assigned to the individual by also identifying the nucleotide at PS18. In a particularly preferred embodiment, the nucleotide at each of PS1-PS28 is identified.

In another embodiment, the haplotyping method comprises determining whether an individual has one or more of the PERI haplotypes shown in Table 5. This can be accomplished by identifying, for one or both copies of the individual's PERI gene, the phased sequence of nucleotides present at each of PS1-PS28. This identifying step does not necessarily require that each of PS1-PS28 be directly examined. Typically only a subset of PS1-PS28 will need to be directly examined to assign to an individual one or more of the haplotypes shown in Table 5. This is because at least one polymoφhic site in a gene is frequently in strong linkage disequilibrium with one or more other polymoφhic sites in that gene (Drysdale, CM et al. 2000 PNAS 97:10483-10488; Rieder MJ et al. 1999 Nature Genetics 22:59-62). Two sites are said to be in linkage disequilibrium if the presence of a particular variant at one site enhances the predictability of another variant at the second site (Stephens, JC 1999, Mol. Diag. 4:309-317). Techniques for determining whether any two polymoφhic sites are in linkage disequilibrium are well-known in the art (Weir B.S. 1996 Genetic Data Analysis II, Sinauer Associates, Inc. Publishers, Sunderland, MA). -

In another embodiment of a haplotyping method of the invention, a PERI haplotype pair is determined for an individual by identifying the phased sequence of nucleotides at one or more polymoφhic sites selected from the group consisting of PSl, PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS11, PS12, PS13, PS14, PS15, PS16, PS17, PS19, PS20, PS21, PS22, PS23, PS24, PS25,

PS26, PS27 and PS28 in each copy of the PERI gene that is present in the individual. In a particularly preferred embodiment, the haplotyping method comprises identifying the phased sequence of nucleotides at each of PS1-PS28 in each copy of the PERI gene.

When haplotyping both copies of the gene, the identifying step is preferably performed with each copy of the gene being placed in separate containers. However, it is also envisioned that if the two copies are labeled with different tags, or are otherwise separately distinguishable or identifiable, it could be possible in some cases to perform the method in the same container. For example, if first and second copies of the gene are labeled with different first and second fluorescent dyes, respectively, and an allele-specific oligonucleotide labeled with yet a third different fluorescent dye is used to assay the polymoφhic site(s), then detecting a combination of the first and third dyes would identify the polymoφhism in the first gene copy while detecting a combination of the second and third dyes would identify the polymoφhism in the second gene copy.

In both the genotyping and haplotyping methods, the identity of a nucleotide (or nucleotide pair) at a polymoφhic site(s) may be determined by amplifying a target region(s) containing the polymoφhic site(s) directly from one or both copies of the PERI gene, or a fragment thereof, and the sequence of the amplified region(s) determined by conventional methods. It will be readily appreciated by the skilled artisan that only one nucleotide will be detected at a polymoφhic site in individuals who are homozygous at that site, while two different nucleotides will be detected if the individual is heterozygous for that site. The polymoφhism may be identified directly, known as positive-type identification, or by inference, referred to as negative-type identification. For example, where a SNP is known to be guanine and cytosine in a reference population, a site may be positively determined to be either guanine or cytosine for an individual homozygous at that site, or both guanine and cytosine, if the individual is heterozygous at that site. Alternatively, the site may be negatively determined to be not guanine (and thus cytosine/cytosine) or not cytosine (and thus guanine/guanine).

The target region(s) may be amplified using any oligonucleotide-directed amplification method, including but not limited to polymerase chain reaction (PCR) (U.S. Patent No. 4,965,188), ligase chain reaction (LCR) (Barany et al, Proc. Natl. Acad. Sci. USA 88:189-193, 1991;

WO90/01069), and oligonucleotide ligation assay (OLA) (Landegren et al. Science 241:1077-1080, 1988). Other known nucleic acid amplification procedures may be used to amplify the target region including transcription-based amplification systems (U.S. Patent No. 5,130,238; EP 329,822; U.S. Patent No. 5,169,766, WO89/06700) and isothermal methods (Walker et al, Proc. Natl. Acad. Sci. USA 89:392-396, 1992).

A polymoφhism in the target region may also be assayed before or after amplification using one of several hybridization-based methods known in the art. Typically, allele-specific oligonucleotides are utilized in performing such methods. The allele-specific oligonucleotides may be used as differently labeled probe pairs, with one member of the pair showing a perfect match to one variant of a target sequence and the other member showing a perfect match to a different variant. In some embodiments, more than one polymoφhic site may be detected at once using a set of allele- specifiς oligonucleotides or oligonucleotide pairs. Preferably, the members of the set have melting temperatures within 5°C, and more preferably within 2°C, of each other when hybridizing to each of the polymoφhic sites being detected. Hybridization of an allele-specific oligonucleotide to a target polynucleotide may be performed with both entities in solution, or such hybridization may be performed when either the oligonucleotide or the target polynucleotide is covalently or noncovalently affixed to a solid support. Attachment may be mediated, for example, by antibody-antigen interactions, poly-L-Lys, streptavidin or avidin-biotin, salt bridges, hydrophobic interactions, chemical linkages, UV cross-linking baking, etc. Allele- specific oligonucleotides may be synthesized directly, on the solid support or attached to the solid support subsequent to synthesis. Solid-supports suitable for use in detection methods of the invention include substrates made of silicon, glass, plastic, paper and the like, which may be formed, for example, into wells (as in 96-well plates), slides, sheets, membranes, fibers, chips, dishes, and beads. The solid support may be treated, coated or derivatized. to facilitate the immobilization of the allele- specific oligonucleotide or target nucleic acid.

The genotype or haplotype for the PERI gene of an individual may also be determined by hybridization of a nucleic acid sample containing one or both copies of the gene, mRNA, cDNA or fragment(s) thereof, to nucleic acid arrays and subarrays such as described in WO 95/11995. The arrays would contain a battery of allele-specific oligonucleotides representing each of the polymoφhic sites to be included in the genotype or haplotype.

The identity of polymoφhisms may also be determined using a mismatch detection technique, including but not limited to the RNase protection method using riboprobes (Winter et al, Proc. Natl. Acad. Sci. USA 82:7575, 1985; Meyers et al. Science 230:1242, 1985) and proteins which recognize nucleotide mismatches, such as the E. coli mutS protein (Modrich, P. Ann. Rev. Genet. 25:229-253, 1991). Alternatively, variant alleles can be identified by single strand conformation polymoφhism (SSCP) analysis (Orita et al, Genomics 5:874-879, 1989; Humphries et al, in Molecular Diagnosis of Genetic Diseases, R. Elles, ed, pp. 321-340, 1996) or denaturing gradient gel electrophoresis (DGGE) (Wartell et al, Nucl. Acids Res. 18:2699-2706, 1990; Sheffield et al, Proc. Natl. Acad. Sci. USA 86:232-236, 1989).

A polymerase-mediated primer extension method may also be used to identify the polymoφhism(s). Several such methods have been described in the patent and scientific literature and include the "Genetic Bit Analysis" method (W092/15712) and the ligase/polymerase mediated genetic bit analysis (U.S. Patent 5,679,524. Related methods are disclosed in W091/02087, WO90/09455, W095/17676, U.S. Patent Nos. 5,302,509, and 5,945,283. Extended primers containing a polymoφhism may be detected by mass spectrometry as described in U.S. Patent No. 5,605,798. Another primer extension method is allele-specific PCR (Ruano et al, Nucl. Acids Res. 17:8392, 1989; Ruano et al, Nucl. Acids Res. 19, 6877-6882, 1991; WO 93/22456; Turki et al, J. Clin. Invest.

95:1635-1641, 1995). In addition, multiple polymoφhic sites may be investigated by simultaneously amplifying multiple regions of the nucleic acid using sets of allele-specific primers as described in Wallace et al. (WO89/10414).

In addition, the identity of the allele(s) present at any of the novel polymoφhic sites described herein may be indirectly determined by haplotyping or genotyping another polymoφhic site that is in linkage disequilibrium with the polymoφhic site that is of interest. Polymoφhic sites in linkage disequilibrium with the presently disclosed polymoφhic sites may be located in regions of the gene or in other genomic regions not examined herein. Detection of the allele(s) present at a polymoφhic site in linkage disequilibrium with the novel polymoφhic sites described herein may be performed by, but is not limited to, any of the above-mentioned methods for detecting the identity of the allele at a polymoφhic site.

In another aspect of the invention, an individual's PERI haplotype pair is predicted from its PERI genotype using information on haplotype pairs known to exist in a reference population. In its broadest embodiment, the haplotyping prediction method comprises identifying a PERI genotype for the individual at two or more PERI polymoφhic sites described herein, accessing data containing PERI haplotype pairs identified in a reference population, and assigning a haplotype pair to the individual that is consistent with the genotype data. In one embodiment, the reference haplotype pairs include the PERI haplotype pairs shown in Table 4. The PERI haplotype pair can be assigned by comparing the individual's genotype with the genotypes corresponding to the haplotype pairs known to exist in the general population or in a specific population group, and determining which haplotype pah- is consistent with the genotype of the individual. In some embodiments, comparison of the genotype of the individual to the haplotype pairs identified in a reference population and determination of which haplotype pair is consistent with the genotype of the individual may be performed by visual inspection (for example, by consulting Table 4). When the genotype of the individual is consistent with more than one haplotype pair, haplotype pair frequency data (such as that presented in Table 7) may be used to determine which of these haplotype pairs is most likely to be present in the individual. This determination may also be performed in some embodiments by visual inspection upon consulting Table 7. If a particular PERI haplotype pair consistent with the genotype of the individual is more frequent in the reference population than others consistent with the genotype, then that haplotype pair with the highest frequency is the most likely to be present in the individual. In other embodiments, the comparison may be made by a computer-implemented algorithm with the genotype of the individual and the reference haplotype data stored in computer-readable formats. For example^', as described in PCT/US01/12831, filed April 18, 2001, one computer-implemented algorithm to perform this comparison entails enumerating all possible haplotype pairs which are consistent with the genotype, accessing data containing PERI haplotype pairs frequency data determined in a reference population to determine a probability that the individual has a possible haplotype pair, and analyzing the determined probabilities to assign a haplotype pair to the individual.

Generally, the reference population should be composed of randomly-selected individuals representing the major ethnogeographic groups of the world. A preferred reference population for use in the methods of the present invention comprises an approximately equal number of individuals from Caucasian, African-descent, Asian and Hispanic-Latino population groups with the minimum number of each group being chosen based on how rare a haplotype one wants to be guaranteed to see. For example, if one wants to have a q% chance of not missing a haplotype that exists in the population at a p% frequency of occurring in the reference population, the number of individuals (n) who must be sampled is given by 2n=log(l-q)/log(l-p) where p and q are expressed as fractions. A preferred reference population allows the detection of any haplotype whose frequency is at least 10% with about 99% certainty and comprises about 20 unrelated individuals from each of the four population groups named above. A particularly preferred reference population includes a 3-generation family representing one or more of the four population groups to serve as controls for checking quality of haplotyping procedures.

In a preferred embodiment, the haplotype frequency data for each ethnogeographic group is examined to determine whether it is consistent with Hardy-Weinberg equilibrium. Hardy-Weinberg equilibrium (D.L. Haiti et al. Principles of Population Genomics, Sinauer Associates (Sunderland, MA), 3^rd Ed, 1997) postulates that the frequency of finding the haplotype pair H_l I H₂ is equal to p_H__w(H_l IH₂) = 2p(H_x)p(H₂) if f-/, ≠ H₂ and p_H__w(H H₂) = p(H_λ)p(H₂) if H_λ = H₂ .

A statistically significant difference between the observed and expected haplotype frequencies could be due to one or more factors including significant inbreeding in the population group, strong selective pressure on the gene, sampling bias, and or errors in the genotyping process. If large deviations from

Hardy- Weinberg equilibrium are observed in an ethnogeographic group, the number of individuals in that group can be increased to see if the deviation is due to a sampling bias. If a larger sample size does not reduce the difference between observed and expected haplotype pair frequencies, then one may wish to consider haplotyping the individual using a direct haplotyping method such as, for example, CLASPER System^™ technology (U.S. Patent No. 5,866,404), single molecule dilution, or allele-specific long-range PCR (Michalotos-Beloin et al. Nucleic Acids Res. 24:4841-4843, 1996).

In one embodiment of this method for predicting a PERI haplotype pair for an individual, the assigning step involves performing the following analysis. First, each of the possible haplotype pairs is compared to the haplotype pairs in the reference population. Generally, only one of the haplotype pairs in the reference population matches a possible haplotype pair and that pair is assigned to the individual. Occasionally, only one haplotype represented in the reference haplotype pairs is consistent with a possible haplotype pair for an individual, and in such cases the individual is assigned a haplotype pair containing this known haplotype and a new haplotype derived by subtracting the known haplotype from the possible haplotype pair. Alternatively, the haplotype pair in an individual may be predicted from the individual's genotype for that gene using reported methods (e.g., Clark et al. 1990 Mol Bio Evol 7: 111-22; copending PCT USOl/12831 filed April 18, 2001 ) or through a commercial haplotyping service such as offered by Genaissance Pharmaceuticals, Inc. (New Haven, CT). In rare cases, either no haplotypes in the reference population are consistent with the possible haplotype pairs, or alternatively, multiple reference haplotype pairs are consistent with the possible haplotype pairs. In such cases, the individual is preferably haplotyped using a direct molecular haplotyping method such as, for example, CLASPER System™ technology (U.S. Patent No. 5,866,404), SMD, or allele-specific long-range PCR (Michalotos-Beloin et al, supra).

The invention also provides a method for determimng the frequency of a PERI genotype, haplotype, or haplotype pair in a population. The method comprises, for each member of the population, determining the genotype or the haplotype pair for the novel PERI polymoφhic sites described herein, and calculating the frequency any particular genotype, haplotype, or haplotype pair is found in the population. The population may be e.g., a reference population, a family population, a same gender population, a population group, or a trait population (e.g., a group of individuals exhibiting a trait of interest such as a medical condition or response to a therapeutic treatment).

In another aspect Of the invention, frequency data for PERI genotypes, haplotypes, and/or haplotype pairs are determined in a reference population and used in a method for identifying an association between a trait and a PERI genotype, haplotype, or haplotype pair. The trait may be any detectable phenotype, including but not limited to susceptibility to a disease or response to a treatment. In one embodiment, the method involves obtaining data on the frequency of the genotype(s), haplotype(s), or haplotype pair(s) of interest in a reference population as well as in a population exhibiting the trait. Frequency data for one or both of the reference and trait populations may be obtained by genotyping or haplotyping each individual in the populations using one or more of the methods described above. The haplotypes for the trait population may be determined directly or, alternatively, by a predictive genotype to haplotype approach as described above. In another embodiment, the frequency data for the reference and/or trait populations is obtained by accessing previously determined frequency data, which may be in written or electronic form. For example, the frequency data may be present in a database that is accessible by a computer. Once the frequency data is obtained, the frequencies of the genotype(s), haplotype(s), or haplotype pair(s) of interest in the reference and trait populations are compared. In a preferred embodiment, the frequencies of all genotypes, haplotypes, and/or haplotype pairs observed in the populations are compared. If a particular PERI genotype, haplotype, or haplotype pair is more frequent in the trait population than in the reference population at a statistically significant amount, then the trait is predicted to be associated with that PERI genotype, haplotype or haplotype pair. Preferably, the PERI genotype, haplotype, or haplotype pair being compared in the trait and reference populations is selected from the full- genotypes and full-haplotypes shown in Tables 4 and 5, or from sub-genotypes and sub-haplotypes derived from these genotypes and haplotypes. Sub-genotypes useful in the invention preferably do not include sub-genotypes solely for any one of PS 18 or for any combination thereof. In a preferred embodiment of the method, the trait of interest is a clinical response exhibited by a patient to some therapeutic treatment, for example, response to a drag targeting PERI or response to a therapeutic treatment for a medical condition. As used herein, "medical condition" includes but is not limited to any condition or disease manifested as one or more physical and/or psychological symptoms for which treatment is desirable, and includes previously and newly identified diseases and other disorders. As used herein the term "clinical response" means any or all of the following: a quantitative measure of the response, no response, and/or adverse response (i.e., side effects).

In order to deduce a correlation between clinical response to a treatment and a PERI genotype, haplotype, or haplotype pair, it is necessary to obtain data on the clinical responses exhibited by a population of individuals who received the treatment, hereinafter the "clinical population". This clinical data may be obtained by analyzing the results of a clinical trial that has aheady been run and/or the clinical data may be obtained by designing and carrying out one or more new clinical trials. As used herein, the term "clinical trial" means any research study designed to collect clinical data on responses to a particular treatment, and includes but is not limited to phase I, phase II and phase HI clinical trials. Standard methods are used to define the patient population and to enroll subjects. It is preferred that the individuals included in the clinical population have been graded for the existence of the medical condition of interest. This is important in cases where the symptom(s) being presented by the patients can be caused by more than one underlying condition, and where treatment of the underlying conditions are not the same. An example of this would be where patients experience breathing difficulties that are due to either asthma or respiratory infections. If both sets were treated with an asthma medication, there would be a spurious group of apparent non-responders that did not actually have asthma. These people would affect the ability to detect any correlation between haplotype and treatment outcome. This grading of potential patients could employ a standard physical exam or one or more lab tests. Alternatively, grading of patients could use haplotyping for situations where there is a strong correlation between haplotype pair and disease susceptibility or severity.

The therapeutic treatment of interest is administered to each individual in the trial population and each individual's response to the treatment is measured using one or more predetermined criteria. It is contemplated that in many cases, the trial population will exhibit a range of responses and that the investigator will choose the number of responder groups (e.g., low, medium, high) made up by the various responses. In addition, the PERI gene for each individual in the trial population is genotyped and/or haplotyped, which may be done before or after administering the treatment.

After both the clinical and polymoφhism data have been obtained, correlations between individual response and PERI genotype or haplotype content are created. Correlations may be produced in several ways. In one method, individuals are grouped by their PERI genotype or haplotype (or haplotype pair) (also referred to as a polymoφhism group), and then the averages and standard deviations of clinical responses exhibited by the members of each polymoφhism group are calculated. These results are then analyzed to determine if any observed variation in clinical response between polymoφhism groups is statistically significant. Statistical analysis methods which may be used are described in L.D. Fisher and G. vanBelle, "Biostatistics: A Methodology for the Health Sciences", Wiley-Interscience (New York) 1993. This analysis may also include a regression calculation of which polymoφhic sites in the PERI gene give the most significant contribution to the differences in phenotype. One regression model useful in the invention is described in WO 01/01218, entitled "Methods for Obtaining and Using Haplotype Data".

A second method for finding correlations between PERI haplotype content and clinical responses uses predictive models based on error-minimizing optimization algorithms. One of many possible optimization algorithms is a genetic algorithm (R. Judson, "Genetic Algorithms and Their Uses in Chemistry" in Reviews in Computational Chemistry, Vol. 10, pp. 1-73, K. B. Lipkowitz and D. B. Boyd, eds. (VCH Publishers, New York, 1997). Simulated annealing (Press et al, "Numerical Recipes in C: The Art of Scientific Computing", Cambridge University Press (Cambridge) 1992, Ch. 10), neural networks (E. Rich and K. Knight, "Artificial Intelligence", 2^nd Edition (McGraw-Hill, New York, 1991, Ch. 18), standard gradient descent methods (Press et al, supra, Ch. 10), or other global or local optimization approaches (see discussion in Judson, supra) could also be used. Preferably, the correlation is found using a genetic algorithm approach as described in WO 01/01218.

Correlations may also be analyzed using analysis of variation (ANOVA) techniques to determine how much of the variation in the clinical data is explained by different subsets of the polymoφhic sites in the PERI gene. As described in WO 01/01218, ANOVA is used to test hypotheses about whether a response variable is caused by or correlated with one or more traits or variables that can be measured (Fisher and vanBelle, supra, Ch. 10).

From the analyses described above, a mathematical model may be readily constructed by the skilled artisan that predicts clinical response as a function of PERI genotype or haplotype content. Preferably, the model is validated in one or more follow-up clinical trials designed to test the model. The identification of an association between a clinical response and a genotype or haplotype (or haplotype pair) for the PERI gene may be the basis for designing a diagnostic method to determine those individuals who will or will not respond to the treatment, or alternatively, will respond at a lower level and thus may require more treatment, i.e, a greater dose of a drug. The diagnostic method may take one of several forms: for example, a direct DNA test (i.e., genotyping or haplotyping one or more of the polymoφhic sites in the PERI gene), a serological test, or a physical exam measurement. The only requirement is that there be a good correlation between the diagnostic test results and the underlying PERI genotype or haplotype that is in turn correlated with the clinical response. In a preferred embodiment, this diagnostic method uses the predictive haplotyping method described above.

In another embodiment, the invention provides an. isolated polynucleotide comprising a polymoφhic variant of the PERI gene or a fragment of the gene which contains at least one of the novel polymoφbic sites described herein. The nucleotide sequence of a variant PERI gene is identical to the reference genomic sequence for those portions of the gene examined, as described in the Examples below, except that it comprises a different nucleotide at one or more of the novel polymoφhic sites PSl, PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS11, PS12, PS13, PS14, PS15, PS16, PS17, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS26, PS27 and PS28, and may also comprise an additional polymoφhism of guanine at PS 18. Similarly, the nucleotide sequence of a variant fragment of the PERI gene is identical to the corresponding portion of the reference sequence except for having a different nucleotide at one or more of the novel polymoφhic sites described herein. Thus, the invention specifically does not include polynucleotides comprising a nucleotide sequence identical to the reference sequence of the PERI gene, which is defined by haplotype 15, (or other reported PERI sequences) or to portions of the reference sequence (or other reported PERI sequences), except for the haplotyping and genotyping oligonucleotides described above.

The location of a polymoφhism in a variant PERI gene or fragment is preferably identified by aligning its sequence against SEQ ID NO: 1. The polymoφhism is selected from the group consisting of guanine at PSl, guanine at PS2, thymine at PS3, adenine at PS4, cytosine at PS5, thymine at PS6, cytosine at PS7, thymine at PS8, thymine at PS9, thymine at PS10, guanine at PSl 1, cytosine at PS12, guanine at PS13, cytosine at PS14, cytosine at PS15, cytosine at PS16, thymine at PS17, adenine at PS19, thymine at PS20, cytosine at PS21, adenine at PS22, guanine at PS23, thymine at PS24, guanine at PS25, adenine at PS26, thymine at PS27 and thymine at PS28. In a preferred embodiment, the polymoφhic variant comprises a naturally-occurring isogene of the PERI gene which is defined by any one of haplotypes 1- 14 and 16 - 32 shown in Table 5 below.

Polymoφhic variants of the invention may be prepared by isolating a clone containing the PERI gene from a human genomic library. The clone may be sequenced to determine the identity of the nucleotides at the novel polymoφhic sites described herein. Any particular variant or fragment thereof, that is claimed herein could be prepared from this clone by performing in vitro mutagenesis using procedures well-known in the art. Any particular PERI variant or fragment thereof may also be prepared using synthetic or semi-synthetic methods known in the art. PERI isogenes, or fragments thereof, may be isolated using any method that allows separation of the two "copies" of the PERI gene present in an individual, which, as readily understood by the skilled artisan, may be the same allele or different alleles. Separation methods include targeted in vivo cloning (TIVC) in yeast as described in WO 98/01573*, U.S. Patent No. 5,866,404, and U.S. Patent No. 5,972,614. Another method, which is described in U.S. Patent No. 5,972,614, uses an allele specific oligonucleotide in combination with primer extension and exonuclease degradation to generate hemizygous DNA targets. Yet other methods are single molecule dilution (SMD) as described in Ruano et al, Proc. Natl. Acad. Sci. 87:6296-6300, 1990; and allele specific PCR (Ruano et al, 1989, supra; Ruano et al, 1991, supra; Michalatos-Beloin et al, supra).

The invention also provides PERI genome anthologies, which are collections of at least two PERI isogenes found in a given population. The population may be any group of at least two individuals, including but not limited to a reference population, a population group, a family population, a clinical population, and a same gender population. A PERI genome anthology may comprise individual PERI isogenes stored in separate containers such as microtest tubes, separate wells of a microtitre plate and the like. Alternatively, two or more groups of the PERI isogenes in the anthology may be stored in separate containers.- Individual isogenes or groups of such isogenes in a genome anthology may be stored in any convenient and stable form, including but not limited to in buffered solutions, as DNA precipitates, freeze-dried preparations and the like. A preferred PERI genome anthology of the invention comprises a set of isogenes defined by the haplotypes shown in Table 5 below. A PERI genome anthology is useful in providing control nucleic acids for kits of the invention.

An isolated polynucleotide containing a polymoφhic variant nucleotide sequence of the invention may be operably linked to one or more expression regulatory elements in a recombinant expression vector capable of being propagated and expressing the encoded PERI protein in a prokaryotic or a eukaryotic host cell. Examples of expression regulatory elements which may be used include, but are not limited to, the lac system, operator and promoter regions of phage lambda, yeast promoters, and promoters derived from vaccinia virus, adenovirus, retroviruses, or SV40. Other regulatory elements include, but are not limited to, appropriate leader sequences, termination codons, polyadenylation signals, and other sequences required for the appropriate transcription and subsequent translation of the nucleic acid sequence in a given host cell. Of course, the correct combinations of expression regulatory elements will depend on the host system used. In addition, it is understood that the expression vector contains any additional elements necessary for its transfer to and subsequent replication in the host cell. Examples of such elements include, but are not limited to, origins of replication and selectable markers. Such expression vectors are commercially available or are readily constructed using methods known to those in the art (e.g., F. Ausubel et al, 1987, in "Current Protocols in Molecular Biology", John Wiley and Sons, New York, New York). Host cells which may be used to express the variant PERI sequences of the invention include, but are not limited to, eukaryotic and mammalian cells, such as animal, plant, insect and yeast cells, and prokaryotic cells, such as E. coli, or algal cells as known in the art. The recombinant expression vector may be introduced into the host cell using any method known to those in the art including, but not limited to, microinjection, electroporation, particle bombardment, transduction, and transfection using DEAE- dextran, lipofection, or calcium phosphate (see e.g., Sambrook et al. (1989) in "Molecular Cloning. A Laboratory Manual", Cold Spring Harbor Press, Plainview, New York). In a preferred aspect, eukaryotic expression vectors that function in eukaryotic cells, and preferably mammalian cells, are used. Non-limiting examples of such vectors include vaccinia virus vectors, adenovirus vectors, heφes virus vectors, and baculovirus transfer vectors. Preferred eukaryotic cell lines include COS cells, CHO cells, HeLa cells, NTH/3T3 cells, and embryonic stem cells (Thomson, J. A. et al, 1998 Science 282:1145-1147). Particularly preferred host cells are mammalian cells.

As will be readily recognized by the skilled artisan, expression of polymoφhic variants of the PERI gene will produce PERI mRNAs varying from each other at any polymoφhic site retained in the spliced and processed mRNA molecules. These mRNAs can be used for the preparation of a PERI cDNA comprising a nucleotide sequence which is a polymoφhic variant of the PERI reference coding sequence shown in Figure 2. Thus, the invention also provides PERI mRNAs and corresponding cDNAs which comprise a nucleotide sequence that is identical to SEQ ID NO:2 (Fig. 2), or its corresponding RNA sequence, for those regions of SEQ ID NO:2 that correspond to the examined portions of the PERI gene (as described in the Examples below), except for having one or more polymoφhisms selected from the group consisting of thymine at a position corresponding to nucleotide 109, thymine at a position corresponding to nucleotide 135, guanine at a position corresponding to nucleotide 297, cytosine at a position corresponding to nucleotide 639, adenine at a position corresponding to nucleotide 1521, thymine at a position corresponding to nucleotide 1542, cytosine at a position corresponding to nucleotide 1763, adenine at a position corresponding to nucleotide 2055, thymine at a position corresponding to nucleotide 2247, guanine at a position corresponding to nucleotide 2361 , adenine at a position corresponding to nucleotide 2459 and thymine at a position corresponding to nucleotide 3834. A particularly preferred polymoφhic cDNA variant comprises the coding sequence of a PERI isogene defined by any one of haplotypes 1-11, 13, 14, 17, 19-21, and 23-32. Fragments of these variant mRNAs and cDNAs are included in the scope of the invention, provided they contain one or more of the novel polymoφhisms described herein. The invention specifically excludes polynucleotides identical to previously identified and characterized PERI mRNAs, cDNAs or fragments thereof. Polynucleotides comprising a variant PERI RNA or DNA sequence may be isolated from a biological sample using well-known molecular biological procedures or may be chemically synthesized.

As used herein, a polymoφhic variant of a PERI gene, mRNA or cDNA fragment comprises at least one novel polymoφhism identified herein and has a length of at least 10 nucleotides and may range up to the full length of the gene. Preferably, such fragments are between 100 and 3000 nucleotides in length, and more preferably between 200 and 2000 nucleotides in length, and most preferably between 500 and 1000 nucleotides in length.

In describing the PERI polymoφhic sites identified herein, reference is made to the sense strand of the gene for convenience. However, as recognized by the skilled artisan, nucleic acid molecules containing the PERI gene or cDNA may be complementary double stranded molecules and thus reference to a particular site on the sense strand refers as well to the corresponding site on the complementary antisense strand. Thus, reference may be made to the same polymoφhic site on either strand and an oligonucleotide may be designed to hybridize specifically to either strand at a target region containing the polymoφhic site. Thus, the invention also includes single-stranded polynucleotides which are complementary to the sense strand of the PERI genomic, mRNA and cDNA variants described herein.

Polynucleotides comprising a polymoφhic gene variant or fragment of the invention may be useful for therapeutic puφoses. For example, where a patient could benefit froni expression, or increased expression, of a particular PERI protein isoform, an expression vector encoding the isoform may be administered to the patient. The patient may be one who lacks the PERI isogene encoding that isoform or may aheady have at least one copy of that isogene.

In other situations, it may be desirable to decrease or block expression of a particular PERI isogene. Expression of a PERI isogene may be turned off by transforming a targeted organ, tissue or cell population with an expression vector that expresses high levels of untranslatable mRNA or antisense RNA for the isogene or fragment thereof. Alternatively, oligonucleotides directed against the regulatory regions (e.g., promoter, introns, enhancers, 3' untranslated region) of the isogene may block transcription. Oligonucleotides targeting the transcription initiation site, e.g., between positions -10 and +10 from the start site are preferred. Similarly, inhibition of transcription can be achieved using oligonucleotides that base-pair with region(s) of the isogene DNA to form triplex DNA (see e.g., Gee et al. in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co, Mt. Kisco, N.Y, 1994). Antisense oligonucleotides may also be designed to block translation of PERI mRNA transcribed from a particular isogene. It is also contemplated that ribozymes may be designed that can catalyze the specific cleavage of PERI mRNA transcribed from a particular isogene.

The untranslated mRNA, antisense RNA or antisense oligonucleotides may be delivered to a target cell or tissue by expression from a vector introduced into the cell or tissue in vivo or ex vivo. Alternatively, such molecules may be formulated as a pharmaceutical composition for administration to the patient. Oligoribonucleotides and/or oligodeoxynucleotides intended for use as antisense oligonucleotides may be modified to increase stability and half-life. Possible modifications include, but are not limited to phosphorothioate or 2' O-methyl linkages, and the inclusion of nontraditional bases such as inosine and queosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytosine, guanine, thymine, and uracil which are not as easily recognized by endogenous nucleases. The invention also provides an isolated polypeptide comprising a polymoφhic variant of (a) the reference PERI amino acid sequence shown in Figure 3 or (b) a fragment of this reference sequence. The location of a variant amino acid in a PERI polypeptide or fragment of the invention is identified by aligning its sequence against SEQ ID NO:3 (Fig. 3). A PERI protein variant of the invention comprises an amino acid sequence identical to SEQ ID NO: 3 for those regions of SEQ ID NO:3 that are encoded by examined portions of the PERI gene (as described in the Examples below), except for having one or more variant amino acids selected from the group consisting of serine at a position corresponding to amino acid position 37, proline at a position corresponding to amino acid position 588 and glutamine at a position corresponding to amino acid position 820. Thus, a PERI fragment of the invention, also referred to herein as a PERI peptide variant, is any fragment of a PERI protein variant that contains one or more of the amino acid variations shown in Table 2. The invention specifically excludes amino acid sequences identical to those previously identified for PERI, including SEQ ID NO:3, and previously described fragments thereof. PERI protein variants included within the invention comprise all amino acid sequences based on SEQ ID NO:3 and having the combination of amino acid variations described in Table 2 below. In preferred embodiments, a PERI protein variant of the invention is encoded by an isogene defined by one of the observed haplotypes, 1-11, 13, 14, 17, 19-21, and 23-32, shown in Table 5.

Table 2. Novel Polymoφhic Variants of PERI

Polymoφhic Amino Acid I Ositio

Variant

Number 37 ^' 588 820

1 P L Q

2 P P R

3 P P Q

4 S L R

5 S L Q

6 S P R

7 S P Q

A PERI peptide variant of the invention is at least 6 amino acids in length and is preferably any number between 6 and 30 amino acids long, more preferably between 10 and 25, and most preferably between 15 and 20 amino acids long. Such PERI peptide variants may be useful as antigens to generate antibodies specific for one of the above PERI isoforms. In addition, the PERI peptide variants may be useful in drug screening assays.

A PERI variant protein or peptide of the invention may be prepared by chemical synthesis or by expressing an appropriate variant PERI genomic or cDNA sequence described above. Alternatively, the PERI protein variant may be isolated from a biological sample of an individual having a PERI isogene which encodes the variant protein. Where the sample contains two different PERI isoforms (i.e, the individual has different PERI isogenes), a particular PERI isoform of the invention can be isolated by immunoaffinity chromatography using an antibody which specifically binds to that particular PERI isoform but does not bind to the other PERI isoform.

The expressed or isolated PERI protem or peptide may be detected by methods known in the art, including Coomassie blue staining, silver staining, and Western blot analysis using antibodies specific for the isoform of the PERI protein or peptide as discussed further below. PERI variant proteins and peptides can be purified by standard protein purification procedures known in the art, including differential precipitation, molecular sieve chromatography, ion-exchange chromatography, isoelectric focusing, gel electrophoresis, affinity and inαmunoaffinity chromatography and the like. (Ausubel et. al, 1987, In Current Protocols in Molecular Biology John Wiley and Sons, New York, New York). In the case of inimunoaffinity chromatography, antibodies specific for a particular polymoφhic variant may be used. A polymoφhic variant PERI gene of the invention may also be fused in frame with a heterologous sequence to encode a chimeric PERI protein. The non-PERl portion of the chimeric protein may be recognized by a commercially available antibody. In addition, the chimeric protein may also be engineered to contain a cleavage site located between the PERI and non-PERl portions so that the PERI protein may be cleaved and purified away from the non-PERl portion. An additional embodiment of the invention relates to using a novel PERI protein isoform, or a fragment thereof, in any of a variety of drag screening assays. Such screening assays may be performed to identify agents that bind specifically to all known PERI protein isoforms or to only a subset of one or more of these isoforms. The agents may be from chemical compound libraries, peptide libraries and the like. The PERI protein or peptide variant may be free in solution or affixed to a solid support. In one embodiment, high throughput screening of compounds for binding to a PERI variant may be accomplished using the method described in PCT application WO84/03565, in which large numbers of test compounds are synthesized on a solid substrate, such as plastic pins or some other surface, contacted with the PERI protein(s) of interest and then washed. Bound PERI protein(s) are then detected using methods well-known in the art. In another embodiment, a novel PERI protein isoform may be used in assays to measure the binding affinities of one or more candidate drugs targeting the PERI protein.

In yet another embodiment, when a particular PERI haplotype or group of PERI haplotypes encodes a PERI protein variant with an amino acid sequence distinct from that of PERI protein isoforms encoded by other PERI haplotypes, then detection of that particular PERI haplotype or group of PERI haplotypes may be accomplished by detecting expression of the encoded PERI protein variant using any of the methods described herein or otherwise commonly known to the skilled artisan. In another embodiment, the invention provides antibodies specific for and immunoreactive with one or more of the novel PERI variant proteins described herein. The antibodies may be either monoclonal or polyclonal in origin. The PERI protein or peptide variant used to generate the antibodies may be from natural or recombinant sources or produced by chemical synthesis using synthesis techniques known in the art. If the PERI protein variant is of insufficient size to be antigenic, it may be conjugated, complexed, or otherwise covalently linked to a carrier molecule to enhance the antigenicity of the peptide. Examples of carrier molecules, include, but are not limited to, albumins (e.g., human, bovine, fish, ovine), and keyhole limpet hemocyanin (Basic and Clinical Immunology, 1991, Eds. D.P. Stites, and A.I. Terr, Appleton and Lange, Norwalk Connecticut, San - Mateo, California). In one embodiment, an antibody specifically immunoreactive with one of the novel protein isoforms described herein is administered to an individual to neutralize activity of the PERI isoform expressed by that individual. The antibody may be formulated as a pharmaceutical composition which includes a pharmaceutically acceptable carrier.

Antibodies specific for and immunoreactive with one of the novel protein isoforms described herein may be used to immunoprecipitate the PERI protein variant from solution as well as react with PERI protein isoforms on Western or immunoblots of polyacrylamide gels on membrane supports or substrates. In another preferred embodiment, the antibodies will detect PERI protein isoforms in paraffin or frozen tissue sections, or in cells which have been fixed or unfixed and prepared on slides, coverslips, or the like, for use in immunocytochemical, immunohistochemical, and immunofluorescence techniques.

In another embodiment, an antibody specifically immunoreactive with one of the novel PERI protein variants described herein is used in immunoassays to detect this variant in biological samples. In this method, an antibody of the present invention is contacted with a biological sample and the formation of a complex between the PERI protein variant and the antibody is detected. As described, suitable immunoassays include radioimmunoassay, Western blot assay, immunofluorescent assay, enzyme linked immunoassay (ELISA), chemiluminescent assay, immunohistochemical assay, immunocytochemical assay, and the like (see, e.g., Principles and Practice of Immunoassay, 1991, Eds. Christopher P. Price and David J. Neoman, Stockton Press, New York, New York; Current Protocols in Molecular Biology, 1987, Eds. Ausubel et al, John Wiley and Sons, New York, New York). Standard techniques known in the art for ELISA are described in Methods in Immunodiagnosis, 2nd Ed, Eds. Rose and Bigazzi, John Wiley and Sons, New York 1980; and Campbell et al, 1984, Methods in Immunology, W.A. Benjamin, Inc.). Such assays may be direct, indirect, competitive, or noncompetitive as described in the art (see, e.g., Principles and Practice of Immunoassay, 1991, Eds. Christopher P. Price and David J. Neoman, Stockton Pres, NY, NY; and Oellirich, M, 1984, J. Clin. Chem. Clin. Biochem, 22:895-904). Proteins may be isolated from test specimens and biological samples by conventional methods, as described in Current Protocols in Molecular Biology, supra. Exemplary antibody molecules for use in the detection and therapy methods of the present invention are intact immunoglobulin molecules, substantially intact immunoglobulin molecules, or those portions of immunoglobulin molecules that contain the antigen binding site. Polyclonal or monoclonal antibodies may be produced by methods conventionally known in the art (e.g., Kohler and Milstein, 1975, Nature, 256:495-497; Campbell Monoclonal Antibody Technology, the Production and Characterization of Rodent and Human Hybridomas, 1985, In: Laboratory Techniques in Biochemistry and Molecular Biology, Eds. Burdon et al. Volume 13, Elsevier Science Publishers, Amsterdam). The antibodies or antigen binding fragments thereof may also be produced by genetic engineering. The technology for expression of both heavy and light chain genes in E. coli is the subject of PCT patent applications, publication number WO 901443, WO 901443 and WO 9014424 and in Huse et al, 1989, Science, 246:1275-1281. The antibodies may also be humanized (e.g., Queen, C. et al. 1989 Proc. Natl. Acad. Sci.USA 86; 10029).

Effect(s) of the polymoφhisms identified herein on expression of PERI may be investigated by preparing recombinant cells and/or nonhuman recombinant organisms, preferably recombinant animals, containing a polymoφhic variant of the PERI gene. As used herein, "expression" includes but is not limited to one or more of the following: transcription of the gene into precursor mRNA; splicing and other processing of the precursor mRNA to produce mature mRNA; mRNA stability; translation of the mature mRNA into PERI protein (including codon usage and tRNA availability); and glycosylation and or other modifications of the translation product, if required for proper expression and function. To prepare a recombinant cell of the invention, the deshed PERI isogene may be introduced into the cell in a vector such that the isogene remains extrachromosomal. In such a situation, the gene will be expressed by the cell from the extrachromosomal location. In a preferred embodiment, the PERI isogene is introduced into a cell in such a way that it recombines with the endogenous PERI gene present in the cell. Such recombination requires the occurrence of a double recombination event, thereby resulting in the deshed PERI gene polymoφhism. Vectors for the introduction of genes both for recombination and for extrachromosomal maintenance are known in the art, and any suitable vector or vector construct may be used in the invention. Methods such as electroporation, particle bombardment, calcium phosphate co-precipitation and viral transduction for introducing DNA into cells are known in the art; therefore, the choice of method may lie with the competence and preference of the skilled practitioner. Examples of cells into which the PERI isogene may be introduced include, but are not limited to, continuous culture cells, such as COS, NTH 3T3, and primary or culture cells of, the relevant tissue type, i.e, they express the PERI isogene. Such recombinant cells can be used to compare the biological activities of the different protein variants.

Recombinant nonhuman organisms, i.e, transgenic animals, expressing a variant PERI gene are prepared using standard procedures known in the art. Preferably, a construct comprising the variant gene is introduced into a nonhuman animal or an ancestor of the animal at an embryonic stage, i.e, the one-cell stage, or generally not later than about the eight-cell stage. Transgenic animals carrying the constructs of the invention can be made by several methods known to those having skill in the art. One method involves transfecting into the embryo a refrovirus constructed to contain one or more insulator elements, a gene or genes of interest, and other components known to those skilled in the art to provide a complete shuttle vector harboring the insulated gene(s) as a transgene, see e.g., U.S. Patent No. 5,610,053. Another method involves dhectly injecting a transgene into the embryo. A third method involves the use of embryonic stem cells.^" Examples of animals into which the PERI isogenes may be introduced include, but are not limited to, mice, rats, other rodents, and nonhuman primates (see "The Introduction of Foreign Genes into Mice" and the cited references therein, In: Recombinant DNA, Eds, JD. Watson, M. Gilman, J. Witkowski, and M. Zoller; W.H. Freeman and Company, New York, pages 254-272). Transgenic animals stably expressing a human PERI isogene and producing the encoded human PERI protein can be used as biological models for studying diseases related to abnormal PERI expression and or activity, and for screening and assaying various candidate drags, compounds, and treatment regimens to reduce the symptoms or effects of these diseases. An additional embodiment of the invention relates to pharmaceutical compositions for treating disorders affected by expression or function of a novel PERI isogene described herein. The pharmaceutical composition may comprise any of the following active ingredients: a polynucleotide comprising one of these novel PERI isogenes; an antisense oligonucleotide directed against one of the novel PERI isogenes, a polynucleotide encoding such an antisense oligonucleotide, or another compound which inhibits expression of a novel PERI isogene described herein. Preferably, the composition contains the active ingredient in a therapeutically effective amount. By therapeutically effective amount is meant that one or more of the symptoms relating to disorders affected by expression or function of a novel PERI isogene is reduced and/or eliminated. The composition also comprises a pharmaceutically acceptable carrier, examples of which include, but are not limited to, saline, buffered saline, dextrose, and water. Those skilled in the art may employ a formulation most suitable for the active ingredient, whether it is a polynucleotide, oligonucleotide, protein, peptide or small molecule antagonist. The pharmaceutical composition may be administered alone or in combination with at least one other agent, such as a stabilizing compound. Administration of the pharmaceutical composition may be by any number of routes including, but not limited to oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, intradermal, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co, Easton, PA).

For any composition, determination of the therapeutically effective dose of active ingredient and/or the appropriate route of administration is well within the capability of those skilled in the art. For example, the dose can be estimated initially either in cell culture assays or in animal models. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. The exact dosage will be determined by the practitioner, in light of factors relating to the patient requiring treatment, including but not limited to severity of the disease state, general health, age, weight and gender of the patient, diet, time and frequency of administration, other drugs being taken by the patient, and tolerance/response to the treatment.

Any or all analytical and mathematical operations involved in practicing the methods of the present invention may be implemented by a computer. In addition, the computer may execute a program that generates views (or screens) displayed on a display device and with which the user can interact to view and analyze large amounts of information relating to the PERI gene and its genomic variation, including chromosome location, gene structure, and gene family, gene expression data, polymoφhism data, genetic sequence data, and clinical data population data (e.g., data on ethnogeographic origin, clinical responses, genotypes, and haplotypes for one or more populations). The PERI polymoφhism data described herein may be stored as part of a relational database (e.g., an instance of an Oracle database or a set of ASCII flat files). These polymoφhism data may be stored on the computer's hard drive or may, for example, be stored on a CD-ROM or on one or more other storage devices accessible by the computer. For example, the data may be stored on one or more databases in communication with the computer via a network.

Preferred embodiments of the invention are described in the following examples. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims which follow the examples.

EXAMPLES The Examples herein are meant to exemplify the various aspects of carrying out the invention and are not intended to limit the scope of the invention in any way. The Examples do not include detailed descriptions for conventional methods employed, such as in the performance of genomic DNA isolation, PCR and sequencing procedures. Such methods are well-known to those skilled in the art and are described in numerous publications, for example, Sambrook, Fritsch, and Maniatis, "Molecular Cloning: A Laboratory Manual", 2^nd Edition, Cold Spring Harbor Laboratory Press, USA, (1989).

EXAMPLE 1 This example illustrates examination of various regions of the PERI gene for polymoφhic sites.

Amplification of Target Regions

The following target regions of the PERI gene were amplified using PCR primer pairs. The primers used for each region are represented below by providing the nucleotide positions of their initial and final nucleotides, which correspond to positions in SEQ XD NO:l (Figure 1).

PCR Primer Pahs

Fragment ] "orward Primer Reverse Primer PCR Product

Fragment 1 1649 - 1669 complement of 2237 - ^■ 2217 589 nt

Fragment 2 1917 - 1938 complement of 2511 - ■ 2490 595 nt

Fragment 3 3713 - 3735 complement of 4212 - ■ 4192 500 nt

Fragment- 4 3889 - 3911 complement of 4461 - ■ 4441 573 nt

Fragment 5 4171 - 4193 complement of 4780 ■ - 4758 610 nt

Fragment 6 4412 - 4433 complement of 4940 - - 4919 529 nt

Fragment 7 4634 - 4657 complement of 5127 ■ - 5107 494 nt

Fragment 8 4848 - 4870 complement of 5421 ■ - 5400 574 nt

Fragment 9 6261 - 6284 complement of 6728 ■ - 6707 468 nt

Fragment 10 6449 - 6470 complement of 6911 • - 6889 463 nt

Fragment 11 6716 - 6741 complement of 7280 - - 7259 565 nt

Fragment 12 6932 - 6953 complement of 7499 - - 7477 568 nt

Fragment 13 7126 - 7151 complement of 7721 - 7701 596 nt

Fragment 14 7579 - 7600 complement of 8018 - 7998 440 nt

Fragment 15 7777 - 7800 complement of 8286 - 8264 510 nt

Fragment 16 8084 - 8104 complement of 8539 - 8517 456 nt

Fragment 17 8412 - 8434 complement of 9023 - 9002 612 nt

Fragment 18 9580 - 9601 complement of 10067 ■ - 10044 488 nt

Fragment 19 9654 - 9675 complement of 10151 • - 10131 498 nt

Fragment 20 11040 - 11063 complement of 11638 - - 11616 599 nt

Fragment 21 11734 - 11756 complement of 12310 - 12287 577 nt

Fragment 22 12067 - 12089 complement of 12662 - 12638. 596 nt

Fragment 23 12536 - 12558 complement of ^• 13076 - 13054 541 nt

Fragment 24 13199 - 13221 complement of 13715 - 13690 517 nt

Fragment 25 13445 - 13467 complement of 13976 - 13955 532 nt

These primer pahs were used in PCR reactions containing genomic DNA isolated from immortalized cell lines for each member of the Index Repository. The PCR reactions were carried out under the following conditions:

Reaction volume 10 μl

10 x Advantage 2 Polymerase reaction buffer (Clontech) l μl

100 ng of human genomic DNA l μl

10 mM dNTP 0.4 μl

Advantage 2 Polymerase enzyme mix (Clontech) 0.2 μl

Forward Primer (10 μM) 0.4 μl

Reverse Primer (10 μM) 0.4 μl

Water 6.6μl

Amplification profile: 97°C - 2 min. 1 cycle

97°C - 15 sec. 70°C - 45 sec. 10 cycles 72°C - 45 sec. 35 cycles

Sequencing of PCR Products

The PCR products were purified using a Whatman/Polyfiltronics 100 μl 384 well unifilter plate essentially according to the manufacturers protocol. The purified DNA was eluted in 50 μl of distilled water. Sequencing reactions were set up using Applied Biosystems Big Dye Terminator chemistry essentially according to the manufacturers protocol. The purified PCR products were sequenced in both directions using the primer sets described previously or those represented below by the nucleotide positions of theh initial and final nucleotides, which correspond to positions in SEQ ID NO: 1 (Figure 1). Reaction products were purified by isopropanol precipitation, and run on an Applied Biosystems 3700 DNA Analyzer.

Sequencing Primer Pahs

Fragment Forward Primer Reverse primer

Fragment 1 1671 - 1690 complement of 2213- 2194

Fragment 2 1969- 1988 complement of 2468- 2449

Fragment 3 3762- 3781 complement of 4185- 4166

Fragment 4 3977- 3996 complement of 4435- 4416

Fragment5 4261 - 4280 complement of 4672- 4651

Fragment 6 4480 - 4498 complement of 4886 - 4867

Fragment 7 4729- 4748 complement of 5101 - 5082

Fragment 8 4935- 4954 complement of 5390- 5371

Fragment 9 6317- 6336 complement of 6695- 6676

Fragment 10 6498- 6517 complement of 6851 - 6832

Fragment 11 6780- 6799 complement of 7214- 7195

Fragment 12 7032- 7050 complement of 7450- 7431

Fragment 13 7219- 7239 complement of 7617- 7598

Fragment 14 7604 - 7623 complement of 7982 - 7963

Fragment 15 7824 - 7843 complement of 8261 - 8242

Fragment 16 8106- 8125 complement of 8512- 8493

Fragment 17 8466 - 8486 complement of 8928 - 8909

Fragment 18 9609- 9627 complement of 9962- 9943

Fragments 9687- 9707 complement of 10108- 10089

Fragment 20 11175 - 11194 complement of 11601 - 11580

Fragment 21 11769- 11788 complement of 12209- 12190

Fragment 22 12147- 12166 complement of 12590- 12572

Fragment 23 12637- 12656 complement of 13050- 13031

Fragment 24 13255 - 13274 complement of 13688 - 13669

Fragment 25 13476- 13494 complement of 13922- 13901

Analysis of Sequences for Polymorphic Sites

Sequence information for a minimum of 80 humans was analyzed for the presence of polymoφhisms using the Polyphred program (Nickerson et al. Nucleic Acids Res.14:2745-2751 , 1997). The presence of a polymoφhism was confirmed on both strands. The polymoφhisms and theh locations in the PERI reference genomic sequence (SEQ JD NO:l) are listed in Table 3 below.

Table 3. Polymoφhic Sites Identified in the PERI Gene

Polymoφhic Nucleotide Reference Variant CDS Variant AA

Site Number Polyk Position Allele Allele Position Variant

PSl 2856366 1967 C G

PS2 * 2856364 1979 T G

PS3 2856362 2048 G T

PS4 2856360 2218 G A

PS5 2856358 2324 T C

PS6 2856352 3830 C - T

PS7 2856350 3833 T C

PS8 2856344 3973 C T

PS9 2856342 4131 C T 109 P37S

PS10 2856340 4157 C T 135 T45T

PS11 2856336 4314 A G

PS12 2856332 4365 T C

PS13 2856330 - 4433 C G 297 S99S

PS14 2856324 4962 A C 639 T213T

PS15 2856312 6408 T C

PS16 2856306 7068 T C

PS17 2856302 7116 C T

PS18^R - 2856294 7310 C G

PS19 2856292 7371 G A 1521 T507T

PS20 2856288 7392 C T 1542 A514A

PS21 2856282 7991 T C 1763 L588P

PS22 2856262 8608 G A 2055 A685A

PS23 2856246 965.6 A G

PS24 2856242 9764 C T 2247 ' G749G

PS25 2856240 9878 A G 2361 T787T

PS26 2856238 9976 G A 2459 R820Q

PS27 2856226 12132 C T

PS28 2856214 13622 C T 3834 S1278S a 'P- olyld is a unique identifier assigned to each PS by Genaissance Pharmaceuticals, Inc. ^RPreviously identified in literature

EXAMPLE 2

This example illustrates analysis of the PERI polymoφhisms identified in the Index Repository for human genotypes and haplotypes.

The different genotypes containing these polymoφhisms that were observed in unrelated members of the reference population are shown in Table 4 below, with the haplotype pah indicating the combmation of haplotypes determined for the individual using the haplotype derivation protocol described below. In Table 4, homozygous positions are indicated by one nucleotide and heterozygous positions are indicated by two nucleotides. Missing nucleotides in any given genotype in Table 4 were inferred based on linkage disequilibrium and or Mendelian inheritance. t t

SJΛ o o o

J--3 ι-3 ι-3

H H H ^ H ^ H H H H \ ι-3 H H H

Ω Ω Ω

Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω

H H H H H :-3 H H .****3 H H

Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω

Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω

Ω h-> tπ

3

^•^ d^ co co co co co co cυ co cυ co ro [ t to O t to t to t I-¹ -¹ h-> P H μ μ ω ω i en cπ its. co to i-¹ &

H O lS CO vl ffi ai i^ M H O U) ∞ ~ σi ui *> co ιv> μ-> o ID co ~j m oi ^ co to μ-> o CD

i-3

Ω

ι-3

Ω

ι-3

Ω

Ω

ΩΩΏΏΏΩΏΏΩΏΏΩ

Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω

μ-> μ-> μ-> -¹ π ι-^>. 1 cπ l-¹

μ μ->

Table 4 (Part3) . Genotypes and Haplotype Pairs Observed for PERI Gene

Genotype Polymorphic Sites Number PS21 PS22 P.S23 PS24 PS25 PS26 PS27 PS28 HAP Pair 1 T ..G A T G G C C 7 7

2 * T G A T G G C C 17 17

3 T G A C A G C C 15 15

4 T G A T G G C C 26 26

5 - T G A T G G C C* 11 19 6 G A T G' G C C 7 2

7 T G A T/C G/A G C C 17 30

8 T G A T G G C C 17 26

9 ■ T G A C/T A/G G C C 15 4

10 T ^' G A T/C G/A G C C 17 10 11 T G A C . A G C C 15 22

12 T G A C/T A/G G C C 15 28

^• 13 T G A T G ^' G C C 11 25

14 T G A C A A C C 6 29

15 T G A T G G C C 17- 3 16 T G A T/C G/A G C C 7 27

17 T G A T G G C C 7 8

18 T G A T/C G/A G C/T C -17 14 .19 T G A T G G C- C 17 28

20 T_, G A C A G C C 15 16 21 T G A T G G C C 17 7

22 ^' T G A^' T/C G/A G C C 7 13

23 T G A T/C G/A G C C 17 23

24 T G A C A G C C 16 21

25 T G A C A G C C 15 18 26. T G ^• A C/T A/G G C . C 30 26

27 T G A ^• - T/C G/A G C C 17 9

28 T G/A A C A G C C/T 16 32

29 ^• T G ■ A T/C G/A G* C C 17 1

30 T G A T/C G/A G C C 17 20 31 T G A C/T A/G G C C 15 . 7

32 T G A T G G C C 17 11

33 T G A T/C G/A G C C 17 ' 31

34 T G A T/C G/A O C C 11 30

35 T G A T/C G/A G C C 17 12 36 T G A T G G C C 11 7 ^'

37 T G A C A G C C 15 30

38 T G A T G G C C 17 5

39 T G A T/C G/A G C C 17 15

40 T G A . T- G G ^• C C 11* 24 ^' 41 T G A C/T A/G G C C 15 11

The haplotype pahs shown in Table 4 were estimated from the unphased genotypes using a computer-implemented extension of Clark's algorithm (Clark, A.G.1990 Mol Bio Evol 1, 111-122) for assigning haplotypes to unrelated individuals in a population sample, as described in PCTUS01/12831, filed April 18, 2001. In this method, haplotypes are assigned directly from individuals who are homozygous at all sites or heterozygous at no more than one of the variable sites. This list of haplotypes is then used to deconvolute the unphased genotypes in the remaining (multiply heterozygous) individuals. In the present analysis, the list of haplotypes was augmented with haplotypes obtained from two families (one three-generation Caucasian family and one two-generation African- American family).

By following this protocol, it was determined that the Index Repository examined herein and, by extension, the general population contains the 32 human PERI haplotypes shown in Table 5 below.

A PERI isogene defined by a full-haplotype shown in Table 5 below comprises the regions of the SEQ ID NOS indicated in Table 5, with theh corresponding set of polymoφhic locations and identities, which are also set forth in Table 5.

Table 5. Haplotypes of the PERI Gene

Haplotype . Number³ (Part A) PS' PS SEQ ID Region

1 2 3 4 5 6 7 8 9 10 No.^b Position⁰ No.^d Examined⁶

C C C C C C C C C C 1 1967/30 1/139 1649-2511

G G T T T T T T T T 2 1979/150 1/139 1649-2511

T T G G G G G G G G 3 2048/270 1/139 1649-2511

G G A G G G G G G G 4 2218/390 1/139 1649-2511

T T T C C C C C T T 5' 2324/510 1/139 1649-2511 c C C C C C C C C C 6 3830/630 1/139 3713-5421

T T T T T T T T C c ^• 7 3833/750 1/139 3713-5421 c C C C C c C ^• C C C 8 3973/870 1/139 3713-5421 c C C C C c C C C C 9 4131/990 1/139 3713-5421 c C C C C c C C C T 10 4157/1110 1/139 3713-5421

A A A A A A A A A A 11 4314/1230 1/139 3713-5421

T T T T T T T T T T 12 , 4365/1350 1/139 3713-5421

C c C C C c C G c C 13 4433/1470 1/139 3713-5421

C c A A A .c C C c C 14 4962/1590 1/139 3713-5421

T T T T T c C C T T 15^' 6408/1710 1/139 6261-9023

T T T C T T T T T T 16 7068/1830 1/139 6261-9023

C c C c C c c C c C 17 7116/1950 1/139 6261-9023

G G G c G c c C c C 18 7310/2070 1/139 6261-9023

A G G G G G G G G G 19 7371/2190 1/139 6261-9023

C C C C C c C C C T 20 7392/2310 1/139 6261-9023

T T T T T T T T T T 21 7991/2430 1/139 6261-9023

G G G G G G G G G G 22 8608/2550 1/139 6261-9023

^' A A A A A A A A A A 23 9656/2670 1/139 9580-10151

C T T T T C T T C C 24 9764/2790 1/139 9580-10151

A G G G G A G G A A 25 9878/2910 1/139 9580-10151

G G G G G A G G G G 26 9976/3030 1/139 9580-10151 11040-11638

C C C C C C C C C C 27 12132/3150 1/139 11734-13076

C C C C C C C C C C 28 13622/3270 1/139 13199-13976 Haplotype Number³ ( Part B) PS PS SEQ ID Region 11 12 13 14 15 16 17 18 19 20 No.^b Position⁰ No.^α Examined⁶ C C C C C C C C C C 1 1967/30 1/139 1649-2511

T T T T T T T T T T 2 1979/150 1/139 1649-2511 G G G G G G G G G G 3 2048/270 * 1/139 1649-2511 G G G G G G G G G G 4 2218/390 1/139 1649-2511 T T T T T T T T T T 5 2324/510 1/139 1649-2511 C c C C C C C C C C 6 3830/630 1/139 3713-5421 T T T T T T T T T T 7 3833/750 1/139 3713-5421 c c C C c C C c C C 8 3973/870 1/139 3713-5421 c c C C c C C c C C 9 4131/990 1/139 3713-5421 c c C C c C c c C C 10 4157/1110 1/1-39 3713-5421

A A A A A A A A A A 11 4314/1230 1/139 3713-5421

T T T T T T T T T T^' 12 4365/1350 1/139 3713-5421

C C C C C C C C C c 13 4433/1470 1/139 3713-5421

A A A A A A A A C c 14 4962/1590 1/139 3713-5421

C T T T T T T T C T 15 6408/1710 1/139 6261-9023 T C C c T T T T T c 16 7068/1830 1/139 6261-9023 C C C c C C c T C c 17 7116/1950 1/139 6261-9023 C C G G C G G C C G 18 7310/2070 1/139 6261-9023 G G A A G G G G G G 19 7371/2190 1/139 6261-9023 C C C C C C C c C C 20 7392/2310 1/139 6261-9023 ^" T T T T T T T T T T 21 7991/2.430 1/139 6261-9023 G G G G G G G G G G 22 8608/2550 1/139 6261-9023

A A A A A A A A A A 23 ^•9656/2670 1/139 9580-10151 T C C C C C T C T C 24 9764/2790 1/139 9580-10151

G A A .A A A G A G A 25 9878/2910 1/139 9580-10151 G G G G G G G G G G 26 9976/3030 1/139 9580-10151 11040-11638

C C C T c c c c c c 27 12132/3150 1/139 11734-13076 c c c c c c c c c c 28 13622/3270 1/139 13199-13976

O κ> NJ o IΛ o tΛ O C t

Ω Ω Ω > Ω > Ω 1-3 Ω > Ω Ω Ω ι-3 > Ω H Ω Ω Ω Ω H Ω μ3 Ω Ω H Ω r

Ω Ω Ω Ω > Ω 1-3 Ω Ω Ω Ω Ω H Ω H Ω Ω Ω Ω H Ω H Ω Ω H Ω tv

Ω Ω Ω > Ω Ω 1-3 Ω, Ω Ω Ω Ω H Ω Ω H Ω Ω Ω Ω H Ω H Ω Ω ι-3 Ω t

C

Ω Ω Ω Ω H Ω 1-3 Ω Ω Ω Ω Ω H Ω Ω ι-3 μ3 Ω Ω HI Ω H Ω Ω ι-3 Ω I

Ω Ω Ω Ω H ⁾ Ω 1-3 Ω Ω Ω Ω H H > Ω H Ω H Ω HI Ω 3 Ω Ω ^μ3 Ω t

C

Ω Ω Ω *Ω H > Ω 1-3 Ω Ω Ω Ω H Ω Ω Ω ι-3 Ω Ω Ω Hi 3 Hi Ω Ω H Ω t e

Ω Ω Ω > Ω- U* Ω 1-3 Ω > Ω Ω H H Ω 1-3 > Ω Ω Ω ι-3 Ω ι-3 Ω H H Ω t -

Ω Ω Ω Ω ι-3 > Ω 3 Ω Ω Ω Ω, H Ω Ω Ω ι-3 > Ω Ω Ω ι-3 Ω H Ω H 1-3 Ω t

0

Ω Ω > > Ω > Ω Ή Ω Ω Ω Ω Ω ι-3 Ω Ω H Ω Ω Ω Hi Ω H Ω H H Ω to

Ω Ω Ω Ω Ω H Ω Ω Ω Ω Ω ι-3 Ω Ω H > Ω Ω Ω 1-3 Ω 1-3 Ω 3 3 Ω co o ≥! tv> IV) IV) iv) to IO t t to μ-¹ μ-> μ-> μ-¹ μ-> μ-¹ ιχ> 00 -0 en Cπ *> co ^■

IO O

CO l en Cπ ifc. O to μ-¹ o. SD CO 1 en π .fc. CO to μ-¹ o c μ-¹ SD CO I > 00 *-J -J vl -j vl en •4^ ^•j^ .fc. .fc. co O co IO IO to μ-¹ μ-¹ h co ) l£> 00 -J en σs SD co co co o *> co ω O SD 00 00 CO IO o to ua O en μ-> 1 -J en π o SD SD vl μ-¹ μ-¹ en o en co en cπ O ~J co co PO .fc. ^■^i cn cn

IV) co en 00 *» en 00 μ-> to μ-> o en CO CO to CO cπ vl μ-> CO CO σ .fc. CO CO U5 ~o μ

IO to \ \ \ \ \ ^•v. \ \ '— \ \ V \ \ \ \ \ \ \ \ ^_^ ^•\ ^•^ " . rt

_\ CO to to IO IO t to to to μ-¹ μ-¹ μ-> μ-> μ-¹ μ-> μ-> μ-¹ SD 00 1 en cπ CO IO μ-¹ co μ co co o CO vi en cπ .fc. co μ-¹ o SD CO 1 cπ co IO μ-¹ SD ~J cπ CO μ-¹ SD ~J cπ o O to μ-> CO μ-> SD ~J cπ CO μ-¹ co vl π co μ-> SD ~j cπ co μ-¹ O o o o o O o o 3

~J Cπ o o o o o o o o o o o o o o o o o o o μ-> μ-¹ μ-> μ-^{1 (}-» μ-¹ μ-¹ μ-> μ-¹ μ-> μ-¹ μ-> μ-¹ μ-¹ μ-> μ-> μ-¹ μ-¹ μ-¹ μ-> μ-¹ μ-¹ μ-¹ μ-> μ-¹ μ-¹ μ-> μ-> ■3

\ _\ \ \ "\ \, \ \, _\ \. _\ \ ~v \ \ \ \. \. \ \ -v - ^ ~v. ^ . ^ \ ~\ O μ-¹ μ-> μ-¹ μ-> μ-¹ μ-¹ J-> μ-> μ-> μ-¹ μ-¹ μ-> μ-¹ μ-¹ μ-> μ-> μ-¹ μ-¹ μ-¹ μ-> μ-> .

CO CO CO CO O CO CO O O O O O O O CO O O O O O O CO CO CO CO CO CO CO

SD SD SD CO SD SD SD SD <£> < > 1X> SD < > SD CO SD SD in to t£> **x> SD to SD ιχ> SD ^■VO SD SD σs en en en en en σs en co cπ IO to rv> IO to IO t to vl CO en en on en en <_n σ*. en μ-> o μ-> μ-> μ-¹ μ-> μ-> μ-> μ-> μ-¹ co 1 1 1 1 1 1 1 1 1 1 μ-> co ι > *x> SD SD -sD to cπ o O o o o o o o o .fc.

μ-> to rv> IO IO IO ιv> to iv) to cπ O ω CO co O CO CO O μ-*

Haplotype Number³ (Part D) PS PS SEQ ID Region

31 32 No.° Position⁰ No.^d Examined⁶

C G 1 1967/30 1/139^' 1649-2511

T T 2 1979/150 1/139 1649-2511

T G 3 2048/270 1/139 1649-2511

G G 4 2218/390 1/139 1649-2511

T T 5 ^' 2324/510 1/139 1649-2511

C C 6 3830/630 1/139 3713-5421

T T 7 3833/750 1/139 3713-5421

. C T 8 3973/870 1/139 3713-5421

C C 9 4131/990 1/139 3713-5421

C C 10 4157/1110 1/139 3713-5421

A A 11 4314/1230 1/139 3713-5421

T C 12 4365/1350 1/139 3713-5421

C C 13 4433/1470 1/139 3713-5421

C A 14 4962/1590 1/139 3713-5421

T T 15 6408/1710 1/139 6261-9023

T C 16 7068/1830 1/139 6261-9023

C C 17 7116/1950 1/139 6261-9023

C G 18 7310/2070 1/139 6261-9023

G G 19 7371/2190 1/139 ^• 6261-9023 .

C C 20 7392/2310 1/139 6261-9023

T T 21 7991/2430 1/139 6261-9023

G A 22 8608/2550 1/139 6261-9023

A A ^' 23 9656/2670 1/139 9580-10151

C C 24 9764/2790 1/139 9580-10151

A A 25 9878/2910 1/139 9580-10151

G G 26 9976/3030 1/139 9580-10151 11040-11638

C C 27 12132/3150 1/139 11734-13076

C T 28 13622/3270 1/139 , 13199-13976 ^aAlleles for PERI haplotypes are presented 5 ' to 3 ' in each column; ^bPS = polymoφhic site; ^Position of PS within the indicated SEQ ID NO, with the Imposition number referring to the first SEQ ID NO and the 2^nd position number referring to the 2^nd SEQ ID NO; ^dl^st SEQ ID NO refers to Figure 1, with the two alternative allelic variants of each polymoφhic site indicated by the appropriate nucleotide symbol; 2^nd SEQ ID NO is a modified version of the 1^st SEQ ID NO that comprises the context sequence of each polymoφhic site, PS1-PS28, to facilitate electronic searching of the haplotypes; ^eRegion examined represents the nucleotide positions defining the start and stop positions within the 1^st SEQ ID NO of the sequenced region.

SEQ ID NO: 1 refers to Figure 1, with the two alternative allelic variants of each polymoφhic site indicated by the appropriate nucleotide symbol. SEQ JD NO: 139 is a modified version of SEQ JD NO:l that shows the context sequence of each of PS1-PS28 in a uniform format to facilitate electronic searching of the PERI haplotypes. For each polymoφhic site, SEQ JD NO: 139 contains a block of 60 bases of the nucleotide sequence encompassing the centrally-located polymoφhic site at the 30^th position, followed by 60 bases of unspecified sequence to represent that each polymoφhic site is separated by genomic sequence whose composition is defined elsewhere herein.

Table 6 below shows the percent of chromosomes characterized by a given PERI haplotype for all unrelated individuals in the Index Repository for which haplotype data was obtained. The percent of these unrelated individuals who have a given PERI haplotype pah is shown in Table 7. In Tables 6 and 7, the "Total" column shows this frequency data for all of these unrelated individuals, while the other columns show the frequency data for these unrelated individuals categorized according to theh self-identified ethnogeographic origin. Abbreviations used in Tables 6 and 7 are AF = African Descent, AS = Asian, CA = Caucasian, HL = Hispanic-Latino, and AM = Native American. Table 6. Frequency of Observed PERI Haplotypes In Unrelated Individuals

HAP No. HAPJD Total CA AE AS HL AM

1 2863795 0.62 0.0 2.5 0.0 0.0 0.0

2 2863788 0.62 0.0 0.0 0.0 2.78 0.0

3 2863803 0.62 0.0 0.0 0.0 2.78 0.0

4 2863792 0.62 0.0 2.5 0.0 0.0 0.0

5 2863802 0.62 0.0 0.0 2.63 0.0 0.0

6 2863794 0.62 0.0 0.0 0.0 2.78 0.0

7 2863781 10.49 14.29 10.0 0.0 16.67 16.67

8 2863800 0.62 2.38 . 0.0 0.0 0.0 0.0

9 2863805 0.62 0.0 2.5 0.0 0.0 0.0

10 2863808 0.62 0.0 2.5 0.0 0.0 0.0

11 2863780 11.73 16.67 5.0 7.89 16.67 16.67

12 ^• 2863806 0.62 0.0 0.0 2.63 0.0 0.0

13 2863801 0.62 0.0 2.5 0.0 0,0 0.0

14 2863790 0.62 2.38 0.0 0.0 0.0 0.0

15 2863779 20.99 7.14 17.5 52.63 8.33 16.67

16 2863784 1.85 2.38 5.0 0.0 0.0 0.0

17 2863778 27.16 50.0 22.5 5.26 30.56 16.67

18 2863804 0.62 0.0 0.0 2.63 0.0 0.0

19 2863811 0.62 0.0 0.0 0.0 2.78 0.0

20 2863799 0.62 0.0 2.5 0.0 0.0 0.0

21 2863789 0.62 0.0 2.5 0.0 0.0 0.0

22 2863798 0.62 0.0 2.5 0.0 0.0 0.0

23 2863786 0.62 0.0 2.5 0.0 0.0 0.0

24 2863791 0.62 0.0 2.5 0.0 0.0 0.0

25 2863796 0.62 0.0 0.0 0.0 2.78 0.0

26 2863783 2.47 0.0 10.0 0.0 0.0 0.0

27 2863787 0.62 0.0 0.0 0.0 2.78 0.0

28 2863785 1.23 2.38 0.0 2.63 0.0 0.0

29 2863809 0.62 0.0 0.0 0.0 2.78 0.0

30 2863782 9.26 0.0 2.5 23.68 8.33 33.33

31 2863797 0.62 2.38 0.0 0.0 0.0 0.0

32 2863793 0.62 0.0 2.5 0.0 0.0 0.0 Table 7. Frequency of Observed PERI Haplotype Pahs In Unrelated Individuals

HAP1 HAP2 Total CA AF AS HL AM

7 7 1.23 0.0 0.0 0.0 5.56 0.0

17 17 8.64 19.05 5.0 0.0 11.11 0.0

15 15 7.41 0.0 5.0 26.32 0.0 0.0

26 26 1.23 0.0 5.0 0.0 0.0 0.0

11 19 1.23 0.0 0.0 0.0 5.56 0.0

7 2 1.23 0.0 0.0 0.0 5.56 0.0

17 30 2.47 0.0 0.0 0.0 5.56 33.33

17 26 1.23 0.0 5.0 0.0 0.0 0.0

15 4 1.23 0.0 5.0 0.0 0.0 0.0

17 10 1.23 0.0 5.0 0.0 0.0 0.0

15 22 1.23 0.0 5.0 0.0 0.0 0.0

15 28 1.23 0.0 0.0 5.26 0.0 0.0

11 25 1.23 0.0 0.0 0.0 5.56 0.0

6 29 1.23 0.0 0.0 0.0 5.56 0.0

17 3 1.23 0.0 0.0 0.0 5.56 0.0

7 27 1.23 0.0 0.0 0.0 5.56 0.0

7 8 1.23 4.76 0.0 0.0 0.0 0.0

17 14 1.23 4.76 0.0 0.0 0.0 0.0

17 28 1.23 4.76 0.0 0.0 0.0 0.0

15. 16 1.23 4.76 0.0 0.0 0.0 0.0

17 7 6.17 14.29 0.0 0.0 11.11 0.0

7 13 1.23 0.0 5.0 0.0 0.0 0.0

17 23 1.23 0.0 5.0 0.0 0.0 0.0

16 21 1.23 0.0 5.0 0.0 0.0 0.0

15 18 1.23 0.0 0.0 5.26 0.0 0.0

30 26 1.23 0.0 5.0 0.0 0.0 0.0

17 9 1.23 0.0 5.0 0.0 0.0 0.0

16 32 1.23 0.0 5.0 0.0 , 0.0 0.0

17 1 1.23 0.0 5.0 0.0 0.0 0.0

17 20 ' 1.23 0.0 5.0 0.0 0.0, 0.0

15 7 3.7 0.0 10.0 0.0 0.0 33.33

17 11 7.41 23.81 0.0 0.0 5.56 0.0

17 31 1.23 4.76 0.0 0.0 0.0 0.0

11 30 6:17 0.0 0.0 10.53 11.11 33.33

17 12 1.23 0.0 0.0 5.26 0.0 0.0

11 ^•7 3.7 9.52 5.0 0.0 0.0 0.0

15 30 8.64 0.0 0.0 36.84 0.0 0.0

17 5 1.23 0.0 0.0 5.26 0.0 0.0

17 15 6.17 9.52 5.0 0.0 11.11 0.0

11 24 1.23 0.0 5.0 0.0 0.0 0.0

15 11 2.47 0.0 0.0 5.26 5.56 0.0

The size and composition of the Index Repository were chosen to represent the genetic diversity across and within four major population groups comprising the general United States population. For example, as described in Table 1 above, this repository contains approximately equal sample sizes of African-descent, Asian- American, European- American, and Hispanic-Latino population groups. Almost all individuals representing each group had all four grandparents with the same ethnogeographic background. The number of unrelated individuals in the Index Repository provides a sample size that is sufficient to detect SNPs and haplotypes that occur in the general population with high statistical certainty. For instance, a haplotype that occurs with a frequency of 5% in the general population has a probability higher than 99.9% of being observed in a sample of 80 individuals from the general population. Similarly, a haplotype that occurs with a frequency of 10% in a specific population group has a 99% probability of being observed in a sample of 20 individuals from that population group. In addition, the size and composition of the Index Repository means that the relative frequencies determined therein for the haplotypes and haplotype pahs of the PERI gene are likely to be similar to the relative frequencies of these PERI haplotypes and haplotype pahs in the general U.S. population and in the four population groups represented in the Index Repository. The genetic diversity observed for the three Native Americans is presented because it is of scientific interest, but due to the small sample size it lacks statistical significance.

In view of the above, it will be seen that the several advantages of the invention are achieved and other advantageous results attained.

As various changes could be made in the above methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be inteφreted as illustrative and not in a limiting sense.

All references cited in this specification, including patents and patent applications, are hereby incoφorated in theh entirety by reference. The discussion of references herein is intended merely to summarize the assertions made by theh authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinency of the cited references.

Claims

What is Claimed is:

1. A method for haplotyping the period (Drosophila) homolog 1 (PERI) gene of an individual, which comprises determining which of the PERI haplotypes shown in the table immediately below defines one copy of the individual's PERI gene, wherein each of the PERI haplotypes comprises a sequence of polymoφhisms whose positions and identities are set forth in the table immediately below:

Haplotype Numbei .a PS PS

1 2 3 4 5 6 7 - 8 9 10 No.^b Position⁰

C C C C C C C C C C 1 1967

G G T T T T T T T T 2 1979

T T G G G G G G G , -G 3 2048.

G G A G G G G G G G 4 2218

T T T C C C C C T T 5 2324

C C C C C C C C C C 6 3830 *

T T T T T T T T c c 7 3833 c c c- C C C C C c c 8 3973 c c C C C C C C c c 9 413,1 c c c C C C C C c T 10 4157

A A A A A A A A A A 11 4314

T T T T T T T T T T 12 4365 c c C C C C C G c C 13 4433 c c A A A c C C c c 14 4962

T T T T T c C C T T 15 6408

T T T C T T T T T T 16 7068 c- c C C C c C c c c 17 7116

G G G C G c c c c c 18 7310

A *G G G G G G G G G 19 7371 c C C C C C c C c T ^■ 20 7392

T T T T T T T T T T 21 7991

G G G G G G G G G G 22 8608

A A ' A A A A A A A A 23 9656 c T T T T C T T C C 24 9764

A G G G G A G . G A A 25 9878

G G G _. G G A G G G G 26. 9976

C C C C C C C C C C 27 12132

C C C C C C C C C C 28 13622

Ha]plot;ipe Numbeir³ PS PS

11 12 13 ^' 14 15 16 17 18 19 20 Number^b Position'

C C C C C C C C C C 1 1967

T T T T T T T T T T 2 1979

G G G G G G G G G G 3 2048

G G G G G G G G G G 4 2218

T T T T T T T T T T 5 2324

C C C ^• C C C c c C C 6 3830

T T T T T T , T T T T 7 3833

C C C C C C c c c c 8 3973

C C c C C C c c c c 9 4131

C c c C C C c c . c c 10 4157

A A ^■ A A A A A A A A 11 4314

T T T T T T T T T T 12 4365

C C c C C c C c c C 13 4433

A A A A A • A A A c C 14 4962

C T . T T T T T T c T 15 6408

T C c C T T T T T c 16 7068 c C c C C c C T c c 17 7116 c C G G C G G C c G 18 7310

G G A A G G G G G G 19 7371

C C C C C C C C c C 20 7392

T T T T T T T T T T 21 7991

G G G G G G G G G G 22 8608

A A A A A A A A A A 23 9656

T C C C C C T C T C 24 9764

G A A A A A G A G A 25 9878

G G G G G G G G G G 26 9976

C C C T C C C C C C 27 12132

C C C C C C C C C C ^' 28 13622

Haplotype 1STumbiar^a PS PS

21 22 23 24 25 26 27 28 29 30 Number⁰ Position'

C C C C C C C C C C 1 1967

T T T T T T T T T T 2 1979

G G G G G G T T T T 3 2048

G G G G G G G^' G G G 4 .2218

T T T T T T T T T T 5 2324

C c C C C T c C c C 6 3830

T T T T T T T T T 'T 7 3.833 c c C c C c c C c c 8 3973 c c C c T c c C ^' c c 9 4131 c c C T c c c C c c 10 4157

G G G A A A A A A A 11 4314 ^•

T T T T T T T T T T 12 4365 c c C C C C c C c C 13 4433

A A C C A C A C c C 14 4962

T T T T T C T C T T 15 6408 c C C c T T T T c c 16 7068 c C C c C C c C c c 17 7116

G G G ^' G C ^■ c G C c c 18 7310 .

A G G G G G A G G G 19 7371 c C C C C C C C C C 20 7392

T T T T T T T T T T 21 7991

G G G G G G G G G G 22 8608

A A A A A A A A A A 23 9656 c C C T T T C T C C 24 9764

A A A G G G A G A A 25 9878

G G G G G G G G A G 26 9976

C C C C C- C C C C C ^• 27 12132

C C C C C C C C C C 28 136*22

[a l.otype Number³ PS PS

31 32 No.^b Position⁰

C G 1 1967

T T 2 1979

T G 3 2048

G G 4 2218

T T 5 2324

C C 6 3830

T T 7 3833

C T 8 3973

C C 9 4131

C c 10 4157

A A 11 4314

T c 12 4365

C c 13 4433

C A 14 4962

T T 15 6408

T C 16 7068 c C 17 7116 c G 18 7310

G G 19 7371 c C 20 7392

T T 21 7991

G A 22 8608

A A 23 9656 c C 24 9764

A A 25 9878

G G 26 9976 c C 27 12132 c T 28 13622

'Alleles for haplotypes are presented 5' to 3' in each column

'PS = polymoφhic site;

'Position of PS within SEQ JD NO: 1.

2. The method of claim 1, wherein the determining step comprises identifying the phased sequence of nucleotides present at each of PS1-PS28 on at least one copy of the individual's PERI gene.

3. A method for haplotyping the period (Drosophila) homolog 1 (PERI) gene of an individual, which comprises determining which of the PERI haplotype pahs shown in the table immediately below defines both copies of the individual's PERI gene, wherein each of the PERI haplotype pahs consists of first and second haplotypes which comprise first and second sequences of polymoφhisms whose positions and identities are set forth in the table immediately below: Haplotype Pair³ PS PS /7 17/17 15/15 26/26 11/19 7/2 17/30 17/26 No.^b Position⁰

C/C C/C C/C C/C C/C C/C C/C C/C 1 1967 T/T T/T T/T T/T T/T T/G T/T T/T 2 1979

G/G G/G G/G G/G G/G G/T G/T G/G 3 2048

G/G G/G G/G G/G G/G G/G G/G G/G 4 2218

C/C T/T T/T T/T T/T C/T T/T T/T 5 2324

C/C C/C C/C T/T C/C C/C C/C C/T 6 3830 T/T T/T T/T T/T T/T T/T T/T T/T 7 3833

C/C C/C C/C C/C C/C C/C C/C C/C 8 3973

C/C C/C C/C C/C C/C C/C C/C C/C 9 4131

C/C C/C C/C C/C C/C C/C C/C C/C 10 4157

A/A A/A A/A A/A A/A A/A A/A A/A 11 4314 T/T T/T T/T T/T T/T T/T T/T T/T 12 4365

C/C C/C C/C C/C C/C C/C C/C C/C 13 4433

C/C A/A A/A C/C A/C C/C A/C A/C 14 4962

C/C T/T T/T C/C C/C C/T T/T T/C 15 6408

T/T T/T T/T T/T T/T T/T T/C T/T 16 7068 C/C C/C C/C C/C C/C C/C C/C C/C 17 7116

C/C G/G C/C C/C C/C C/G G/C G/C 18 7310

G/G G/G G/G G/G G/G G/G G/G G/G 19 7371

C/C C/C C/C C/C C/C C/C C/C C/C 20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991 G/G G/G G/G G/G G/G G/G G/G G/G 22 8608

A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

T/T T/T C/C T/T T/T T/T T/C T/T 24 9764

G/G G/G A/A G/G G/G G/G G/A G/G 25 9878

G/G G/G G/G G/G G/G G/G G/G G/G 26 9976 C/C C/C C/C C/C C/C C/C C/C C/C 27 12132

C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

Haplotype Pair³ PS PS 5/4 17/10 _.15/22 15/28 11/25 6/29 17/3 7/27 No.^b Position⁰

C/C C/C C/C C/C C/C C/C C/C C/C 1 1967 .

T/T T/T T/T T/T T/T T/T T/T T/T 2 1979 G/G G/G G/G G/T G/G G/T G/G G/T 3 2048

G/G G/G G/G G/G G/G G/G G/A G/G 4 2218

T/C T/T T/T T/T T/T C/T T/T C/T 5 2324

C/C C/C C/C C/C C/C C/C C/C C/C 6 3830

T/T T/C T/T T/T T/T T/T T/T T/T 7 3833 C/C C/C C/C C/C C/C C/C C/C C/C 8 3973

C/C C/C C/C C/C C/T C/C C/C C/C 9 . 4131

C/C C/T C/C C/C C/C C/C C/C C/C 10 4157

A/A A/A A/G A/A A/A A/A A/A A/A 11 4314

T/T T/T T/T T/T T/T T/T T/T T/T 12 4365 C/C C/C C/C C/C C/C C/C C/C C/C 13 4433

A/A A/C A/A A/C A/A C/C A/A C/A 14 4962

T/T T/T T/T T/C C/T' C/T T/T C/T. 15 6408

T/C T/T T/C T/T T/T T/C T/T T/T 16 7068

C/C C/C C/C C/C C/C C/C C/C C/C 17 7116 C/C G/C C/G C/C C/C C/C G/G C/G 18 7310

G/G G/G G/G G/G G/G G/G G/G G/A 19 7371

C/C C/T C/C C/C C/C C/C C/C C/C 20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/G G/G G/G G/G G/G 22 8608 A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

C/T T/C C/C C/T T/T C/C T/T T/C 24 9764

A/G G/A A/A A/G G/G A/A G/G G/A 25 9878

G/G G/G G/G G/G G/G A/A G/G G/G 26 9976

C/C C/C C/C C/C C/C C/C C/C C/C 27 12132 C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

Haplotype Pair³ PS PS /8 17/14 17/28 15/16 17/7 7/13 17/23 16/21 No.^b Position⁰

C/C C/C C/C C/C C/C C/C C/C C/C 1 1967

T/T T/T T/T T/T T/T T/T T/T T/T 2 1979 G/G G/G G/T G/G G/G G/G G/G G/G 3 2048

G/G G/G G/G G/G G/G G/G G/G G/G 4 2218

C/C T/T T/T T/T T/C C/T T/T T/T 5 2324

C/C C/C C/C C/C C/C C/C C/C C/C 6 3830

T/T T/T T/T T/T T/T T/T T/T T/T 7 3833 C/C C/C C/C C/C C/C C/C C/C C/C 8 3973

C/C C/C C/C C/C C/C C/C C/C C/C 9 4131

C/C C/C C/C C/C C/C C/C C/C C/C 10 4157

A/A A/A A/A A/A A/A A/A A/G A/G 11 4314

T/T T/T T/T T/T T/T T/T T/T T/T 12 4365 C/G C/C C/C C/C C/C C/C C/C C/C 13 4433

C/C A/A A/C A/A A/C C/A A/C A/A 14 4962

C/C T/T T/C T/T T/C C/T T/T T/T 15 6408

T/T T/C T/T T/T T/T T/C T/C T/C 16 7068

C/C C/C C/C C/C C/C C/C C/C C/C 17 7116 C/C G/G G/C C/G G/C C/G G/G G/G 18 7310

G/G G/A G/G G/G G/G G/A G/G G/A 19 7371

C/C C/C C/C C/C C/C C/C C/C C/C 20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/G G/G G/G G/G G/G 22 8608 A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

T/T T/C T/T C/C T/T T/C T/C C/C 24 9764

G/G G/A G/G A/A G/G G/A G/A A/A 25 9878

G/G G/G G/G G/G G/G G/G G/G G/G 26 9976

C/C C/T C/C C/C C/C C/C C/C C/C 27 12132 C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

Haplotype Pair³ PS3 PS 5/18 30/26 17/9 16/32 17/1 17/20 15/7 17/11 No >.^b Position⁰

C/C C/C C/C C/G C/C C/C C/C C/C 1 1967

T/T T/T T/T T/T T/G T/T T/T T/T 2 1979 G/G T/G G/G G/G G/T G/G G/G G/G 3 2048

G/G G/G G/G G/G G/G G/G G/G G/G 4 2218 ^'

T/T T/T T/T T/T T/T T/T T/C T/T 5 2324

C/C C/T C/C C/C C/C C/C C/C C/C 6 3830

T/T T/T T/C T/T T/T T/T T/T T/T 7 3833 C/C C/C C/C C/T C/C C/C C/C C/C 8 3973

C/C C/C C/C C/C C/C C/C C/C C/C 9 4131

C/C C/C C/C C/C C/C C/C C/C C/C 10 4157

A/A A/A A/A A/A A/A A/A A/A A/A 11 4314

T/T _. T/T T/T T/C T/T T/T T/T T/T 12 4365 C/C C/C C/C C/C C/C C/C C/C C/C 13 4433

A/A C/C ^■ A/C A/A A/C A/C A/C A/A 14 4962

T/T T/C T/T T/T T/T T/T T/C T/C 15 6408

T/T C/T T/T T/C T/T T/C T/T T/T 16 7068

C/T C/C C/C C/C C/C C/C C/C C/C 17 7116 C/C C/C G/C G/G G/G G/G C/C G/C 18 7310

G/G G/G G/G G/G G/A G/G- G/G G/G 19 7371

C/C C/C C/C C/C C/C C/C C/C C/C 20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 ^• 7991

G/G G/G G/G G/A G/G G/G G/G G/G 22 8608 A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

C/C C/T T/C C/C T/C T/C. C/T T/T 24 . 9764

A/A A/G G/A A/A G/A G/A A/G G/G 25 9878

G/G G/G G/G G/G G/G G/G G/G G/G 26 9976

C/C C/C C/C C/C C/C C/C C/C C/C 27 12132 C/C C/C C/C C/T C/C C/C C/C C/C 28 13622

Haplotype Pair³ PS PS 7/31 11/30 17/12 11/7 15/30 17/5 17/15 11/24 No.b Position⁰

C/C C/C C/C C/C C/C C/C C/C C/C 1 1967

T/T T/T T/T T/T T/T T/T T/T T/T 2 1979 G/T G/T G/G G/G G/T .G/G G/G G/G 3 2048

G/G G/G G/G G/G G/G G/G G/G G/G 4 ^'2218

T/T T/T T/T T/C T/T T/C T/T T/T 5 2324

C/C C/C C/C C/C C/C C/C C/C C/C 6 3830

T/T T/T T/T T/T T/T T/T T/T T/T 7 3833 C/C C/C C/C C/C C/C C/C C/C C/C 8 3973

C/C C/C C/C C/C C/C C/C C/C C/C 9 4131

C/C C/C C/C C/C C/C C/C C/C C/T 10 4157

A/A A/A A/A A/A A/A A/A A/A A/A 11 4314

T/T T/T T/T T/T T/T T/T T/T T/T 12 4365 C/C C/C C/C C/C C/C C/C C/C C/C 13 4433

A/C A/C A/A A/C A/C A/A A/A A/C 14 4962

T/T C/T T/T C/C T/T T/T T/T C/T 15 6408

T/T T/C T/C T/T T/C T/T T/T T/C 16 7068

C/C C/C C/C C/C C/C C/C C/C C/C 17 7116 G/C C/C G/C C/C C/C G/G G/C C/G 18 7310

G/G G/G G/G G/G G/G G/G G/G^' G/G 19- 7371

C/C C/C C/C C/C C/C C/C C/C C/C 20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/G G/G G/G G/G G/G 22 8608 A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

T/C T/C T/C T/T C/C T/T T/C T/T 24 9764

G/A G/A G/A G/G A/A G/G G/A G/G 25 9878

G/G G/G G/G G/G G/G G/G G/G G/G 26 9976

C/C C/C C/C C/C C/C C/C C/C C/C 27 12132 C/C C/C C/C C/C C/C C/C C/C C/C 28 13622.

Haplotype Pair³ PS PS

15/11 Nθ.^b Position⁰

C/C 1 1967

T/T 2 1979

G/G 3 2048

G/G 4 2218

T/T 5 2324

C/C 6 3830

T/T 7 3833

C/C 8 3973

C/C 9 4131

C/C 10 4157

A/A 11 4314

T/T 12 4365

C/C 13 4433

A/A 14 4962

T/C 15 6408

T/T 16 7068

C/C 17 7116

C/C 18 7310

G/G 19 7371

C/C 20 7392

T/T 21 7991

G/G 22 8608

A/A 23 9656

C/T 24 9764

A/G 25 9878

G/G 26 9976

C/C 27 12132

C/C 28 13622 ; with alleles of each haplotype column;

4. The method of claim 3, wherein the determining step comprises identifying the phased sequence of nucleotides present at each of PS1-PS28 on both copies of the individual's PERI gene.

5. A method for genotyping the period (Drosophila) homolog 1 (PERI) gene of an individual, comprising determining for the two copies of the PERI gene present in the individual the identity of the nucleotide pah at one or more polymoφhic sites (PS) selected from the group consisting of PSl, PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS11, PS12, PS13, PS14, PS15, PS16, PS17, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS26, PS27 and PS28, wherein the one or more PS have the position and alternative alleles shown in SEQ ID NO: 1.

6. The method of claim 5, wherem the determining step comprises:

(a) isolating from the individual a nucleic acid mixture comprising both copies of the PERI gene, or a fragment thereof, that are present in the individual;

(b) amplifying from the nucleic acid mixture a target region containing one of the selected polymoφhic sites;

(c) hybridizing a primer extension oligonucleotide to one allele of the amplified target region, wherein the oligonucleotide is designed for genotyping the selected polymoφhic site in the target region;

(d) performing a nucleic acid template-dependent, primer extension reaction on the hybridized oligonucleotide in the presence of at least one terminator of the reaction, wherein the terminator is complementary to one of the alternative nucleotides present at the selected polymoφhic site; and

(e) detecting the presence and identity of the terminator in the extended oligonucleotide.

7. The method of claim 5, which comprises determining for the two copies of the PERI gene present in the individual the identity of the nucleotide pah at each of PS1-PS28.

8. A method for haplotyping the period (Drosophila) homolog 1 (PERI) gene of an individual which comprises determining, for one copy of the PERI gene present in the individual, the identity of the nucleotide at two or more polymoφhic sites (PS) selected from the group consisting of PSl, PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PSl 1, PS12, PS13, PS14,

. PS15, PS16, PS17, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS26, PS27 and PS28, wherein the selected PS have the position and alternative alleles shown in SEQ JD NO:l.

9. The method of claim 8, further comprising deteπnining the identity of the nucleotide at PS 18, which has the location and alternative alleles shown in SEQ JD NO: 1.

10. The method of claim 8, wherein the determining step comprises:

(a) isolating from the individual a nucleic acid sample containing only one of the two copies of the PERI gene, or a fragment thereof, that is present in the individual; '

(b) amplifying from the nucleic acid sample a target region containing one of the selected polymoφhic sites;

(c) hybridizing a primer extension oligonucleotide to one allele of the amplified targef region, wherein the oligonucleotide is designed for haplotyping the selected polymoφhic site in the target region;

(d) performing a nucleic acid template-dependent, primer extension reaction on the hybridized oligonucleotide in the presence of at least one terminator of the reaction, wherein the terminator is complementary to one of the alternative nucleotides present at the selected polymoφhic site; and

(e) detecting the presence and identity of the terminator in the extended oligonucleotide.

11. A method for predicting a haplotype pair for the period (Drosophila) homolog 1 (PERI) gene of an individual comprising:

(a) identifying a PERI genotype for the individual, wherein the genotype comprises the nucleotide pah at two or more polymoφhic sites (PS) selected from the group consisting of PSl, PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS11, PS12, PS13, PS14, PS15, PS16, PS17, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS26, PS27 and PS28, wherein the selected PS have the position and alternative alleles shown in SEQ ID NO:l; (b) comparing the genotype to the haplotype pah data set forth in the table immediately below; and (c) determining which haplotype pah is consistent with the genotype of the individual and with the haplotype pah data:

Haplotype Pair³ PS PS /7 17 /17 15 /15 26/26 11/19 7 /2 17 /30 17 /26 No.^b Position' C/C C/C C/C C/C C/C C/C C/C C/C 1 1967 _{τ / τ τ}/_τ - _{τ /τ τ}/_{τ τ}/_{τ T /Q τ}/_{τ τ}/_τ 2 1979

G/G G/G G/G G/G G/G ^' G/T G/T G/G 3 2048

G/G G/G G/G G/G G/G G/G G/G G/G 4 2218

C/C T/T T/T T/T T/T C/T T/T T/T 5 2324 C/C C/C C/C T/T C/C C/C C/C C/T 6 3830

T/T T/T T/T T/T T/T T/T T/T T/T 7 ^• 3833

C/C C/C C/C C/C C/C C/C C/C C/C 8 3973

C/C C/C C/C C/C. C/C C/C C/C . C/C 9 ^' 4131 c/c c/c c/c c/e c/c c/c c/c c/c 10 4157 A/A A/A A/A A/A A/A A/A A/A A/A 11 4314

T/T T/T T/T T/T T/T T/T T/T T/T 12 4365 c/c c/c c/c c/c c/c c/c c/c c/c 13 4433

C/C A/A A/A C/C A/C C/C A/C A/C 14 4962

C/C T/T T/T C/C C/C C/T' T/T T/C 15 6408 T/T T/T T/T T/T T/T . T/T T/C T/T 16 7068

C/C C/C C/C C/C C/C C/C c/c c/c 17 7116

C/C G/G C/C C/C C/C C/G G/C G/C 18 ^' 7310

G/G G/G G/G G/G G/G G/G G/G G/G 19 7371

C/C C/C C/C C/C C/C C/C C/C C/C 20 7392 T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/G G/G G/G G/G G/G 22 8608

A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

T/T T/T C/C T/T T/T T/T T/C T/T 24 9764

G/G G/G A/A G/G G/G G/G G/A ^' G/G 25 9878 G/G G/G G/G G/G G/G G/G G/G G/G 26 9976

C/C C/C C/C C/C C/C C/C C/C C/C 27 12132

C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

Haplotype Pair³ PS PS 15/4 17/10 15/22 15/28 11/25 6/29 17/3 7/27 No.^b Position⁰

C/C C/C C/C C/C C/C C/C C/C C/C 1 1-967 '

T/T T/T T/T T/T T/T T/T T/T T/T 2 1979

G/G G/G G/G G/T G/G G/T G/G G/T 3 2048

G/G G/G G/G G/G G/G G/G G/A G/G 4 2218 T/C T/T T/T ^■ T/T T/T C/T T/T C/T 5 2324

C/C C/C C/C C/C C/C C/C c/c c/c 6 3830

T/T T/C T/T T/T T/T T/T T/T T/T 7 3833

C/C C/C C/C C/C C/C C/C C/C c/c 8 3973

C/C C/C C/C C/C C/T c/c c/c c/c 9 4131 C/C C/T C/C C/C C/C C/C C/C C/C 10 4157

A/A A/A A/G A/A A/A A/A A/A A/A 11 4314

T/T T/T T/T ^"T/T T/T T/T T/T T/T 12 4365

C/C c/c c/c c/c c/c c/c c/c c/c 13 4433

A/A A/C A/A A/C A/A C/C A/A C/A 14 4962 T/T T/T T/T T/C C/T C/T T/T C/T 15 ^' 6408

T/C T/T T/C T/T T/T T/C T/T T/T 16 7068 c/c c/c c/c c/c c/c c/c c/c c/c 17 7116

C/C G/C C/G C/C C/C C/C G/G C/G 18 7310

G/G G/G G/G G/G G/G G/G^' G/G G/A 19 ^' 7371 C/C C/T C/C C/C C/C C/C C/C C/C 20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/G G/G G/G G/G G/G 22 8608

A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

C/T T/C C/C C/T T/T C/C T/T T/C 24 9764 A/G G/A A/A A/G G/G A/A G/G G/A 25 9878

G/G G/G G/G G/G G/G A/A G/G G/G 26 9976

C/C C/C C/C C/C C/C C/C C/C C/C 27 12132

C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

75 Haplotype Pair^{3 »}s PS

7/8 17/14 17/28 15/16 17/7 7/13 17/23 16/21 No.^b Position⁰

C/C C/C C/C C/C C/C C/C C/C C/C 1 1967

T/T T/T T/T T/T T/T T/T T/T T/T 2 1979

G/G G/G G/T G/G G/G' G/G G/G G/G 3 2048

80 G/G G/G G/G G/G G/G G/G G/G G/G 4 2218

C/C T/T T/T T/T T/C C/T T/T T/T 5 2324

C/C C/C C/C C/C C/C C/C C/C C/C 6 3830

T/T T/T T/T T/T T/T T/T T/T ^' T/T 7 3833

C/C C/C C/C C/C C/C C/C c/c c/c 8 3973

85 c/c c/c c/c c/c c/c c/c c/c c/c 9 4131 c/c c/c c/c c/c c/c c/c c/c -c/c 10 4157

A/A A/A A/A A/A A/A A/A A/G A/G 11 4314

T/T T/T T/T T/T T/T T/T T/T T/T 12 4365

C/G c/c c/c c/c c/c c/c c/c c/c 13 4433

90 C/C A/A A/C A/A A/C C/A A/C A/A 14 4962

C/C T/T T/C T/T T/C C/T T/T T/T 15 6408

T/T T/C T/T T/T T/T T/C T/C T/C 16 7068

C/C C/C C/C C/C C/C C/C c/c c/c 17 7116

C/C G/G G/C C/G G/C C/G G/G G/G 18 7310

95 G/G G/A G/G G/G G/G G/A G/G G/A 19 7371

C/C C/C C/C C/C C/C C/C C/C C/C 20^' 7392 ^•

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/G G/G G/G G/G G/G ^' 22 8608

A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

100 T/T T/C T/T C/C T/T T/C T/C C/C 24 9764

G/G G/A G/G A/A G/G G/A G/A A/A 25 9878

G/G G/G G/G G/G G/G G/G G/G G/G 26 9976

C/C .C/T C/C C/C C/C C/C C/C C/C 27 12132

C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

105

Haplotype Pair³ PS PS

15/18 30/26 17/9 16/32 17/1 17/20 15/7 17/11 No.^b Position⁰

C/C C/C C/C C/G C/C C/C C/C C/C 1 1967

T/T T/T T/T T/T T/G T/T T/T T/T 2 1979

110 G/G T/G G/G G/G G/T G/G G/G G/G 3 2048

G/G G/G G/G G/G G/G G/G G/G G/G 4 2218

T/T T/T T/T T/T T/T T/T T/C T/T 5 2324 ^■

C/C C/T C/C C/C C/C C/C C/C C/C 6 3830

T/T T/T T/C T/T T/T T/T T/T T/T 7 ^' 3833

115 C/C C/C C/C C/T C/C C/C C/C C/C 8 3973

C/C C/C C/C C/C C/C C/C C/C C/C 9 4131

C/C C/C C/C C/C C/C C/C C/C C/C 10 4157

A/A A/A A/A A/A A/A A/A A/A A/A 11 4314

T/T T/T T/T T/C T/T T/T T/T T/T 12 4365

120 C/C C/C C/C C/C C/C C/C C/C C/C 13 - 4433

A/A C/C A/C A/A A/C A/C A/C A/A 14 4962

T/T T/C T/T T/T T/T T/T T/C T/C 15 6408

T/T C/T T/T T/C T/T T/C T/T T/T 16 7068

C/T C/C C/C C/C C/C C/C C/C C/C 17 7116

125 ^' C/C C/C G/C G/G G/G G/G C/C G/C 18 7310

G/G G/G G/G G/G G/A G/G G/G G/G 19 7371

C/C C/C C/C C/C C/C C/C C/C C/C 20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/A G/G G/G G/G G/G 22 8608

130 A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

C/C C/T T/C C/C T/C T/C C/T T/T 24 9764

A/A A/G G/A A/A G/A G/A A/G G/G 25 9878

G/G G/G G/G G/G G/G G/G G/G G/G 26 9976

C/C C/C C/C C/C C/C C/C C/C C/C 27 12132

135 C/C C/C C/C C/T C/C C/C C/C C/C 28 13622

Haplotype Pair³ PS PS

17/31 11/30 17/12 11/7 15/30 17/5 17/15 11/24 No.b Position⁰

C/C C/C C/C C/C C/C C/C C/C C/C 1 1967

140 ^■ T/T T/T T/T T/T T/T T/T T/T T/T 2 1979

G/T G/T G/G G/G G/T G/G G/G G/G 3 2048

G/G G/G G/G G/G G/G G/G G/G G/G 4 2218

T/T T/T T/T T/C T/T T/C T/T T/T 5 2324

C/C C/C C/C C/C C/C C/C C/C C/C 6 3830

145 T/T T/T T/T T/T T/T T/T T/T T/T 7 3833

C/C C/C C/C C/C C/C C/C C/C C/C 8 3973

C/C C/C C/C C/C C/C C/C C/C C/C 9 4131

C/C C/C C/C C/C C/C C/C C/C C/T 10 4157

A/A A/A A/A A/A A/A A/A A/A A/A 11 4314

150 ^■ T/T T/T T/T T/T . T/T T/T T/T T/T 12 4365

C/C C/C C/C C/C C/C C/C C/C C/C 13 4433

A/C A/C ^' A/A A/C A/C A/A A/A A/C 14 4962

T/T C/T T/T C/C T/T T/T T/T C/T 15 6408

T/T T/C T/C T/T T/C T/T T/T T/C 16 7068

155 C/C C/C C/C C/C C/C C/C C/C C/C 17 7116

G/C C/C G/C C/C C/C G/G G/C C/G 18 7310

G/G G/G ^' G/G ^■ G/G G/G G/G G/G G/G 19 7371

C/C C/C C/C C/C C/C C/C C/C C/C .20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

160 G/G G/G G/G G/G G/G G/G G/G G/G 22 8608

A/A A/A A/A A/A A/A A/A A/A A/A 23 .9656

T/C T/C T/C T/T C/C T/T T/C T/T 24 9764

G/A G/A G/A G/G A/A G/G G/A G/G 25 9878

G/G G/G G/G G/G G/G G/G G/G G/G 26 9976

165 C/C C/C C/C C/C C/C C/C C/C C/C 27 12132

C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

Haplotype Pair³ PS PS

15/11 No.^b Position⁰

170 C/C 1 1967

T/T 2 1979

G/G 3 2048

G/G 4 2218

T/T 5 2324

175 C/C 6 3830

T/T 7. 3833 c/c 8 3973 c/c 9 4131 c/c 10 4157

180 A/A 11 4314

T/T 12 4365

C/C 13 4433

A/A •14 4962

T/C 15 6408

185 T/T 16 7068

C/C 17 ^' 7116

C/C 18 7310

G/G 19 7371

C/C 20 7392

190 T/T 21 7991

G/G 22 8608

A/A . 23 9656

C/T 24 9764

A/G 25 9878

195 G/G 26 9976

C/C 27 12132

C/C 28 13622

Ηaplotype pahs are represented as 1^st haplotype/2^nd haplotype; with alleles of each haplotype 200 shown 5 ' to 3' as 1^st polymoφhism/2^nd polymoφhism in each column; ^bPS = polymoφhic site; Position of PS in SEQ ID NO:l.

12. The method of claim 11, wherein the identified genotype of the individual comprises the nucleotide pah at each of PS1-PS28,^' which have the position and alternative alleles shown in SEQ JD NO:l.

13. A method for identifying an association between a trait and at least one haplotype or haplotype 5 pair of the period (Drosophila) homolog 1 (PERI) gene which comprises comparing the frequency of the haplotype or haplotype pah in a population exhibiting the trait with the frequency of the haplotype or haplotype pah in a reference population, wherein the haplotype is selected from haplotypes 1-32 shown in the table presented immediately below, wherein each of the haplotypes comprises a sequence of polymoφhisms whose positions and identities are set 10 forth in the table immediately below: Haplotype Numbei.a PS PS

1 2 3 4 5 6 7 8 9 10 No.^b Position' c C C C C C C C C c 1 1967

G G T T T T T T T T 2 1979

T T G G G G G G G G 3 2048

G G A G G G G G G G 4 2218

T T T C C C C C T T 5 2324

C C C C C C C C C C 6 3830

T T T T T T T T C C 7 3833 c C c c C C C c C C 8 3973 c C c c C C C c C C 9 4131 c c c c C c C c C T 10 4157

A A A A A A- A A A A 11 4314

T T T T T T T T T T 12 4365 c c C C c c c G C c 13 4433 c c A A A C c C C c 14 4962

T T T T T C c C T T 15 6408

T T T c T T T T T T 16 7068 c c C c C C c c c c 17 7116

G G G c G C c c c c 18 7310

A G G G G G G G G G 19 7371^'

C C C C C C C C C T 20 7392

T T T T T T T T T T 21 7991

G G G G G G G G G G 22 8608

A A A A A A A A A A 23 9656

C T T T T C T T C C 24 9764

A G G G G A G G A A 25 9878

G G G G G A G G G G 26 9976

C C C C C C C C C C 27 12132

C C C C C C C C C C 28 13622

Haplotype Numbe:r³ PS PS

11 12 13 14 15 16 17 18 19 20 Number^b Position' c C C C C C C C C C 1 1967^'

T T T T T T T T T . ^τ 2 1979

G G G G G G* G G G G 3 2048-

G G G G G G G G G G 4 2218

T T T T T T T T T T 5 2324

C C C c C C C C C C 6 ¹3830

T T T T T T T T T T 7 3833 c c C c C C C C C c 8 3973 c c C c C C C C C c 9 4131 c c C c C C C C C c 10 4157

A A A A ^•A A A A A A 11 4314

T T T T T T T T T T 12 4365

C C C c c C C C C c 13 4433

A A A A A A A A C c 14 4962

C T T T T T T T C T 15 6408

T C C C T T T T T c 16 7068

C C C C C C C T C c 17 7116 c C G G C G G c c G 18 7310

G G A' A G G G G G G . 19 7371

C C C C C C C C C C 20 7392

T T T T T T T T T T 21 . _.7991

G G G G G G G G G G 22 8608

A A A A A ^' A A A A A 23 9656

T C C C C C T C T C 24 9764

G A A A A A G . A G A 25 9878

G G G G G G G G G G 26 9976

C C C T C C C C C C 27 ^' 12132

C C C C C C C C C C 28 13622

Haplotype Numb*sr^a PS PS

75 21 22 23 24 25 26 27 28 29 30 Number^b Position⁰

C C C C C C C C C C 1 1967

T T T T T T T T T T 2 1979

G G G G G G T T T T 3 2048

G G G G G G G G G G 4 2218

80 T T T T T T T T T T 5 2324

C C C C C T C C c C 6 3830

T T T T T T T T T T 7 3833 c C C C c C C C c c 8 3973 c C C C T C C C c c 9 4131

85 c C C T c C C C c c 10 4157

G G G A A A A A A A 11 4314

T T T T T T T T T T 12 4365

C C C C c C C C C C 13 4433

A A C C A C A C c C 14 4962

90 T T T T T C T C T T 15 6408

C C C C T T T T c c 16 7068

C C c C C c C c c c 17 7116

G G G G C c G c c c 18 7310

A G G G G G A G G G 19 7371

95 C C C C C c C C C C 20 7392

T T T T T T T T T T 21 7991

G G G G G G G G G G 22 8608

A A A A A A A A A A 23 9656

C C C T T T C T C C 24 9764

100 A A A G G G A G A A 25 9878

G G G G G G G G A G 26 9976

C C C C C C C C C C 27 12132

C C C C c C C C C C 28 13622

aplotype Number³ PS PS

31 32 No.^b Position⁰

C G 1 1967

T T 2 1979

T G 3 2048

G G 4 2218

T T ^' 5 2324

C C 6 3830^'

T T 7 3833

C T 8 3973

C c 9 4131

C c 10 4157

A A 11 4314

T C 12 4365 c C 13 4433 c A 14 4962

T T* 15 6408

T C ^" 16 7068 c C 17 7116 c G 18 7310

G G 19 7371

C C 20 7392

T T 21 7991

G A 22 8608

A A 23 9656

C C 24 9764

A A 25 9878

G G 26 9976

C C 27 12132

C T 28 ^' 13622 "Alleles for haplotypes are presented 5 ' to 3 ' in each column; ^bPS = polymoφhic site; "Position of PS in SEQ JD NO:l; and wherein the haplotype pah is selected from the haplotype pahs shown in the table immediately below, wherein each of the PERI haplotype pahs consists of first and second haplotypes which comprise first and second sequences of polymoφhisms whose positions and identities are set forth in the table immediately below:

Haplotype Pair³ PS PS

.7/7 17/17 15/15 26/26 11/19 7/2 17/30 17/26 No.^b Position⁰

145 C/C C/C C/C C/C C/C C/C C/C C/C 1 1967

T/T T/T T/T T/T T/T T/G T/T T/T 2 1979 ^•

G/G G/G G/G G/G G/G G/T G/T G/G 3 2048

G/G G/G G/G G/G G/G G/G G/G G/G 4 2218

C/C T/T T/T T/T T/*T C/T T/T T/T 5 2324

150 C/C C/C C/C T/T C/C C/C C/C C/T 6 3830

T/T T/T T/T T/T T/T T/T T/T T/T 7 3833

C/C C/C C/C C/C c/c c/c c/c c/c 8 3973 ^• c/c c/c c/c c/c c/c c/c c/c c/c 9 4131 c/c c/c c/c c/c ^■ c/c c/c c/c c/c 10 4157

155 ^' A/A A/A A/A A/A A/A A/A A/A A/A 11 4314

T/T T/T T/T^' T/T T/T T/T T/T T/T 12 4365 c/c c/c c/c c/c c/c c/c c/c c/c 13^' 4433

C/C A/A A/A C/C A/C C/C A/C A/C 14 4962

C/C T/T T/T C/C C/C C/T T/T T/C 15 6408

160 T/T T/T T/T T/T T/T T/T T/C T/T 16 7068

C/C C/C C/C C/C c/c c/c c/c c/c 17 7116

C/C G/G C/C C/C C/C C/G G/C G/C 18 7310

G/G G/G G/G G/G G/G G/G G/G G/G 19 7371

C/C C/C C/C C/C C/C C/C C/C C/C 20 7392

165 T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/G G/G - G/G G/G G/G 22 8608

A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

T/T T/T C/C T/T T/T T/T T/C T/T 24 , 9764

G/G G/G A/A G/G G/G G/G G/A G/G 25 9878 ^•

170 G/G G/G G/G G/G G/G G/G G/G G/G 26 _.9976

C/C C/C C/C C/C C/C C/C C/C C/C 27 12132

C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

Haplotype Pair³ PS PS

175 15/4 17/10 15/22 15/28 11/25 6/29 17/3 7/27 No.^b Position⁰

C/C C/C^' C/C C/C C/C C/C C/C C/C 1 1967

T/T T/T T/T T/T T/T T/T T/T T/T 2 1979

G/G G/G G/G G/T G/G G/T G/G G/T 3 2048

G/G G/G G/G G/G G/G G/G G/A G/G 4 2218

180 T/C T/T T/T T/T T/T C/T T/T C/T 5 2324

C/C C/C C/C C/C C/C C/C C/C C/C 6 3830

T/T T/C T/T T/T T/T T/T T/T T/T 7 3833 c/c c/c c/c c/c c/c c/c c/c c/c 8 3973 c/c c/c C/C C/C C/T c/c c/c c/c 9 4131

185 C/C C/T c/c c/c c/c c/c c/c c/c 10 4157

A/A A/A A/G A/A A/A A/A A/A A/A 11 4314

T/T T/T T/T T/T T/T T/T T/T T/T 12 4365 c/c c/c c/c c/c c/c c/c c/c c/c 13 4433

A/A A/C A/A A/C A/A C/C A/A C/A 14 4962

190 T/T T/T T/T T/C C/T' C/T T/T C/T 15 6408

T/C T/T T/C T/T T/T T/C T/T T/T 16 7068

C/C C/C C/C C/C C/C C/C C/C C/C 17 7116

C/C G/C C/G C/C C/C C/C G/G C/G 18 7310

G/G G/G G/G G/G G/G G/G G/G G/A 19 7371

195 C/C C/T C/C C/C C/C C/C C/C C/C 20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/G G/G G/G G/G G/G 22 8608

A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

C/T T/C C/C C/T T/T C/C T/T T/C 24 9764

200 A/G G/A A/A A/G G/G A/A G/G G/A 25 9878

G/G G/G G/G G/G G/G A/A G/G G/G 26 9976

C/C C/C C/C C/C C/C C/C C/C C/C 27 12132

C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

205 Haplotype Pair³ PS PS

^' 7/8 17/14 17/28 15/16 17/7 7/13 17/23 16/21 No >..^b Position⁰

C/C C/C C/C C/C C/C c/c c/c c/c 1 1967

T/T T/T T/T T/T T/T T/T T/T T/T 2 1979

G/G G/G G/T G/G G/G G/G G/G G/G 3 2048

210 G/G G/G G/G G/G G/G G/G G/G G/G 4 2218

C/C T/T T/T T/T T/C C/T T/T T/T 5 2324

C/C C/C C/C C/C C/C C/C C/C c/c 6 3830

T/T T/T T/T T/T T/T T/T T/T^' T/T 7 3833 c/c c/c c/c c/c c/c c/c c/c c/c 8 3973

215 c/c c/c c/c c/c c/c c/c c/c c/c 9 4131 c/c c/c c/c c/c c/c c/c c/c c/c 10 4157

A/A A/A A/A A/A A/A A/A A/G A/G 11 4314

T/T T/T T/T T/T T/T T/T T/T T/T 12 4365

C/G C/C C/C c/c c/c c/c c/c c/c 13 4433

220 • C/C A/A A/C A/A A/C C/A A/C A/A 14 4962

C/C T/T T/C T/T T/C C/T T/T T/T 15 6408 -

* T/T T/C T/T T/T T/T T/C T/C T/C 16 7068

C/C C/C C/C C/C C/C C/C 'C/C C/C 17 7116

C/C G/G G/C C/G G/C C/G G/G G/G 18 7310

225 G/G G/A G/G G/G G/G G/A G/G G/A* 19 7371

C/C C/C C/C C/C C/C C/C C/C C/C 20 7392

T/T T/T T/T ^' T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/G G/G G/G G/G G/G 22 8608

A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

230 T/T T/C T/T C/C T/T T/C T/C C/C 24 9764

G/G G/A G/G A/A G/G G/A G/A A/A 25 9878

G/G G/G G/G G/G G/G G/G G/G G/G 26 9976

C/C C/T C/C C/C C/C C/C C/C C/C 27 12132

C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

235

Haplotype Pair³ PS PS

15/18 30/26 17/9 16/32 17/1 17/20 15/7 17/11 No.^b Position⁰

C/C C/C C/C C/G C/C C/C C/C C/C 1 1967

T/T T/T T/T T/T T/G T/T T/T T/T 2 1979

240 G/G T/G G/G G/G G/T G/G G/G G/G 3 2048

G/G G/G G/G G/G G/G G/G G/G G/G 4 2218

T/T T/T T/T T/T T/T T/T T/C T/T 5 2324

C/C C/T C/C C/C C/C C/C C/C C/C 6 3830

T/T T/T T/C T/T T/T T/T T/T T/T 7 3833

245 C/C C/C C/C C/T C/C C/C C/C C/C 8 3973

C/C C/C C/C C/C C/C C/C C/C C/C 9 4131

C/C C/C C/C C/C C/C C/C C/C C/C 10 4157^'

A/A A/A A/A A/A A/A A/A A/A A/A 11 4314

T/T T/T T/T T/C T/T T/T T/T T/T 12 4365

250 C/C C/C C./C C/C C/C C/C C/C C/C 13 4433

A/A ^' C/C A/C A/A A/C A/C A/C A/A 14 4962

T/T T/C T/T T/T T/T T/T T/C T/C 15 6408

T/T C/T T/T T/C T/T T/C T/T T/T 16 7068

C/T C/C C/C C/C C/C C/C C/C C/C 17 7116

255. C/C C/C G/C G/G G/G G/G C/C G/C 18 7310

. G/G G/G G/G G/G G/A G/G G/G G/G 19 7371

C/C C/C C/C C/C C/C C/C C/C C/C ^' 20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/A G/G G/G G/G G/G 22 8608

260 A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

C/C C/T T/C C/C T/C T/C C/T T/T 24 9764

A/A A/G G/A A/A G/A G/A A/G G/G 25 9878

G/G G/G G/G G/G G/G G/G G/G G/G 26 9976

C/C C/C C/C C/C C/C C/C C/C C/C 27 12132

265 C/C C/C C/C C/T C/C C/C C/C C/C 28 13622

Haplotype Pair³ PS PS

17/31 11/30 17/12 11/7 15/30 17/5 17/15 11/24 No.^b Position⁰

C/C C/C C/C C/C c/c c/c c/c c/c 1 1967

270 T/T T/T T/T T/T T/T T/T T/T T/T 2 1979

G/T G/T G/G G/G G/T G/G G/G G/G 3 2048

G/G G/G G/G G/G G/G G/G G/G G/G 4 2218

T/T T/T T/T T/C T/T T/C T/T T/T 5 2324

C/C C/C C/C C/C C/C C/C C/C c/c 6 3830

275 T/T T/T T/T T/T T/T T/T T/T T/T 7 3833 c/c c/c c/c c/c c/c c/c c/c c/c 8 3973 c/c c/c c/c c/c c/c c/c c/c c/c 9 4131 c/c c/c c/c C/C C/C C/C C/C C/T 10 4157

A/A A/A A/A A/A A/A A/A A/A A/A 11 4314

280 T/T T/T T/T T/T T/T T/T T/T T/T 12 4365

C/C C/C C/C C/C C/C C/C C/C c/c 13 4433

A/C A/C A/A A/C A/C A/A A/A A/C 14 4962

T/T C/T T/T C/C T/T T/T T/T C/T 15 6408 '

T/T T/C T/C T/T T/C T/T T/T T/C 16 7068

285 C/C C/C C/C C/C C/C C/C C/C C/C 17 7116

G/C C/C G/C C/C C/C G/G G/C C/G 18 7310

G/G G/G G/G G/G G/G G/G G/G G/G 19 7371

C/C C/C C/C C/C C/C C/C C/C C/C 20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

290 G/G G/G G/G G/G G/G G/G G/G G/G 22 8608

A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

T/C T/C T/C T/T C/C T/T T/C T/T 24 9764

G/A G/A G/A G/G A/A G/G G/A G/G -25 9878

G/G G/G G/G G/G G/G G/G G/G G/G 26 9976

295 C/C C/C C/C C/C C/C C/C C/C C/C 27 12132

C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

Haplotype Pair³ PS PS

15/11 No.^b Position'

300 C/C 1 1967

T/T 2 1979

G/G 3 2048

G/G 4 2218

T/T 5 2324

305 C/C 6 3830

T/T 7 3833 c/c 8 3973 c/c 9 4131 c/c 10 4157

310 A/A 11 4314

T/T 12 4365

C/C 13 4433 ^'

A/A 14 4962

T/C 15 6408

315 T/T 16 7068

C/C 17 7116

C/C 18 7310

G/G 19 7371

C/C 20 7392

320 T/T ^• 21 7991

G/G 22 8608

A/A 23 9656

C/T 24 9764

A/G 25 9878

325 G/G 26 9976

C/C 27 12132

C/C 28 13622

Ηaplotype pahs are represented as 1^st haplotype/2^nd haplotype; with alleles of each haplotype 330 shown 5 ' to 3 ' as 1^st polymoφhism/2^nd polymoφhism in each column; PS = polymoφhic site; "Position of PS in SEQ JD NO:l;

wherein a higher frequency of the haplotype or haplotype pah in the trait population than in the 335 reference population indicates the trait is associated with the haplotype or haplotype pah.

14. The method of claim 13, wherein the trait is a clinical response to a drug targeting PERI .

15. An isolated oligonucleotide designed for detecting a polymoφhism in the period (Drosophila) homolog 1 (PERI) gene at a polymoφhic site (PS) selected from the group consisting of PSl, PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS11, PS12, PS13, PS14, PS15, PS16, PS17, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS26, PS27 and PS28, wherein the selected PS have the position and alternative alleles shown in SEQ JD NO:l.

16. The isolated oligonucleotide of claim 15, which is an allele-specific oligonucleotide that specifically hybridizes to an allele of the PERI gene at a region containing the polymoφhic site.

17. The allele-specific oligonucleotide of claim 16, which comprises a nucleotide sequence selected from the group consisting of SEQ JD NOS:4-30, the complements of SEQ JD NOS:4-30, and

SEQ JD NOS:31-84.

18. The isolated oligonucleotide of claim 15 , which is a primer-extension oligonucleotide.

19. The primer-extension oligonucleotide of claim 18,which comprises a nucleotide sequence selected from the group consisting of SEQ JD NOS:85-138.

20. A kit for haplotyping or genotyping the period (Drosophila) homolog 1 (PERI) gene of an individual, which comprises a set of oligonucleotides designed to haplotype or genotype each of polymoφhic sites (PS) PSl, PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS11, PS12, PS13, PS14, PS15, PS16, PS17, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS26, PS27 and PS28, wherein the selected PS have the position and alternative alleles shown in SEQ ID NO: 1.

21. The kit of claim 20, which further comprises oligonucleotides designed to genotype PS 18, having the location and alternative alleles shown in SEQ ID NO: 1.

22. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) a fhst nucleotide sequence which comprises a period (Drosophila) homolog 1 (PERI) isogene, wherein the PERI isogene is selected from the group consisting of isogenes 1- 14 and 16 - 32 shown in the table immediately below and wherein each of the isogenes comprises the regions of SEQ JD NO: 1 shown in the table immediately below and wherein each of the isogenes 1- 14 and 16 - 32 is further defined by the corresponding sequence of polymoφhisms whose positions and identities are set forth in the table immediately below; and

Ω Ω Ω > Ω Ω H Ω > Ω Ω 1-3 ι-3 Ω Ω Hi Ω Ω Ω HI Ω Hi Ω ι-3 Ω Ω μ-> cn

O iQ

Ω Ω Ω Ω H Ω ι-3 Ω Ω Ω Ω 1-3 1-3 Ω Ω H > Ω 1-3 Ω HI Ω 1-3 Ω Ω to CD

0

CD

Ω Ω Ω Ω ι-3 Ω H Ω Ω Ω Ω H Hi Ω H Ω Ω Ω t-3 Ω HI Ω H Ω co

Ω Ω Ω Ω ι-3 !> Ω -H Ω Ω Ω Ω Ω ι-3 > Ω H > Ω Ω Ω ι-3 Ω Ω Ω Ω ι-3 Ω *^*

Ω Ω Ω Ω H ! Ω Hi Ω Ω Ω Ω ι-3 3 > Ω 3 > Ω Ω Ω ι-3 Ω Ω Ω Ω ι-3 Ω C_π

Ω Ω ■ ■ Ω Ω 1-3 Ω Ω Ω Ω H Ω Ω Ω H > Ω Ω 1-3 Ω Ω Ω Ω *H! Ω cn

Ω Ω Ω Ω i-3 -> Ω ι-3 Ω Ω Ω Ω HI Ω Ω Ω H > Ω Ω Ω 1-3 Ω Ω Ω Ω HI Ω -J a ft⁾

Ω Ω Ω Ω H ^■ Ω HI Ω Ω Ω Ω ι-3 Ω Ω Ω ι-3 > Ω Ω Ω ι-3 Ω Ω Ω Ω HI Ω CO ,-r

Ω Ω Ω ^■ Ω • Ω Hi Ω Ω Ω Ω ι-3 H Ω Ω H > Ω Ω Ω Ω Ω ι-3 Ω Ω H Ω co >

Ω Ω Ω •> Ω ^■ Ω H i-3 Ω Ω Ω HI HI Ω Ω r-3 > H Ω Ω Ω Ω ι-3 Ω Ω H Ω I*-*

t to t M M t t M M μ μ H CO 00 ι cn cπ ifc. co to a a

CO vl cn cπ J^ o io O CD Oo σ*. cπ ifc. co to μ-> o o ω

-0 μ-> μ-¹ u) ω ω u3 ra i o o o o θ (rι ^ *Λ *Λ ιji *Λ ιb ω ω ω M M μ μ iτj o to ω ∞ o σi m ω u ω ω μ o ib D ^ ω ω μ ^μ D ra co ω M o ifl ifl O ha cn μ*-¹ vi vi en ui o co o ^i μ-' μ-' ri o σi ω σ^ Cπ c ^i o co io μ-' ifc. vi σi ω to co m co ^ m co μ M μ o m o^j π⁾ t ^,J Ui * i μ ω ω o *. α⁾ (!o iD i H* to to r+ μ- o

•3 o l-ⁱ μ-¹ μ-> CD O CD CD en en cn σs σs σι en σs ω C co co co co co co co μ-* μ-¹ μ-¹ μ-> μ-¹ ra O μ*-* n cπ cπ cπ IO t IO to rx> IO IO IO -j -J vl -J v] v] vl -J en cn en cn cn IX t CDo μ-> 1 o CO 00 00 CO σs en en σs en σs en ^■cn μ-¹ μ-¹ μ-¹ μ-> μ-¹ μ-> l-> μ-> Oi. ft⁾ ιQ

CO CO o o o o μ-» μ-> μ-> μ-¹ μ-- μ-¹ μ-> μ-^» CO CO CO O CO co co co co CO CD >X> CO CD 3 μ*

SD O 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I I 1 1 1 1 1 1 1 μ-

I 1 1 μ-> h-^» μ-> O co co CD CD CD CD CD cπ cπ cπ cπ cπ cπ cπ Cπ cn IV) IV) IO to to P o μ-> μ-^» μ-¹ o o o o o o o O O O O O .fc. .fc. .fc. .fc. .fc. .fc. .fc. cπ cπ cπ Cπ Cπ CD a

CO CO μ-¹ μ-¹ μ-¹ μ-> to to to to to to IO t IO to IO to to to to to ιv> μ-> μ-> μ-¹ I-¹

CD o cn cπ cπ cπ cπ CO CO CO CO CO CO CO O μ-¹ μ-> μ-> μ-> μ-¹ μ-> μ-¹ μ-> μ-¹ μ-> μ-¹ μ-> μ-¹ μ-> d 1 ~o co μ-> μ-> μ-> μ-¹ en cn 00

μ-¹ Ω Ω Ω Ω H ^ Ω H Ω Ω Ω Ω H Ω ^ Ω H ^ Ω Ω Ω ^μS Ω H Ω H Ω μ->

Ω Ω ^ Ω ^ Ω H Ω Ω Ω Ω Ω H ^ Ω H ^ Ω Ω Ω iHl Ω H Ω i-^ Ω IO Ω Ω

Ω H Ω

Ω Ω Ω » Ω ' Ω 3 Ω Ω Ω Ω 3 ι-3 ;ϊ-' Ω ^μ3 Ω Ω Ω ^μ3 Ω ^μ3 Ω Ω ι-3 Ω I-'

■cn

Ω Ω Ω Ω i-3 Ω i- Ω Ω ^μ3 Ω i-3 Ω Ω ^μ Ω ^μ3 Ω Ω 3 Ω i-'

Ω Ω Ω Ω ' Ω Hi Ω Ω ιHi H ι^ ' Ω ^μ l Ω Ω ι-3 Ω ^μ3 Ω *H Ω l-' co

Ω Ω Ω Ω Hl Ω Hi Ω Ω Ω Ω ^μ3 Ω Ω Ω ^μ3 ^l Ω Ω Ω iHi Ω ιHi Ω Ω H Ω I-' co

Ω Ω Ω ^ Ω ^ H Ω Ω Ω Ω Ω H Ω Ω H ^ Ω Ω Ω H Ω -HI i-^ Ω t

O

to to M M M M N M M μ μ μ μ μ μ μ μ μ iD θ i (Λ ϋi *. ω M μ

00 -O m ui MAi μ o ιo co *j σι ui ιfc. ω M μ o oo μ-¹ l ι CO CO CO C0 vl vJ vl vl vJ vl cn tfc> ιfc. ιfc. ιfc. ιt> ι*!^ co co co lo to to μ-¹ μ-¹

CO IV⁾ ιc oj Kj\ m cD ) ω ω μ o * co ιj!. ω ω μ co oo co co lo o o co cn I-* o o m *ι o cD U) i μ μ σι o σι ω σι μ ι ω ~j co co to ifc. -o σs °CO to co m co *. <τι ω t μ o m o3 co M ω αi ι& o μ co co o ifc. oo co © _^ι μ- to to r+ μ-

O

3

Ω Ω Ω > Ω > Ω H Ω > Ω Ω Ω r-3 * Ω ι-3 Ω Ω Ω Ω i-3 Ω 3 Ω Ω HI Ω

Ω Ω Ω > Ω > Ω i-3 Ω Ω Ω Ω Ω H > Ω HI Ω. Ω Ω Ω H Ω H Ω Ω H Ω

Ω Ω Ω > Ω Ω H Ω Ω Ω Ω Ω ι-3 Ω Ω HI Ω Ω Ω Ω H Ω H Ω Ω H Ω

Ω Ω Ω Ω Hi Ω Hi Ω Ω Ω Ω Ω H Ω Ω H > H Ω Ω HI Ω H Ω Ω ι-3 Ω

Ω Ω Ω Ω 3 Ω Ω Ω r-3 Hi > Ω ι-3 Ω HI Ω HI Ω 1-3 Ω Ω ι-3 Ω

Ω Ω Ω Ω ι-3 ■ Ω Hi Ω Ω Ω H Ω Ω Ω J-3 >.Ω Ω Ω ι-3 ι-3 HI Ω Ω HI Ω

Ω Ω Ω > Ω > Ω ι-3 Ω > Ω Ω r-3 H > Ω H < Ω Ω Ω H Ω ι-3 Ω ι-3 H Ω

Ω Ω Ω Ω Hi ti n n Ω Ω Ω ι-3 Ω Ω Ω HI > Ω Π Ω H Ω 1-3 Ω Hi H Ω

Ω Ω > > Ω Ω ι-3 Ω Ω Ω Ω Ω Hi Ω Ω H > Ω Ω Ω H Ω H Ω H Hi Ω

Ω Ω Ω > Ω > Ω H Ω Ω Ω Ω. Ω H Ω Ω 1-3 > Ω Ω Ω ι-3 Ω H Ω H HI Ω

to to to to to to to to to μ^j μ-^l μ^j CD co ι cn cπ ιfc. co to μ-> a o*

CO ~J σι cπ ifc. ω to μ o *vO OO l cn Cn ifc. CO !V) O vl μ-¹ μ-> CO CO *CO CO OO I I ~J ^ι ^i (jι *. Λ ιJ=>' iβ. ^ *^ ω ω ω M M μ μ ifl co to co oo vi cn cn co co co co μ-> o ~ * -*. *co~ *fc -> co co so ~ c~o. o~o .o. .t., o_ . CD_ .CO_ ^« O cn μ-> ~J vi c .n . c _π o co co -J μ μ .-¹ c _n. o_ c_n. c-o. c_n. .μ-¹ c _π c -o. ~j . c —o c -o- to μ-> cn cn to co cn ∞ *4^ en co μ-> [o μ^J o cn co oo ιo co cπ *ji. ι ι— " co co o ifc. 00 00 CD ^■vi μ- to ro rr μ- o 3

Isogene Number³ (Part : D) PS PS Region

31 32 No . ^b Position⁰ Examined^d

C G 1 1967 1649-2511

T T 2 1979 1649-2511

T G 3 2048 1649-2511 ^'

G G 4 2218 1649-2511

T T 5 2324 1649-2511

C C 6 3830 3713-5421

T T 7 3833 3713-5421

C T 8 3973 3713-5421

C C 9 4131 3713-5421

C c ' 10 4157 3713-5421

A A 11 4314 3713-5421

T C 12 4365 3713-5421

C C 13 4433 3713-5421

C A 14 4962 3713-5421

T T 15 6408 6261-9023

T c 16 7068 6261-9023 c c 17 7116 6261-9023 c G 18 7310 6261-9023

G G 19 7371 6261-9023

C C 20 7392 6261-9023

T T 21 7991 6261-9023

G A 22 8608 6261-9023

A A 23 9656 9580-10151

C C 24 9764 9580-10151

A A 25 9878 9580-10151

G G 26 9976 9580-10151 11040-11638

C C 27 12132 11734-13076

C T 28 13622 13199-13976 ^aAlleles for isogenes are presented 5' to 3' in each column; ^bPS = polymoφhic site;

"Position of PS in SEQ JD NO:l; ^dRegion examined represents the nucleotide positions defining the start and stop positions within the 1^st SEQ JD NO of the sequenced region.

(b) a second nucleotide sequence which is complementary to the first nucleotide sequence.

23. The isolated polynucleotide of claim 22, which is a DNA molecule and comprises both the first and second nucleotide sequences and further comprises expression regulatory elements operably linked to the first nucleotide sequence.

24. A recombinant nonhuman organism transformed or transfected with the isolated polynucleotide of claim 22, wherein the organism expresses a PERI protein that is encoded by the first nucleotide sequence.

25. The recombinant nonhuman organism of claim 24, which is a transgenic animal.

26. An isolated fragment of a period (Drosophila) homolog 1 (PERI) isogene, wherein the fragment comprises at least 10 nucleotides in one of the regions of SEQ JD NO: 1 shown in the table immediately below and wherein the fragment comprises one or more polymoφhisms selected from the group consisting of guanine at PSl, guanine at PS2, thymine at PS3, adenine at PS4, cytosine at PS5, thymine at PS6, cytosine at PS7, thymine at PS8, thymine at PS9, thymine at PS10, guanine at PSl 1, cytosine at PS12, guanine at PS13, cytosine at PS14, cytosine at PS15, cytosine at PSl 6, thymine at PS 17, adenine at PS 19, thymine at PS20, cytosine at PS21, adenine at PS22, guanine at PS23, thymine at PS24, guanine at PS25, adenine at PS26, thymine at PS27 and thymine at PS28, wherein the selected polymoφhism has the position set forth in the table immediately below:

Isogene Number³ (Part A) PS PS Region

1 2 3 4 5 6 7 8 9 10 No.^b Position⁰ Examined^*3

C C C C C C C C C C 1 1967 1649-2511

G G T T T T T T T T 2 1979 1649-2511

T T G G G G G G G G 3 2048 1649-2511

G G A G G G G G G G 4 2218 1649-2511

T T T C C C C C T T 5 2324 1649-2511

C C C C C C C C C C 6 3830 3713-5421

T T^' T T T T T T C C 7 3833 3713-5421

C c C C c c C c C C 8 3973 3713-5421

C c C c c c c c C C 9 4131 3713-5421

C c C c c c c c C T 10 4157 3713-5421

A A A A A A A A A A 11 4314 3713-5421

T T T T T T T T T T 12 4365 3713-5421

C C C C C C c G C C 13 4433 3713-5421

C c A A A C c C C C 14 4962 3713-5421

T T T T T C C C T T 15 6408 6261-9023

T T T C T T T T T T 16 7068 6261-9023

C c c C C c C C C c 17 7116 6261-9023

G G G c G c C C C c 18 7310 6261-9023

A G G G G G G G G G 19 7371 6261-9023

C C. C C C C C C C T 20 7392. 6261-9023

T T T T T T T T T T 21 7991 6261-9023

G G G G G G G G G G 22 8608 6261-9023

A A A A A A A A A A 23 9656 9580-10151

C T T T T C T T C C 24 9764 9580-10151

A G G G .G A G G A A 25 9878 9580-10151

G G G G G A G G G G 26 9976 9580-10151 11040-11638

C C C C C C C C C C 27 12132 11734-13076

C C C C C C C C C C 28 13622 13199-13976

vl ON σ CΛ CΛ

CΛ o CΛ t-Λ o CΛ μ->

Ω Ω Ω Ω μ3 ' Ω H Ω Ω Ω Ω H Ω Ω H > Ω Ω Ω HI Ω iH: Ω Ω Hi Ω I-'

H

Ω Ω Ω 0 > Q HI Ω Ω n n Ω ι-3 Ω i-3 θ n- Ω ι-3 0 *-3 Q θ r-3 0 t

Ω Ω Ω Ω Ω HI Ω tC» Ω Ω Ω μ3 > O HI Ω Ω O ι-3 Ω i-3 Ω cn ι-3 θ ω μ->

Ω r-3 Ω ' Ω Ω Hi Ω Ω Ω Ω H ' H ' Ω Ω μ3 Ω 3 Ω Hi Ω *>

Ω Ω Ω Ω ' Ω HI Ω Ω Ω Ω μ3 μ3 Ω μ3 | Ω Ω Ω H Ω ιHi Ω Ω _*Hi Ω I-^ι cn

Ω Ω Ω Ω H ^l ^ H Ω Ω ^ Ω l^ H >^ H ι Ω Ω H Ω μ^ Ω ^ Hl Ω I-^,

Ω Ω Ω Ω Ω H Ω Ω Ω ι-3 H H Ω ι^***3 ; Ω Ω Ω H Ω H Ω Ω H Ω I-' oo

Ω Ω Ω Ω '-3 ' Ω ι-3 Ω Ω 3 Ω Ω 3 ⁱ Ω 3 3 HI -¹

CD

Ω Ω Ω ^ Ω lP Ω H Ω Ω Ω Ω Ω H Ω Ω H ^' Ω Ω Ω iHI Ω i-S Ω Ω H Ω tO o

lo to M M iO M to M M μ μ μ μ μ μ μ μ μ cD θD *o m cji ιfc. ω M

00 vl σ^ Cπ ιfc. co to μ-> o cD Cθ ι cn cπ ιfc. co to μ-> o

00 t

μ-¹ μ-¹ CD o D co cn cn cn -σi en cn cn σi co co CO CO CO co o co CO μ-> ■_*, M co μ-¹ cn cπ Cπ cπ to MM M M W M MO O o o o -J -J ~J cn cn cn μ-> vi oo oo co co cn cn cn cn cn cn cn cn ^μ-^{1 μ}-¹ μ-> μ-> μ*-* μ-> μ-> μ-> μ-> co co o o o o μμμμ μ μ μ μω to co o o co co co co o

CO ifc- I I 1 I I 1 I I I I I I I I I I I 1 1 I I

I I-*-*-* μ-> μ-> co co co co CD co co CD cπ cπ Cπ Cπ cπ cπ i ) to to to 3 μ-¹ o o o o o o o o o o o O ifc. ifc. ifc. .fc* .fc* .fc* cπ Cπ Cπ Cπ 2 ω ω μ μ μ μ μ M M t IO to to to to to to to to to to μ->

ID o cn Cπ cπ Cπ cπ co co co co ωωωωμ μμ μ-> μ->

-J viuμ μ μ-¹ μ-¹ cn cn oo

Isogene Number³ (Part C) PS PS Region 21 22 23 24 25 26 27 28 29 30 No.¹ Position⁰ Examined^0"

C C C C C C C C C C 1 1967 1649-2511 T T T T T T T T T T 2 1979 1649-2511 G G G G G G T T* T T 3 2048 1649-2511 G G G G G G G G G G 4 2218 1649-2511 T T T T T- T T T T T 5 2324 1649-2511 C C C C C T C C C C .6 3830 3713-5421 T T T T T T T T T T 7 3833 3713-5421 c c c c C c C C c c 8 3973 3713-5421 c c c c T^' c C C c c 9 4131 3713-5421 c c c T c c C C c c 10 4157 3713-5421

G G G A A A A A. A A- 11 4314 3713-5421 T T T T T T T T T T 12 4365 3713-5421 C c C c C C C C C C 13 4433 3713-5421

A A C c A C A C C C 14 4962 3713-5421

T T T T T C T ,C T T 15 6408 6261-9023

C c C c T T T T c C 16 7068 6261-9023 C c c c C C C C c c 17 7116 6261-9023 G G G G C C G C c c 18 7310 6261-9023 A G G G G G A G G G 19 7371 6261-9023 C C C C C C C C C C 20 7392 6261-9023 T T T T T T T T T T 21 7991 6261-9023 G G G G G G G G G G 22 8608 6261-9023

A A A A A A A A A A 23 9656 9580-10151

C C C T T T C T C C 24 9764 9580-10151

A A A G G G A G A A 25 9878 9580-10151

G G G G G G G G A G 26 9976 9580-10151

11040-11638

C C C C C C C C C C 27 12132 11734-13076 C C C C C C C C C C 28 13622 13199-13976

I so gene Number³ ( Part : D) PS PS Region

31 32 No . ^b Position⁰ Examined^d

C G 1 1967 1649-2511

T T 2 1979 1649-2511

T G 3 2048 1649-2511

G G 4 2218 1649-2511

T T 5 2324 1649-2511

C C 6 3830 3713-5421

T T 7 3833 3713-5421 c T 8 , 3973 3713-5421 c C 9 4131 3713-5421 c C 10 4157 3713-5421

A A 11 4314 3713-5421

T C 12 4365 3713-5421 c C 13 4433 3713-5421

C A 14 4962 3713-5421

T T 15 6408 6261-9023

T C 16 7068 6261-9023 c C 17 7116 6261-9023 c G 18 7310 6261-9023

G G 19 7371 6261-9023

C C 20 7392 6261-9023

T T 21 7991 6261-9023

G A 22 8608 6261-9023

A A 23 9656 9580-10151

C C 24 9764 9580-10151

A A 25 9878 9580-10151

G G 26 9976 9580-10151 11040-11638

C C 27 12132 11734-13076

C T 28 13622 13199-13976 ^aAlleles for isogenes are presented 5 ' to 3 ' in each column;

''PS = polymoφhic site; "Position of PS in SEQ JD NO:l; ^dRegion examined represents the nucleotide positions defining the start and stop positions within the 1^st SEQ JD NO of the sequenced region.

27. An isolated polynucleotide comprising a PERI coding sequence, wherein the coding sequence is selected from the group consisting of 1-11, 13, 14, 17, 19-21, and 23-32 shown in the table immediately below, and wherein each of the coding sequences comprises the regions of SEQ JD NO:2 that are defined by exons 2-6 and 9-23, except at each of the polymoφhic sites which have the positions in SEQ JD NO:2 and polymoφhisms set forth in the table hnmediately below: Coding Sequence Haplotype Number³ PS PS lc 2c 3c ^' 4c 5c 6c 7c 8c 9c 10c No.^b Position⁰

C C C C C C C C C C 9 109 C C C C C C C C C T 10 135 C C C C C C C G C C 13 297 C C A A A C C C C C 14 639 A G G G G G G G G G 19 1521 C C C C C C C C C T 20 1542 T T T T T T T T T T 21 1763 G G G G G G G G G G 22 2055 C T T T T C T T C C 24 2247 A G G G G A G G A A 25 2361 G G G G G A G G G G 26 2459 C C C C C C C C C C 28 3834

Coding Sequence Haplotype Number³ PS PS lie 13c 14c 17c 19c 20c 21c 23c 24c 25c No.^b Position⁰

C C C C C C C C C T 9 109. C C C C C C C C T C 10 135 C C C C C C C C C^' C 13 297 A A A A C C A C C A 14 639 G A A . G G G A G G G 19 1521 C C C C C C C C C C 20 1542 - T T T T T T T T T T 21 1763 G G G G G G G G G G 22 2055 T C C T T C C C T T 24 2247 G A A G G A A A G G 25 2361 G G G G G G G G G G 26 2459 C C C C C C C C C C 28 3834

Coding Sequence Haplotype Number³ PS PS

26c 27c 28c 29c 30c 31c 32c No. Position c C C C C C C 9 109 c C C C C C C 10 135 c C C C C C C 13 297 c A C C ^' C C A 14 639

G A G G G G G 19 1521

C C C C C C C 20 1542

T T T T T • T T 21 1763

G G G G G G A 22 2055

T C T C C C C 24 2247

G A G A A A A 25 2361

G ^' G G A G G G 26 2459

C C C C C C T 28 3834

"Alleles for the isogene coding sequence are presented 5 ' to 3' in each column; the numerical portion of the isogene coding sequence number represents the number of the parent full PERI isogene: b P- S = polymoφhic site; Position of PS in SEQ JD NO:2.

28. A recombinant nonhuman organism transformed or transfected with the isolated polynucleotide of claim 27, wherein the organism expresses a period (Drosophila) homolog 1 (PERI) protein that is encoded by the polymoφhic variant sequence.

29. The recombinant nonhuman organism of claim 28, which is a transgenic animal.

30. An isolated fragment of a PERI cDNA, wherein the fragment comprises one or more . polymoφhisms selected from the group consisting of thymine at a position corresponding to nucleotide 109, thymine at a position corresponding to nucleotide 135, guanine at a position corresponding to nucleotide 297, cytosine at a position corresponding to nucleotide 639, adenine at a position corresponding to nucleotide 1521, thymine at a position corresponding to nucleotide 1542, cytosine at a position corresponding to nucleotide 1763, adenine at a position corresponding to nucleotide 2055, thymine at a position corresponding to nucleotide 2247, guanine at a position corresponding to nucleotide 2361, adenine at a position corresponding to nucleotide 2459 and thymine at a position corresponding to nucleotide 3834 in SEQ JD NO:2.

31. An isolated polypeptide comprising an amino acid sequence which is a polymoφhic variant of a reference sequence for the period (Drosophila) homolog 1 (PERI) protein, wherein the reference sequence comprises SEQ JD NO:3 for the regions encoded by exons 2-6 and 9-23, except the polymoφhic variant comprises one or more variant amino acids selected from the group consisting of serine at a position corresponding to amino acid position 37, proline at a position corresponding to amino acid position 588 and glutamine at a position corresponding to amino acid position 820.

32. An isolated monoclonal antibody specific for and immunoreactive with the isolated polypeptide of claim 31.

33. A method for screening for drugs targeting the isolated polypeptide of claim 31 which comprises contacting the PERI polymoφhic variant with a candidate agent and assaying for binding activity.

34. An isolated fragment of the PERI polypeptide, wherein the fragment comprises one or more variant amino acids selected from the group consisting of serine at a position corresponding to amino acid position 37, proline at a position corresponding to amino acid position 588 and glutamine at a position corresponding to amino acid position 820 in SEQ JD NO:3.

35. A computer system for storing and analyzing polymoφhism data for the period (Drosophila) homolog 1 gene, comprising:

(a) a central processing unit (CPU);

(b) a communication interface;

(c) a display device;

(d) an input device; and

(e) a database containing the polymoφhism data; wherein the polymoφhism data comprises any one or more of the haplotypes set forth in the table immediately below: -I***- co O t t o cn o CΛ o CΛ

Ω Ω Ω > Ω > Ω ι-3 Ω • Ω Ω r-3 r-3 Ω Ω 1-3 > Ω Ω Ω Hi Ω 1-3 Ω H Ω Ω μ->

Ω Ω Ω Ω 3 > Ω 1-3 Ω Ω Ω Ω r-3 HI Ω Ω i-3 > Ω Ω Ω H Ω ι-3 Ω H Ω Ω to

Ω Ω Ω Ω ι-3 > Ω r-3 Ω Ω Ω Ω H r-3 > Ω H > Ω Ω Ω r-3 Ω HI > Ω HI Ω co ft) T3

I-

Ω Ω Ω Ω H > Ω r-3 Ω Ω Ω Ω Ω H > Ω H > Ω Ω Ω 1-3 Ω Ω Ω Ω r-3 Ω rot

Ω Ω Ω Ω ι-3 > Ω r-3 Ω Ω Ω Ω r-3 r-3 > Ω 1-3 > Ω Ω Ω H Ω Ω Ω Ω r-3 Ω Cπ 13 CD

Ω Ω Ω > Ω H Ω Ω Ω Ω r-3 Ω Ω Ω μ3 Ω Ω Ω r-3 Ω Ω Ω Ω r-3 Ω cn

Ω Ω Ω Ω Hi > Ω r-3 Ω Ω Ω Ω r-3 Ω Ω Ω H > Ω Ω Ω HI Ω Ω Ω Ω H Ω

Ω Ω Ω Ω H

> Ω r-3 Ω Ω Ω Ω r-3 Ω Ω Ω r-3 > Ω Ω Ω HI Ω Ω Ω Ω μ3 Ω 00

Ω Ω Ω > Ω Ω H Ω Ω Ω Ω ι-3 ι-3 Ω Ω H! Ω Ω Ω Ω Ω ^"r-3 Ω Ω H Ω CD

Ω Ω Ω Ω Ω r-3 H Ω Ω Ω ι-3 3 Ω Ω r-3 > r-3 Ω Ω Ω Ω ι-3 Ω Ω HI Ω o to IV⁾ I ⁾ IV) to to to IO IO μ-> μ-> μ-> μ-> μ-¹ μ-> μ-¹ μ-¹ CD 00 1 cn Cπ .fc. co IO μ-¹ a

00 1 cn cπ CO to μ-> o CO CO vl en cπ O to μ-¹ O o CO oo μ-> l-» CO CD co CO CO 1 vj vl cn co CO co to to to μ-¹ μ-¹ ha ha

CO to CO 00 1 cn cn CD co μ-> o CO co O μ-> μ-¹ CD 00 ∞ CO to o CD CO co cn 1 σs cπ o O CD μ-> σs o en CO cn μ-> cπ CO vl co co to μ-¹ o cn ω tv> CO cn CO cn CO to en CO CO to co Cπ CO CO o 00 00 CD 1 μ- to IO ri- μ- o 3

^{7371 0 731}

Ha]plotype Number^{3 '} PS PS

11 12 13 14 15 16 17 18 19 20 Number" Position⁰ c C C C C C C C C c 1 1967

T T T T T T T T T T 2 1979

G G G G G G G G G G 3 2048

G G G G G G G G G G 4 2218

T T T T T T T T T T 5 2324

C C C C C C C C C C 6 3830

T T T T T T T T T T 7 3833

C C C c C c C C C c 8 3973

C c ^• C c C c c c C c 9 4131

C C C c c c c c C c 10 4157-

A A A A A A A A A A 11 4314

T T T T T T T T T T 12 4365

C C C C c C c C c C 13 4433

A A A* A A A A A c C 14 * 4962

C T T T T T T T c T 15 6408

T -C C c T T T T T c 16 7068

C C C c C c c T c c 17 7116

C C G G C G G C c G 18 7310

G G A A G G G G G G 19 7371

C C C C C C C C C C 20 7392

T T T T T T T T T T 21 7991

G G G G G G G G G G 22 ^'8608

A A A A A A A A A A 23 9656

T C C C C C T C T C .24 9764

G A A A A A G A G A 25 9878

G G G G G G G G G G 26 9976

C C C T C C C C C C 27 12132

C C C C C C C C c C ^' 28 13622

CO CD o H N iη ^ in D oD OT O ri cM fo ^ m cD ra

CM ■^■S CM oo LO CD f~-'00 Cϋ H H H H ri H H H H H ( CSl CM 01 ιM ( (M (M CM

00 U EH EH CD EH O EH O O O rtl EH O O Eπ O O O CD O EH CD rtl O rtl CD O O σ*.

CM O EH EH CD EH O EH O O O rti EH O O EH O O O O O EH CD iiCi O rtl rtl O O oo

CM O EH EH CD En O EH O O O rtl EH O O O EH O O CD O EH CD rtl EH CD CD O O o*

CM O EH EH CD EH O EH O O O <; EH O i H H O O <; O EH CD rt; 0 * D O O ra CD

CM O EH CD CD EH Eπ Eπ O O O rtl EH O O O EH O O O O EH CD rtl EH CD CD O O

CD

9 CM o EH CD CD H O Eπ O EH O rti EH O rtl H H O O CD O EH CD i i EH O cD O O a ft o EH O CD H O En O O En * EH O O H O O a cD O EH CD rt| EH CD CD O O 1

■P oo

© o o EH CD CD EH O B O O O O EH U U EH U O CD CD O Eπ CD rtl O rti CD O O

SO ft r5

© o EH CD CD EH O H O O O H O -^ EH O O CD CD O EH CD rti O rti CD O O o

C CMM oO EHn COD COD H O H O O O O H O rtl EH O O O rtl O EH CD rtl O rtJ O O O

IT) o o sn o t-^*- oo 00 σs σs o

CO O t t o CΛ o CΛ <-Λ

Ω Ω Ω > Ω > Ω HI O Ω Ω Ω HI ι-3 Ω Ω ^'ι-3 > O θ n Hi n HI Ω r-3 HI Ω C μ-

Haplotype Pair^a PS PS

140 7/7 17/17 15/15 26/26 11/19 7/2 17/30 17/26 No.^b Position⁰

C/C C/C c/c c/c c/c c/c c/c c/c 1 1967

T/T T/T T/T T/T T/T T/G T/T T/T 2 . 1979

G/G G/G G/G G/G G/G G/T G/T G/G 3 2048

G/G G/G G/G G/G G/G G/G G/G G/G 4 2218

145 C/C T/T T/T T/T T/T C/T T/T T/T 5 2324

C/C C/C C/C T/T C/C C/C C/C C/T 6 3830

T/T T/T T/T T/T T/T T/T T/T T/T 7 3833 c/c c/c c/c c/c c/c c/c c/c c/c 8 3973 c/c c/c c/c c/c c/c c/c c/c c/c 9 4131

150 c/c c/c c/c c/c c/c c/c c/c c/c 10 4157

A/A A/A A/A A/A A/A A/A A/A A/A 11 4314

T/T T/T T/T T/T T/T T/T T/T T/T 12 4365 c/c c/c c/c c/c c/c c/c c/c c/c 13 4433

C/C A/A A/A C/C A/C C/C A/C A/C 14 4962

155 C/C T/T T/T C/C C/C C/T T/T T/C 15 6408

T/T T/T T/T T/T T/T T/T T/C T/T 16 ^■ 7068

C/C C/C C/C C/C C/C C/C C/C c/c 17 7116

C/C G/G C/C C/C _, C/C C/G G/C G/C 18 7310

G/G G/G G/G G/G G/G G/G G/G G/G 19 7371

160 C/C C/C C/C C/C C/C C/C C/C C/C 20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/G G/G G/G G/G G/G 22 8608

A/A A/A .A/A A/A A/A A/A A/A A/A 23 9656

T/T T/T C/C T/T T/T T/T T/C T/T 24 9764

165 G/G G/G A/A G/G G/G G/G G/A G/G 25 9878

G/G G/G G/G G/G G/G G/G G/G G/G 26 9976

C/C C/C C/C C/C C/C C/C C/C C/C 27 12132

C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

170 Haplotype Pair³ PS PS

15/4 17/10 15/22 15/28 11/25 6/29 17/3 7/27 No.^b Position^0'

C/C C/C C/C C/C c/c c/c c/c c/c 1 1967

T/T T/T T/T T/T T/T T/T T/T T/T 2 . 1979

G/G G/G G/G G/T G/G G/T G/G G/T 3 2048

175 G/G G/G G/G G/G G/G G/G G/A G/G 4 2218

T/C T/T T/T T/T T/T C/T T/T C/T 5 2324

C/C C/C C/C C/C C/C C/C C/C c/c 6 3830

T/T T/C T/T T/T T/T T/T T/T T/T 7 3833

C/C C/C C/C C/C C/C c/c c/c c/c 8 3973 .

180 C/C C/C C/C C/C C/T c/c c/c c/c 9 4131

C/C C/T c/c c/c c/c c/c c/c c/c 10 4157

A/A A/A A/G A/A A/A A/A A/A A/A 11 4314

T/T T/T T/T T/T T/T T/T T/T T/T 12 4365 c/c c/c c/c c/c c/c c/c c/c c/c 13 4433

185 A/A A/C A/A A/C A/A ^• C/C A/A C/A 14 4962

T/T T/T T/T T/C C/T C/T T/T C/T 15 6408

T/C T/T T/C T/T T/T T/C T/T T/T 16 7068

C/C C/C C/C C/C c/c c/c c/c c/c 17 7116

C/C G/C C/G C/C C/C C/C G/G C/G 18 7310

190 G/G G/G G/G G/G G/G G/G G/G G/A 19 7371

C/C C/T C/C C/C C/C C/C C/C C/C 20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/G G/G G/G G/G G/G 22 . 8608

¹ A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

195 C/T T/C C/C C/T T/T C/C T/T T/C 24 9764

A/G G/A A/A A/G G/G A/A G/G G/A 25 9878

G/G G/G G/G G/G G/G A/A G/G G/G 26 9976

C/C C/C C/C C/C C/C C/C C/C C/C 27 12132

C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

200

Haplotype Pair³ PS PS

7/8 17/14 17/28 15/16 17/7 7/13 17/23 16/21 No.^b Position⁰

C/C C/C C/C C/C C/C C/C C/C C/C 1 1967

T/T T/T T/T T/T T/T T/T T/T T/T 2 1979

205 G/G G/G G/T G/G .G/G G/G G/G G/G 3 2048

G/G G/G G/G G/G G/G G/G G/G G/G 4 2218

C/C T/T T/T T/T T/C C/T T/T T/T 5 2324

C/C C/C C/C C/C C/C C/C C/C C/C 6 3830

T/T T/T T/T T/T T/T T/T T/T T/T 7 3833

210 C/C C/C C/C C/C C/C C/C C/C C/C 8 3973

C/C C/C C/C C/C C/C C/C C/C C/C 9 4131

C/C C/C C/C C/C C/C C/C C/C C/C 10 4157

A/A A/A A/A A/A A/A A/A A/G A/G 11 4314

T/T T/T T/T T/T T/T T/T T/T T/T 12 4365

215 C/G C/C C/C C/C " C/C C/C C/C C/C 13 4433

C/C A/A A/C A/A A/C C/A A/C A/A 14 4962

C/C T/T T/C T/T T/C. C/T T/T T/T 15 6408

T/T T/C T/T T/T T/T T/C T/C T/C ^• 16 7068

C/C C/C C/C C/C C/C C/C C/C C/C 17 7116 -

220 C/C G/G G/C C/G G/C C/G G/G G/G 18 7310

G/G G/A G/G G/G G/G G/A G/G G/A 19 7371

C/C C/C C/C C/C C/C C/C C/C C/C 20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/G G/G G/G G/G G/G 22 8608

225 A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

T/T T/C T/T C/C T/T T/C T/C C/C - 24 9764

G/G G/A G/G A/A G/G G/A G/A A/A 25 9878

G/G G/G G/G G/G G/G G/G G/G G/G 26 9976

C/C C/T C/C C/C C/C C/C C/C C/C 27 12132

230 C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

Haplotype Pair³ PS PS

15/18 30/26 17/9 16/32 17/1 17/20 15/7 17/11 No.° Position⁰

C/C C/C C/C C/G C/C C/C C/C C/C ^' 1 1967

235 T/T T/T T/T T/T T/G T/T T/T T/T 2 1979

G/G T/G G/G G/G G/T G/G G/G G/G 3 2048

G/G G/G G/G G/G G/G G/G G/G G/G 4 2218

T/T T/T T/T T/T T/T T/T T/C T/T 5 2324

C/C C/T C/C C/C C/C C/C C/C C/C 6 3830

240 ^' T/T T/T T/C T/T T/T T/T T/T T/T 7 3833

C/C C/C C/C C/T C/C C/C c/c c/c 8 3973 c/c c/c c/c c/c c/c c/c c/c c/c 9 4131 c/c c/c c/c c/c c/c c/c c/c c/c 10 4157

A/A A/A A/A A/A A/A. A/A A/A A/A 11 4314

245 T/T T/T T/T T/C T/T T/T T/T T/T 12 4365

C/C C/C C/C C/C C/C C/C c/c c/c 13 4433

A/A _. C/C A/C A/A A/C A/C A/C A/A 14 4962

T/T T/C T/T T/T T/T T/T-^' T/C T/C 15 6408

T/T C/T T/T T/C T/T T/C T/T T/T 16 7068

250 C/T C/C C/C C/C C/C C/C ^~ c/c c/c 17 7116

C/C C/C G/C G/G G/G G/G C/C G/C 18 7310

G/G G/G G/G G/G G/A G/G G/G G/G 19 7371

C/C C/C C/C C/C C/C C/C C/C C/C 20 7392

T/T T/T T/T T/T T/T T/T T/T T/T 21 7991

255 G/G G/G G/G G/A G/G G/G G/G G/G 22 8608

A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

C/C C/T T/C C/C T/C T/C C/T T/T 24 9764

A/A A/G G/A A/A G/A G/A A/G G/G 25 9878

G/G G/G G/G G/G G/G G/G G/G G/G 26 9976

260 C/C C/C C/C C/C C/C C/C C/C C/C 27 12132

C/C C/C C/C C/T C/C C/C C/C C/C 28 13622

Haplotype Pair³ PS PS

17/31 11/30 17/12 11/7 15/30 17/5 17/15 11/24 N Ioo..^b Position⁰

265 C/C C/C C/C C/C C/C C/C C/C C/C 1 1967

T/T T/T T/T' T/T T/T T/T T/T T/T 2 1979

G/T G/T G/G G/G G/T G/G G/G G/G 3 2048

G/G G/G G/G G/G G/G G/G G/G G/G 4 2218

T/T T/T T/T T/C T/T T/C T/T T/T 5 2324

270 C/C . C/C C/C C/C C/C C/C C/C C/C 6 3830

T/T T/T T/T T/T T/T T/T T/T T/T 7 3833

C/C C/C C/C C/C c/c c/c c/c c/c 8 3973 c/c c/c c/c c/c c/c c/c c/c c/c 9 4131 c/c c/c c/c c/c C/C C/C C/C C/T 10 4157

275 A/A A/A A/A A/A A/A A/A A/A A/A 11 4314

T/T T/T T/T T/T T/T T/T T/T T/T 12 4365

C/C C/C C/C C/C C/C C/C C/C c/c 13 4433

A/C A/C A/A A/C A/C A/A A/A A/C 14 4962

T/T C/T T/T C/C T/T T/T T/T C/T 15 6408

280 T/T T/C T/C T/T T/C T/T T/T T/C 16 7068

C/C c/c c/c c/c c/c c/c c/c c/c 17 7116

G/C C/C G/C C/C C/C G/G G/C C/G 18 7310

G/G G/G G/G G/G G/G G/G G/G G/G 19 7371

C/C C/C C/C C/C C/C C/C C/C C/C 20 7392

285 T/T * T/T T/T T/T T/T T/T T/T T/T 21 7991

G/G G/G G/G G/G G/G G/G G/G G/G 22 8608

A/A A/A A/A A/A A/A A/A A/A A/A 23 9656

T/C T/C T/C T/T C/C T/T T/C T/T 24 9764

G/A G/A G/A G/G A/A G/G G/A G/G 25 9878

290 . G/G G/G G/G G/G G/G G/G G/G G/G 26 -9976

C/C C/C C/C C/C C/C C/C C/C C/C 27 12132

C/C C/C C/C C/C C/C C/C C/C C/C 28 13622

Haplotype Pair PS PS

295 15/11 No.^b Position'

C/C 1 1967

T/T 2 1979

^■ G/G 3 2048

G/G 4 2218

300 T/T 5 2324

C/C 6 3830

T/T 7 3833

C/C 8 3973

C/C 9 4131

305 C/C 10 4157

A/A 11 - 4314

T/T 12 4365

C/C 13 4433

A/A 14 4962

310 T/C 15 6408

T/T 16 7068

C/C 17 7116

C/C 18 7310

G/G 19 7371

315 C/C 20 7392

T/T 21 7991

G/G 22 8608

A/A 23 9656,

C/T 24 9764

320 A/G 25 9878

G/G 26 9976

C/C 27 12132

C/C 28 13622

325 Ηaplotype pahs are represented as 1^st Haplotype/2^nd Haplotype; with alleles of each haplotype shown 5 ' to 3 ' as 1^st polymoφhism/2^πd polymoφhism in each column; "Position of PS in SEQ JD NO:l; and the frequency data in Tables 6 and 7.

36. A genome anthology for the period (Drosophila) homolog 1 (PERI) gene which comprises two or more PERI isogenes selected from the group consisting of isogenes 1-32 shown in the table immediately below, and wherein each of the isogenes comprises the regions of SEQ JD NO: 1 shown in the table immediately below and wherein each of the isogenes 1-32 is further defined

5 by the corresponding sequence of polymoφhisms whose positions and identities are set forth in the table immediately below: O O o t t CΛ CΛ o CΛ o

Ω Ω Ω > Ω Ω ⁽-3 Ω > Ω Ω r-3 r-3 Ω Ω r-3 > Ω Ω Ω μ3 Ω H Ω 1-3 Ω Ω

Ω Ω Ω Ω 1-3 > Ω 3 Ω Ω Ω Ω 1-3 3 Ω Ω H Ω Ω Ω r-3 Ω μ3 Ω 3 Ω Ω Ω Ω Ω Ω 3 > Ω 3 Ω Ω Ω Ω μ3 r-3 Ω ι-3 Ω Ω Ω 1-3 Ω H Ω ι-3 Ω

Ω Ω Ω Ω 1-3 > Ω r-3 Ω Ω Ω Ω Ω r-3 Ω 1-3 > Ω Ω Ω 1-3 Ω Ω Ω Ω r-3 Ω

Ω Ω Ω Ω H > Ω r-3 Ω Ω Ω Ω r-3 r-3 ^• Ω H Ω Ω Ώ r-3 Ω Ω Ω Ω r-3 Ω

Ω Ω > > Ω > Ω 3 Ω Ω Ω Ω H Ω Ω Ω r-3 > Ω Ω Ω ι-3 Ω Ω Ω Ω i-3 Ω σi

Ω Ω Ω Ω H Ω 3 Ω Ω Ω Ω 1-3 Ω Ω Ω HI > Ω Ω Ω 1-3 Ω Ω Ω Ω r-3 Ω -J ha ft⁾ l-S

Ω Ω Ω Ω r-3 > Ω ι-3 Ω Ω Ω Ω r-3 Ω Ω Ω H Ω Ω Ω ι-3 Ω Ω Ω Ω H Ω 00 ,-,

Ω Ω Ω > Ω > Ω 1-3 Ω Ω Ω Ω H ι-3 Ω Ω H > >

Ω Ω Ω Ω Ω μ3 Ω Ω ι-3 Ω

Ω Ω Ω > Ω > Ω 3 r-3 Ω Ω Ω Hi ι-3 Ω Ω H > r-3 Ω Ω Ω Ω H Ω Ω H Ω μ-> o to to to IO to IO to t IO μ-¹ μ-> μ-¹ μ-¹ μ-¹ μ-¹ μ-¹ μ-> μ-> CD CO vl cn Cπ CO to μ-> a a

00 cn Cπ CO to μ-> O CD CO ~o s Cπ co to μ-> o o co

-o CO

μ-¹ μ-¹ O CO CD CD cn cn cn cn cn cn cn cn co co co CO CO CO CO CO μ-¹ μ-¹ μ-¹ El iΛ co μ-¹ μ-¹ Cπ Cπ. Cπ Cπ K) t t > t K) K> t -0 l i -J -J vl -J -o cn cn •cn cn cn X CD μ-> 1 o oo oo oo co cn cn cn cn cn cn cn cn μ-¹ μ-¹ μ-> μ-¹ μ-¹ μ-¹ μ-¹ *. ft!

CO O o o o o μ-> μ-> μ-> μ-^l μ-^l μ-' μ-^l μ-ι o o o co co co o o CD CD O CD CD 3 •nμ

CO o I I I I I I I I I I I I I I I I I I 1 I I 1 1 μ-

1 1 1 I μ-¹ μ-¹ CD CD CD CO CO CO CO CO cπ cπ cπ cπ Cπ cπ t to t o

IO IO 3 3 μ-> μμ--¹> o o o o o o o o o o o o Cπ cπ cπ Cπ Cπ CD O O ¹ μ-¹ to to to to to to to to IO IO IO IO to to to to μ-> μ-¹ μ-¹ ft

CO o CJS cπ cπ cπ cπ co co co co co co co co μ-¹ μ-¹ μ-¹ μ-¹ μ-¹ μ-¹ μ-¹ ι-> μ-¹

-J vl CO μ-¹ μ-> μ-> σs cn CO

n σ CΛ ^■CΛ 4^ o CΛ o CΛ n

Ω Ω Ω Ω H > Ω 3 Ω Ω μ3 Ω > Ω J-3 > Ω Ω H Ω ι-3 Ω Ω HI

Ω Ω Ω Ω Q H O Ω Ω Ω Ω r-3 > Ω r-3 > Ω Ω Ω 3 Ω 1-3 Ω Ω HI

Ω Ω Ω Ω > Ω r-3 Ω > Ω Ω Ω ι-3 * Ω ι-3 > Ω Ω Ω H Ω H Ω Ω HI

Ω ι-3 Ω > Ω Ω r-3 Ω Ω Ω Ω Hi > Ω H Ω Ω H Ω 3 Ω Ω HI

Ω Ω Ω > Ω n i3 n Ω Ω Ω t-3 H Ω r-3 Ω Ω r-3 Ω r-3 Ω Ω HI

Ω Ω Ω Ω > Ω HI Ω Ω Ω Ω ι-3 H > Ω r-3 Ω Ω Ω r-3 Ω r-3 Ω Ω HI Ω cn

Ω Ω Ω Ω ι-3 > Ω H Ω Ω Ω Ω HI HI Ω r-3 ^■ Ω Ω Ω H Ω HI Ω Ω HI Ω -J ¹

Ω Ω Ω > Ω Ω ι-3 Ω Ω Ω ι-3 ι-3 H Ω r-3 Ω Ω Ω H Ω ι-3 Ω Ω HI Ω co

Ω Ω Ω Ω Hi ^■ Ω ι-3 Ω Ω Ω Ω ι-3 Ω Ω Ω r-3 > Ω Ω ι-3 Ω H Ω Ω HI Ω CO

IO

Ω Ω Ω > Ω > Ω r-3 Ω Ω Ω Ω Ω r-3 Ω Ω 3 Ω Ω Ω ι-3 Ω HI Ω Ω ι-3 Ω o a to t to io io to to to to μ-^> μ-^» μ-> μ-> μ-> μ-> μ-> o σi u * ω to μ o

00 vl cn cπ ifc. co to μ-¹ o co oo -j cn Cπ ifc. ω w μ o

00 μ-¹ μ-> CD CO CO CO 00 l l vl vl vl vl cn *J^ ifc' i^ ifc. ^ ifc' C0 C0 C M [O IO )-' co to co oo vi cn cn co co co co μ-' o ^. CD ^ co co μ-> μ-¹ O 00 00 CO to o CO CD cn μ-¹ O O (Λ Ui O C0 U) O μ μ m o m ω n cπ co vl CO o t cn cn to co oι co ** m o μ M μ o m ffl ( ) r ω ϋi ^ ^j μ u ω o *Λ co co cD -J μ to io rt μ o

3

o o oo oo -0 o CΛ o CΛ CΛ

Ω Ω Ω > Ω Ω ι-3 Ω Ω Ω Ω H > Ω ι-3 Ω Ω Ω Ω ι-3 Ω r-3 Ω Ω 1-3 Ω

Ω Ω Ω > Ω > Ω 1-3 Ω Ω Ω Ω Ω r-3 > Ω r-3 Ω Ω Ω Ω r-3 Ω HI Ω Ω r-3 Ω

Ω Ω Ω Ω > Ω r-3 Ω Ω Ω Ω Ω r-3 Ω ir i-3 Ω Ω Ω Ω r-3 Ω HI Ω Ω ι-3 Ω

Ω Ω Ω Ω t-3 ^• Ω r-3 Ω Ω Ω Ω Ω H Ω Ω r-3 > ^μ3 Ω Ω 1-3 Ω H Ω Ω 3 Ω t .fc

Ω Ω Ω Ω ^μ3 > Ω r-3 Ω Ω Ω Ω 1-3 r-3 > Ω 1-3 Ω H Ω ι-3 Ω HI Ω Ω r-3 Ω t C

Ω Ω Ω Ω r-3 > Ω H Ω Ω Ω Ω ι-3 Ω Ω Ω <-3 > Ω Ω Ω ι-3 r-3 HI Ω Ω r-3 Ω Ω Ω Ω Ω > Ω ι-3 Ω > Ω Ω r-3 H Ω H > Ω Ω Ω 3 Ω HI Ω H ι-3 Ω

Ω Ω Ω Ω ι-3 Ω 1-3 Ω Ω Ω Ω r-3 Ω Ω Ω r-3 > Ω Ω Ω ^μ3 Ω ι-3 Ω ι-3 ι-3 Ω I

C

Ω Ω > > Ω > Ω H Ω Ω Ω Ω Ω t-3 Ω Ω H > Ω Ω Ω >-3 Ω 3 Ω ι-3 1-3 Ω io

Ω Ω Ω Ω > Ω 1-3 Ω Ω Ω Ω Ω r-3 Ω Ω H > Ω Ω Ω r-3 Ω 3 Ω HI ^μ3 Ω co o to to to to to to to tv> to μ-> μ-> μ-> μ-> μ-> μ-> μ-¹ μ-> CO co vl cn Cπ **. CO to μ-¹

00 cn Cπ .fc. co IO μ-> o CD 00 cn Cπ

co IO μ-¹ o

μ-> I-¹ D CD CO CO CO -0 -0 -j -0 1 cn co co co to t IO μ-> μ-> co IO CD 00 -J cn cn co co co CO μ-> o CD co co μ-¹ μ*-* CO co CO CO ro o CO O cn μ-¹ -4 vl cn Cπ o CD CD vl μ-> μ-> on o cn O cn μ-¹ Cπ CO -J CO CO to μ-¹ .fc. en to O CT) CO cn 00 μ-⁵ to μ-> o cn 00 CO IO co cπ μ-> CO CO o 00 00 CO to IO μ o 3

²¹²²²os^tP -fc. CO O to t o CΛ o CΛ o C

C

Ω Ω ^l Ω ^l Ω μ3 Ω Ω Ω Ω μ3 μ3 Ω Ω 3 ; ^' Ω Ω Ω μ3 ι-3 Ω ι-3 μ3 Ω

O